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1.1 Surgical Oncology 
Surgery was, for an extended period in the past, the only treatment for cancer. Only 
in the last century non-surgical treatments have been used as adjunct modalities 
(chemotherapy and radiation therapy) or more rarely (for example, in case of 
leukemia), as an alternative to surgery. Although nowadays non-surgical treatments 
are being used, surgery is still the mainstay treatment for solid tumors.  
The goal of surgical treatment is the resection of all malignant tissue with an 
adequate resection margin while preserving important adjacent healthy anatomical 
structures, and therefore maintaining their functionality. In surgical oncology, the 
resection margin is the smallest distance between the tumor border and the resection 
cut surface. The length of the needed resection margin depends on the type of tumor 
and its location in the body.  
Unfortunately, resection margins are often positive, which means that, after surgery, 
tumor is present at the resection surface of the specimen, and therefore, it may also 
be in the wound bed of the patient. The presence of residual tumor is associated with 
poor survival and need for additional surgery, adjuvant chemotherapy, radiation 
therapy, or a combination of these. For that reason, achieving adequate resection 
margins is decisive for disease control and survival of the patients. However, it is 
challenging to attain an adequate resection. Currently, the assessment of the 
resection margins is based on palpation, visual inspection, and, when possible, 
evaluation of intra-operative frozen sections (1). Palpation and visual inspection are 
subjective and have low sensitivity and specificity. Evaluation of frozen sections is a 
much more accurate diagnostic technique, but it is labor intensive and limited to a 
few inspection sites. Therefore, there is a need for intra-operative guidance (IOG) 
tools that can be used to inspect the margins with high spatial resolution, and in real-
time. Currently, there are no universal objective intra-operative guidance tools ready 
for use but techniques like intra-operative real-time MRI, intra-operative ultrasound, 
intra-operative OCT, fluorescence and Raman spectroscopy are being explored for 
IOG already in operating room environments (2-16). These techniques have been 
mainly investigated for brain cancer surgery and breast cancer surgery (9-16). 
Obviously, this is useful for all kinds of cancer surgeries, and especially for head and 
neck surgical oncology. Head and neck cancer can damage many important 
functional systems and sensory organs. Due to the complexity of the anatomical 
structures of the head and neck region, there is a fine balance between remaining 
function, physical appearance and adequate margins. Therefore, the development 
and implementation of an IOG tool for head and neck surgical oncology is a crucial 
step towards improvement of head and neck surgical outcomes (17,18). 
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The goal of this thesis was to investigate how high-wavenumber Raman 
spectroscopy can be used as an IOG tool for head and neck surgical oncology.  
This chapter serves as an introduction to this research question and provides 
background information on the medical application field and the various IOG tools 
that are being developed, with a special focus on Raman spectroscopy. In subchapter 
1.2, the epidemiology and the standard treatment method of head and neck cancer is 
described. The state-of-the-art regarding the techniques that are being investigated 
for intra-operative assessment of head and neck cancers are described in subchapter 
1.3, with a focus on the advantages, disadvantages and results obtained with these 
techniques. The Raman effect, the history of Raman spectroscopy and the 
instrumentation used for Raman spectroscopy are described in detail in the 
subchapter 1.3.7. Finally, the subchapter 1.4 describes the scope of this thesis. 
 
1.2 Head and neck cancer: epidemiology and treatment  
Every year, >680,000 new cases of head and neck cancer are diagnosed worldwide. 
The mortality rate of head and neck cancers is >370,000 (22). As head and neck 
cancers are included: cancer of the oral cavity (OCC), nasopharynx, oropharynx, 
hypopharynx, and the larynx. More than 90% of head and neck cancers are 
squamous cell carcinomas that originate from the mucosa of the oral cavity, 
oropharynx and larynx (23). 
Oral cavity squamous cell carcinoma (OCSCC) is the most frequent type of head 
and neck cancer (22). The macroscopic aspect of an advanced OCSCC of the tongue 
is shown in the figure 1. 
 
Figure 1. OCSCC of the tongue. 
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Worldwide, 300,000 new cases of OCSCC are diagnosed per year (22). The 
mortality of OCSCC is high (145.000 deaths are registered worldwide) (22,24,25). 
These numbers demonstrate that OCSCC is a major worldwide health issue. The 
most cited risk factor for developing OCSCC is the use of tobacco, which raises 3-
fold the risk of developing OCSCC. Concomitant alcohol consumption increases the 
risk 10- to 15-fold (26). The use of smokeless tobacco also increases the risk of 
developing OCSCC (27). Furthermore, genetic syndromes, like Fanconi anemia and 
dyskeratosis congenita, are also strongly related with the development of OCSCC. 
For OCSCC, the average 5-year survival is between 50-60%. Depending on stage, 
age, race, comorbidity, and location of the tumor in the oral cavity, the 5-year 
survival can vary from 10% to 82% (28,29). In addition, the presence of nodal 
metastases (spread of tumor cells to regional lymph nodes) can drastically affect the 
survival, reducing it by 50% (30,31). 
Local-regional control (control of cancer spread from the primary tumor subsite) is 
especially difficult to achieve for tongue (even in early stage tumors) compared with 
the oral subsites of the oral cavity. This difficulty exists due to: lack of anatomic 
barriers, which could avoid the cancer spread, robust lymphatic drainage, and the 
capacity for contralateral spread (32).  
The standard treatment options of OCSCC are: surgery, chemotherapy, radiotherapy, 
or a combination of these modalities.  
In Erasmus University Medical Center Rotterdam, a team of different specialists 
(medical oncologists, radiation oncologists, head and neck surgeons, pathologists 
and radiologists) weekly discuss the best management option for all the head and 
neck patients. If, for a particular patient, surgery is selected, the main goal of the 
oncological surgery will be to achieve an adequate tumor resection with acceptable 
remaining function of the anatomical structures and appearance. According to the 
Royal College of Pathologists (33), the distance between tumor border and the 
nearest resection surface determines the adequacy of the surgical procedure. This 
distance is measured in millimeters and is called resection margin. A resection 
margin can be classified as clear (>5 mm), close (1 to 5 mm) and positive (<1 mm) 
(33). Clear margins are regarded as adequate, close and positive margins as 
inadequate. Achieving adequate resection margins is critically important because, if 
the tumor is not completely removed, there is a high risk of local recurrence and 
decrease of survival (34-39). When the margins are inadequate (i.e. <5 mm) 
adjuvant therapy (chemotherapy and/or radiation therapy) or re-resection is 
necessary. These therapies have a negative effect on patient morbidity. Therefore, 
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improvement of disease control, survival and patient morbidity is directly correlated 
with adequate resection margins (40, 41,34-38). 
During resection of the tumor, surgeons rely on visual inspection and palpation, but 
it is often very difficult to remove the tumor in remote anatomical locations in close 
vicinity to critical structures, even in expert hands. These challenges are frequently 
encountered in the head and neck region, because of the complexity and location of 
this region in respect to the location of vital structures, such as cranial nerves and 
major vessels supplying the brain. The lack of reliable intra-operative guidance and 
the proximity of tumors to vital structures are the common causes of inadequate 
tumor resection.  
Earlier, Smits et al. (2015) have reported the surgical results obtained in two Dutch 
centers (Erasmus University Medical Center Rotterdam and Leiden University 
Medical Center). For OCSCC surgery adequate resection margins were obtained in 
only 15% of the cases (40).  A similar result was reported by the Harborview 
Medical Center and the University of Washington Medical Center in Seattle (USA) 
(41). Clearly, visual inspection and palpation of the tumor and healthy surrounding 
tissue by the surgeon are insufficient to warrant adequate tumor resection. 
Intra-operative assessment (IOA) can be performed on the resection surface of the 
specimen or on the wound bed of the patient. IOA of the specimen's resection 
surface (i.e. specimen driven approach, see figure 2) has been reported to be superior 
to the assessment of the wound bed (i.e. defect driven approach).  
Several studies indicate that specimen driven IOA leads to a higher surgical success 
rate and increase of patient survival than defect-driven or no IOA at all (38,42-44). 
In Erasmus University Medical Center Rotterdam, specimen driven IOA has been 
adopted since 2013. Additionally, the eight edition of the American Joint Committee 
of Cancer (AJCC) also recommends the specimen driven IOA (45). During head and 
neck surgery, IOA of resection margins can be done by means of a frozen section 
procedure (37). This procedure, in which the pathologist performs microscopic 
evaluation of a piece of suspicious tissue, is currently the gold standard of intra-
operative diagnostics (46-48).  The main limitation of the frozen section procedure is 
that only a fraction of the resection margins can be investigated. The method is 
prone to sampling errors, which often leads to false negative results (40,46). Ideally, 
not only a small portion of the resection margin should be evaluated but the entire 
resection surface should be evaluated intra-operatively, which requires an objective 
and fast technology. Moreover, a study performed by McIntosh et al (2015) 
described that frozen section analysis is also limited by histologic disruption 
introduced by freezing of the tissue. The same study also explains that certain 
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tissues, such as fat and bone, do not freeze well and are difficult to cut with a 
microtome (instrument used to produce the thin sections). Intra-operative frozen 
sections consultation for bone specimen is particularly challenging. These 
technically difficult frozen sections can lead to an inadequate slide for review. These 
factors contribute to a certain degree of diagnostic inaccuracy, and as a result the 
frozen section procedure is not very effective in improving surgical success rate 
(49).  
 
Figure 2. Surgical resection of a OCSCC tongue specimen and the respective specimen 
driven IOA. Surgeon delineates where the resection will take place. b) Resection is made. 
c) Pathologist indicates where there is suspicion of an inadequate resection margin. e) A 
cross section is performed on the suspicious region. f) The resection margin is measured 
(d mm), which is the smallest distance between the tumor border and the resection 
surface. 
This clarifies that there is need for a new technique for assessment of the margin 
status and that does not have the limitations of the current IOA procedure. The 
technique should be fast enough to allow the inspection of whole resection planes, 
should be objective, and should not be only applicable to soft tissue but also to bone. 
15432-Barroso_BNW.indd   17 05-04-18   08:54
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The high incidence, high mortality rate, high number of inadequate resections and 
the lack of an objective IOG tool in head and neck surgical oncology demonstrate 
that there is room for improvement and that this thesis may have an impact in the 
future of the head and neck surgical oncology field.  
1.3 Evolving techniques for intra-operative guidance of 
oral surgical oncology 
Various techniques like imaging-based modalities, imprint cytology, and optical 
techniques have been investigated for intra-operative use in surgical oncology (50-
65). The techniques that are being applied specifically, for intra-operative 
assessment of the resection margins of patients that underwent OCSCC surgery were 
recently reviewed by Ravi et al and Miles et al (48,49). The current technologies 
being tested for intra-operative guidance for margin control in head and neck surgery 
are: tissue auto-fluorescence, near infrared imaging, fluorescence imaging, narrow 
band imaging, confocal microscopy, high resolution microendoscopy, ultrasound 
imaging, optical coherence tomography, and Raman spectroscopy (19,20). These 
techniques and their results are described in the following sub-chapters.  
1.3.1 Fluorescence imaging technology 
Fluorescence imaging technologies; such as: tissue auto-fluorescence, near infrared 
imaging and fluorescent probe imaging systems; have been used for the screening, 
detection, and delineation of head and neck squamous cell carcinoma (66-74). 
Tissue auto-fluorescence 
Auto-fluorescence is a well-known phenomenon that is caused by the presence of 
endogenous fluorophores in biological samples. Auto-fluorescence imaging is an 
optical technique that measures the intrinsic fluorescence emitted by fluorophores 
that are present in the tissue (e.g. flavins, collagen or hemoglobin). Tissues are 
illuminated with a short-wavelength light source and the fluorescence emitted is 
captured in real-time. Differences in emitted fluorescence can be used for lesion 
detection and/or characterization (75). 
Several research groups have been investigating the use of auto-fluorescence 
imaging for intra-operative margin control.  
Klatt et al, has described the method as having potential for head and neck oncologic 
surgery. This conclusion was based on time-resolved auto-fluorescence 
measurements in tumor and in healthy tissue of the oral cavity ex-vivo. Klatt et al, 
observed that the fractal dimension of malignant tissue was significantly higher than 
the fractal dimension of healthy mucosa (66).  
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Based on a retrospective study, Poh et al reported that patients who underwent 
surgery with fluorescence visualization (VELscope) for high-grade dysplasia or oral 
carcinoma had a dramatic reduction in the 3-year local recurrence rate. Although, 
they reported that fluorescence imaging is an excellent method to guide surgical 
resection, they have also mentioned that this technique is somewhat limited by 
issues related to specificity. Phase 3 clinical trials of the VELscope have 
demonstrated that the specificity of this technique is extremely variable.  They have 
observed that not only malignant tissue exhibits decreased auto-fluorescence, but a 
variety of other tissue conditions may also exhibit less fluorescence signal, such as 
inflammation, keratosis, and benign lesions (67). 
Near infrared imaging 
Biological tissue has a minimum absorption coefficient when using near infrared 
light (650 to 900nm). Absorption of electromagnetic radiation is characterized by the 
transfer of energy of a photon into internal energy of the absorber, for example as 
thermal energy. The near infrared optical imaging window also allows minimal light 
scattering, minimal nonspecific fluorescence, and an increase of the penetration of 
the light in the tissue. These advantages contribute to the use of NIR in applications 
for image-guided surgery (76,77).  
In most head and neck squamous cell carcinomas the epidermal growth factor 
receptor (EGFR) is expressed. Cetuximab is a known therapeutic antibody that 
interacts with EGFR. Cetuximab has been combined with Cy 5.5 (fluorophore that 
has excitation at 678nm and emission at 703nm). This combination was used to 
guide surgical resections in head and neck mouse tumor models (78). 
The production of the vascular endothelial growth factor (VEGF) is also up-
regulated in tumor cells, which promotes angiogenesis. The conjugation of Cy 5.5 to 
bevacizumab (anti-VEGF antibody, for head and neck tumors) has also been tested 
in a mouse model and a study reported a sensitivity of 80.9% and a specificity of 
91.7% (79). 
Other different strategies have been proposed and tested in the optical imaging field 
of NIR light but, the clinical translation of the results is difficult. Pharmacokinetic 
studies are required for each fluorophore-conjugate. In addition, to use this system 
intra-operatively the development of better camera systems is necessary (77). 
Fluorescence Probe imaging 
Tumor cells can be imaged using antibodies or ligands conjugated to an optically 
active fluorophore. The principal of fluorescence imaging is based on the signal-to-
background ratio concept (equivalent to tumor-to-background ratio). The 
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conventional fluorescence imaging techniques use probes in the visible light 
spectrum (400-600nm). This is the main difference between the other two 
modalities.  
For example, transferrin receptor (TfR), which is a cell-membrane internalizing 
receptor mainly responsible for iron sequestration, is overexpressed in many head 
and neck tumors. The conjugation of the TfR antibody to Alexa-488 (excitation at 
494nm and emission at 519nm) has been used for non-invasive imaging of a head 
and neck tumor mouse model (80).  
Some disadvantages are associated with the use of the conventional fluorescence 
imaging in the visible light spectrum. First, there is a relatively low tumor-to-
background ratio, which is due to the relatively high-level of non-specific 
background. Additionally, there is another disadvantage related with the use of 
visible light: biological chromophores can limit the depth penetration of the light and 
increase the scattering of the light, such as hemoglobin. Kereweer et al have 
mentioned that the light properties of this spectrum are not sufficient to achieve the 
required sensitivity and specificity for image-guided surgery (77). 
1.3.2 Narrow band imaging (NBI) 
The narrow band imaging system has been developed to improve the quality of 
endoscopic images and to enhance the visualization of microvasculature on mucosal 
surfaces. NBI consists of a sequential electronic endoscope system and a light source 
unit equipped with narrow-band filters. The light source unit has a xenon lamp and a 
filter disk that is mounted with three interference filters (red:485-515nm, green:430-
460nm and blue:400-430nm filters). Longer wavelengths propagate more deeply, 
while shorter wavelengths propagate to the shallow region of the mucosa. The 
system takes advantage of the absorption peak of haemoglobin. Therefore, NBI can 
image the surface characteristics of mucosal tissue as well as vascular differences 
between tissues. In general, areas of non-dysplastic tissue have fine capillary 
patterns with normal size and distribution. Areas with high-grade dysplasia have an 
abnormal capillary pattern (increased number, size and dilation) (81).  
NBI has been investigated to guide head and neck cancer surgery. Orita et al used 
NBI to delineate intra-operative margins in a 62-year-old patient that underwent 
partial hypopharyngectomy. Based on the satisfactory results the authors 
hypothesized that this system could be used for intra-operative assessment of the 
resection margins (81). Another study, conducted by Tirelli et al, reported that NBI 
was used after macroscopic margin delineation. For this study, NBI showed a 
sensitivity of 100% and a specificity of approximately 88% (82). NBI has also been 
used in combination with transoral robotic surgery (TORS) to reduce the positive 
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margin rate. Vicini et al, has performed a retrospective study to compare the results 
obtained from 32 patients (that underwent TORS with intra-operative NBI 
evaluation) with the results of 21 patients (that underwent standard TORS with white 
light evaluation). The rate of negative superficial lateral margins in NBI-TORS 
group and the rate of the standard TORS group was 87.9% and 57.9%, respectively. 
In this study the specificity of NBI was 66.7% (83). Garafolo et al, compared a 
cohort of 82 patients that underwent cordectomies for laryngeal malignancy using 
lesion delineation with NBI and a cohort of patients that had a similar procedure but 
with standard microscopic evaluation during the surgery. Positive superficial 
margins were compared. The rate of positive margins for the cohort group that used 
NBI was 3.6%, while for the control group the rate of positive margins was 23.7% 
(84). 
In all the previous studies described the authors have concluded that NBI of head 
and neck lesions dramatically decreased the rate of final positive superficial margins. 
However, NBI specificity varies with the endoscopic magnification system used and 
with the experience of the clinician that is responsible for the analysis of the images 
(83,84).  
1.3.3 Confocal microscopy (CFM) 
Confocal microscopy is a method for non-invasive imaging of superficial soft 
tissues. The confocal microscope consists of a source of light that is focused to a 
small 3D illuminated spot, also called as voxel (within the tissue). The light from 
this voxel is collected by the detector (passing through a pinhole), which forms the 
pixel. To look at large areas or volumes of tissue, the voxel is scanned in two 
dimensions (optical sectioning). The optical sections are parallel to the tissue 
surface. Optical sections can be taken in depth by translating the microscope lens 
toward or away from the tissue. This technique allows imaging of sub-cellular 
structures (85,86). 
CFM has been extensively applied in the field of dermatology to determine the 
margins of skin lesions (87). Although some studies have evaluated the use of CFM 
for detection of oral malignancy, the application of this technique in head and neck 
oncology is still limited. The limitations are: CFM systems are expensive, there are 
relatively few experts trained in image interpretation for the oral mucosa, and the 
large size of the equipment limits imaging to certain areas in the mouth (88).  
1.3.4 High resolution microendoscopy (HRME) 
HRME is a non-invasive technique that uses a fluorescence microscope coupled to a 
flexible fiber optic probe. This imaging technology obtains images in real-time of 
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tissue that is topically stained with a fluorescent nuclear contrast agent (more 
commonly, 0.01% proflavine) (89,90). This technique allows the visualization of 
nuclear and cellular morphology, including: epithelial architecture, cell nuclear 
morphology of and nuclear size, nuclear-to-cytoplasm ratio, and nuclear dispersion. 
This device has been validated for detection of head and neck squamous cell 
carcinoma ex-vivo (sensitivity of 98% and specificity of 92%) (91). A clinical trial 
has reported the ability of HRME to distinguish benign from malignant tissue in 33 
patients with squamous cell carcinoma of the oral cavity. The mean accuracy of the 
trial was 95.1%, the mean sensitivity was 96% and the mean specificity was 95%. 
Although the authors of the clinical trial concluded that HRME had a high reliability 
to distinguish benign from malignant mucosa, they reported that some issues related 
to the image acquisition of inflammation, keratin debris, bleeding, and contrast 
artifacts happened. They also noted that there is a significant limitation of the 
technology, at the current time the technology is limited to a reduced surface 
imaging (50 µm) (20).  
1.3.5 Ultrasound imaging 
Ultrasonic systems are another non-invasive real-time technology. The basic 
principle of ultrasound is the use of pulse-echo approach with a brightness-mode 
display. This approach involves transmitting small pulses of ultrasound echo from a 
transducer into the body. The ultrasound waves penetrate the tissues with different 
acoustic impedances. Some waves are reflected back to the transducer (echo 
signals), others continue penetrating the tissue. Echo signals are processed and 
combined to generate an image. Therefore, an ultrasound transducer works as a 
speaker (generating sound waves) as well as a microphone (receiving sound waves). 
The ultrasound pulse can be also called as ultrasound beam (92).  
Ultrasonic systems have been used for the detection of tumor prior and during 
surgical resection. A study conducted by Yuen et al, used intraoral ultrasonography 
to document tumor thickness prior to resection. Results demonstrated that the 
accuracy of ultrasound in tumors from 3-15mm thick was >91%. Although the 
results were very promising, this study was performed as a pre-operative evaluation 
and not during the surgical procedure (93). Another study used ultrasonography 
prior to resection of T1-T2 tongue squamous cell carcinomas (tumor with <4 cm), 
who underwent a partial glossectomy (tongue resection). Histologic sectioning 
ultrasonographical tumor thickness was compared to the tumor histologic thickness 
and resulted a ratio of 91.4% to 98.2% (94). Tominaga et al, have used 
ultrasonography to control resection margins right after resecting the tumor. For the 
study the freshly excised specimen was immersed in a gelatine solution and 
ultrasound measurements were performed. An excellent correlation of the depth of 
the tumor measured with the ultrasound and the histologic depth of the tumor was 
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reported. This study demonstrated that the method allows a real-time assessment of 
adequacy of the resection margins (95). Also, Baek et al reported that intraoral 
ultrasonography in patients with T1-T2 tongue squamous cell carcinoma resulted in 
a more adequate deep margin when compared with conventional resection, which is 
only based in palpation and visual inspection (96). 
Although, these studies illustrate the real advantage of the ultrasound imaging for 
assessment/control of the resection margins to ensure adequate deep margin 
resection, this technique is associated to some limitations. The effectiveness and 
accuracy of the technique relies on the experience and skill of the operator for image 
interpretation (93-96).  
1.3.6 Optical coherence tomography (OCT) 
OCT is a non-invasive imaging technology that has been used extensively in a 
variety of applications in the medical field. This technology is a light interference-
based optical technique that allows 3D across sectional imaging within biological 
samples. The spatial resolution of this technique is high (1-15µm). Therefore, this 
technique is used to perform high-resolution cross-sectional imaging of the 
microstructure of tissues by measuring the echo time delay and magnitude of 
backscattered light. OCT is analogous to ultrasound imaging however, high image 
resolutions can be achieved in the OCT case. In an OCT system the light (low-
coherence source) is split into two paths by a coupler. The couplers direct the light 
along two different arms of an interferometer. One arm is the reference and the other 
is the sample arm. The light that exits both arms are shaped by several optical 
components (mirror, lenses, etc.). These components control specific beam 
parameters, such as depth of focus and the intensity distribution of the light. The 
light is back-reflected by the reference arm, into the interference system, 
propagating along the same path but in the opposite direction. The same happens in 
the sample arm, but in this case the beam is backscattered by the sample. Different 
structures within the sample will have different indices of refraction. The returning 
light is recombined at the coupler and generates an interference pattern. This pattern 
is recorded by the detector. The translation of the mirror along the propagation 
direction of the light generates interference patterns from different depths within the 
sample. The OCT signal recorded during complete travel of the reference mirror is 
called the depth scan (97). 
OCT has been used in intra-operative margin detection of cutaneous, vulvar, breast 
and gastro-intestinal malignancy. This technique has also been investigated for 
detection and diagnostic applications in the head and neck (larynx, oral), however, 
there are not that many studies that show the ability of OCT to intra-operatively 
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assess resection margins from the head and neck region. Hamdoon et al, has used 
OCT for intra-operative margin evaluation of patients with T1 and T2 (N0M0) oral 
cavity squamous cell carcinoma (N=28). The margins were evaluated with OCT and, 
after, confirmed by histopathology. OCT had an overall sensitivity and specificity of 
81.5% and 87%, respectively. The positive predictive value was 61.5% and the 
negative predictive value was 95%. The positive margins could be identified by 
architectural changes and an increase of the epithelial layer thickness, as mentioned 
by the authors (98). 
The studies demonstrated that with OCT the positive superficial margins (mucosa) 
could be identified however, the use of OCT-technology is limited. The OCT image 
can be affected by the lack of normal tissue perfusion. This means that the resolution 
and contrast of the OCT images are influenced by the "ex-vivo nature" of the 
approach. Moreover, as HRME, OCT has the disadvantage that it requires 
complicated subjective image-interpretation (97,98). 
1.3.7 Raman spectroscopy 
Raman spectroscopy is the optical technique that was investigated for intra-operative 
evaluation of the OCSCC surgical margins in this thesis. Raman spectroscopy is an 
objective technique based on inelastic scattering of monochromatic light that 
provides detailed quantitative and qualitative information about the molecular 
composition of tissue. The technique is non-destructive and there is no need for 
reagents or labelling, which promotes easy translation to the clinics (76,99-102). 
This technique can be applied to assess the mucosa, as well as, the deep soft tissue 
layers (61-66). 
In 2015, Cals et al have investigated the potential of Raman spectroscopy for oral 
cancer detection in surgical margins. They have acquired 88 spectra from tumor and 
632 spectra from healthy surrounding tissue. Linear discriminant analysis was used 
to create classification models that could distinguish tumor from adipose tissue, 
nerve, muscle, gland, connective tissue and squamous epithelium in 100%, 100%, 
97%, 94%, 93%, and 75% of the cases, respectively. This study showed how well 
Raman spectroscopy enables discrimination between tumor and surrounding healthy 
tissue structures (21).  
In 2016, Cals et al have reported that with a 2-step PCA-LDA model tongue 
squamous cell carcinoma could be discriminated from healthy tissue with a 
sensitivity of 100% and a specificity of 78% (102).  
To better understand what is Raman spectroscopy and when was for the first time 
found the Raman effect, the history and Raman instrumentation is below described. 
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Raman effect 
The Raman effect results from the interaction of the light with molecules through 
inelastic scattering of light (optical effect). Light can interact with molecules in three 
different ways: absorption, elastic scattering and inelastic scattering (76). Only a 
small part of the incident photons undergoes inelastic scattering, about 1 in a million 
to 1 in a 100 million (99). In the Raman scattering process, the incident light 
transfers energy to the illuminated molecules, which causes frequency shifts in the 
light that is scattered.  
The energy of the scattered photon can either increase or decrease. If the photon 
transfers energy to a molecule, the frequency of the light decreases, and the 
wavelength increases (Stokes inelastic scattering). If the molecule transfers energy 
to the photon, the frequency of the light increases, and the wavelength of the 
scattered light will be shorter than the wavelength of the incident light (anti-Stokes 
inelastic scattering) (100).  
The molecule only transfers energy to photon if it is already in an excited vibrational 
state, which is rare at room temperature. Therefore, Stokes scattering has higher 
signal than anti-Stokes scattering, and is mostly used for Raman spectroscopy 
applications (101). 
The change between initial and final energy of the molecule is called the Raman 
shift, and is given by: 
    
 
  
 
 
  
      (1.2.1.1)  
where    is the Raman shift (cm-1),    is the initial photon wavelength (nm), and    
is the final photon wavelength after a scattering event (nm). Raman shifts are 
typically expressed in relative wavenumbers (cm-1).  
The energy needed to excite a molecular vibration is quantified and depends on the 
mass and strength of the chemical bonds between the atoms of that specific 
molecule. The chemical bonds behave like springs that can stretch and bend (76). 
There are different vibrational modes, such as: asymmetric and symmetric 
stretching, rocking (atoms remain in the same plane), wagging, scissoring and 
twisting, see figure 3.  
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Figure 3. Some examples of molecular vibration modes. 
Stretching modes change the chemical bond length. Rocking, wagging, and twisting 
modes change the angle of the chemical bonds. The independent number of 
vibrational modes, also known as normal modes, can be given by 
                       
                           
                                
  
(1.2.1.2)  
where   is the number of atoms in the molecules. Every atom inside a molecule, 
contributing to a specific normal mode, vibrates with a certain frequency, the 
frequency of the normal mode (76). This frequency depends on the mass of the 
atoms. Two molecules only have the same normal modes if they are identical. A 
Raman spectrum of a molecule shows the intensity of all possible vibrations as a 
function of the Raman shift. Even though two different molecules can have 
completely different Raman spectra caused by their composition, if they have some 
chemical groups in common, the Raman signal will present peaks at identical Raman 
shifts, but with different intensity. This means that the molecules can be identified 
by their vibrational properties and that the inelastic scattering of a molecule is highly 
specific (76).  
Therefore, Raman spectroscopy is a quantitative technique: a Raman spectrum of a 
sample with different (non-interacting) molecules is a linear superposition of the 
spectra of the all individual molecules in their relative concentrations. A Raman 
spectrum of a tissue sample is a very complex spectrum, reflecting all different 
molecules (and their interactions) that are present. Therefore, a tissue spectrum is 
very specific and can be regarded as an optical fingerprint of the tissue. Slight 
changes in a tissue, induced by a disease, will lead to changes in the tissue spectrum, 
and therefore, tissue Raman spectra can be used to discriminate between healthy and 
diseased tissue (76). 
The Raman spectrum is often divided in two major regions: the fingerprint region 
with wavenumbers ranging from about 200 cm-1 to 2000 cm-1, and the high-
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wavenumber region with wavenumbers ranging from about 2400 cm-1 up to 4000 
cm-1. The fingerprint region is very rich in spectroscopic information. The high-
wavenumber region contains mainly information on the CH-, OH- and NH-
stretching vibrations (76).  
For this thesis the focus of study was the high-wavenumber region. The interest for 
using high-wavenumber Raman spectroscopy in-vivo and/or ex-vivo has increased 
in the last years. A study by Koljenović et al. showed that, for discriminating cancer 
from healthy tissue, essentially the same diagnostic information is obtained in either 
of the two spectral regions (fingerprint or high-wavenumber) (103). Raman 
spectroscopy in the high-wavenumber region demonstrates significant advantages 
for ex-vivo and in-vivo use when compared to the commonly used fingerprint 
region. The intensity of the signal in the high-wavenumber region is higher than in 
the fingerprint region, and measurements can be performed in shorter integrations 
times. Additionally, fiber-optic materials like fused silica do not have Raman signal 
at the high-wavenumber region of the Raman spectrum (103). This enables the use of 
simple and cheap single fiber optic probes that can be easily inserted in endoscopes 
and/or needles to perform in-vivo measurements in hollow organs or surface 
assessment of solid organs such as oral cavity (104,105), lung (106,107), upper 
gastrointestinal tract (108-110) and colorectal (111,112).   
History of Raman spectroscopy 
The first experimental evidence of the Raman effect was reported in the afternoon of 
28 February 1928 by Raman (Sir Chandrasekhara Venkata Raman) and Krishnan 
(Sir Kariamanickam Srinivasa Krishnan), see figure 4. They examined the scattered 
track through a direct vision spectroscope, using a narrow range of transmission of 
the incident radiation. They discovered that there was a wavelength shift between 
the scattered light and the incident light (101,113). 
 
Figure 4. Portraits of C. V. Raman and K. S. Krishnan. 
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This work was addressed as ‘New Radiation’ and it was given to South India 
Science Association at Bangalore on 16 March 1928 (101,113). The effect became 
known as the ‘Raman effect’. The first line of a spectrum, which was first seen on 28 
February 1928 was given publicity on the following day through the Associated 
Press of India. Raman published the results in a letter sent to Nature on 8 March 
1928, appearing on 21 April 1928 (114). It is said that the referee had rejected the 
letter but that the Editor of Nature (Sir Richard Gregory) took the responsibility on 
publishing this letter. To give maximal publicity to his discovery, Raman, after 
publication of his historical paper in the Indian Journal of Physics, obtained 2000 
reprints of his article and posted them to all the relevant physicists that at the time 
were working on the scattering of light, and to scientific institutions all over the 
world (101). 
In 1930, Professor Raman was awarded with the Nobel Prize for physics, and with 
the Hughes Medal of the Royal Society of England.  
Raman spectroscopy started to be used for biological samples after the invention of 
the laser, in 1960 (115). Ten years after that, charge coupled devices (CCD) were 
developed. This invention was a major development in the use of Raman 
spectroscopy, because it allowed collection of a full spectrum at once, and 
tremendously decreased the time needed for collection of a high-quality spectrum 
(116).  
In 1990, Puppels combined Raman spectroscopy with confocal microscopy. For the 
first time it was possible to perform Raman spectroscopy inside cells and distinguish 
different cellular structures (117).   
Thanks to the microcomputer revolution, multivariate statistical analysis of Raman 
spectra can be applied in real time for extracting the relevant information that is 
present in the spectra. This has helped Raman spectroscopy to become a powerful 
analytical technique that can be used for many diagnostic applications.  
More recently, fiber-optic probes have enabled the use of Raman spectroscopy for 
in-vivo biomedical applications. The integration of Raman spectroscopy with other 
diagnostic techniques has been reported as a major step towards the development of 
clinical applications, such as biopsy guidance and early cancer diagnosis. An 
example of this integration is the insertion of fiber probes into endoscopic channels, 
which enabled in-vivo measurements in hollow organs or surface assessment of 
solid organs: oral cavity (118,119), lung (120,121), upper gastrointestinal tract 
(37,122-126), colorectal (127,128), bladder (129), and cervical cancers (130-134). In 
the last years, several Raman probes have been designed for specific clinical targets, 
such as the specific pathophysiology of the disease, and the specific anatomy of the 
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region of interest, by optimizing e.g. the accessibility of the tissue, sample size, and 
sampling depth (1,134). 
Raman Instrumentation 
A Raman system typically consists of four major components. These are an 
excitation source, illumination/collection optical system, a wavelength 
separator/filter and a detector.  
The excitation source should be monochromatic. Because a laser has a small 
bandwidth compared to other types of light source, it is a proper choice for a 
monochromatic light source. The choice of laser wavelength depends on the Raman 
region of interest.  
Illumination of the tissue sample and collection of the Raman scattered light can be 
achieved by using a lens system (e.g. a microscope) or optical ﬁbers. An optical ﬁber 
is a very thin a circular waveguide for light that can be used to make thin Raman 
probes for accessing vary parts of the body that otherwise cannot be reached. One 
ﬁber or multiple fibers can be used for both illuminating and collection. The 
(fraction of the) scattered light that is collected is directed to the spectrometer, where 
the collected light is dispersed, mostly using a diffraction or transmission grating.  
 
Figure 5. The absorption spectra of main human tissue light absorbers: water and 
hemoglobin (Hb and HbO2). Raman signal window is marked with pink (800-920 nm). 
Biological tissues have very low absorption in the Raman signal window presented (with 
exception of melanin). 
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The grating acts as a wavelength separator, because it diffracts photons with 
different wavelengths under different angles. The dispersed light is then focused on 
a multichannel detector, which is in most cases a CCD (Charge Coupled Device), 
but also other types are used such as a photodiode arrays, CMOS detectors, and 
InGaAs detectors. For this thesis the Raman region of interest is the high-
wavenumber region (wavenumbers ranging from about 2400 cm-1 up to 4000 cm-1). 
The laser selected has an excitation wavelength of 671 nm. For the measurements 
described in this thesis, both, a microscope and optical fibers were used for 
illumination and collection of light. The separator/filter allowed the collection of 
Raman signal in the range 800-920 nm. The characteristics of the setup guarantee 
minimal absorption of the light by water and hemoglobin (HbO2 and Hb), as shown 
in the figure 5. These substances are in abundance in the human body. 
 
1.4 This thesis 
The goal of this thesis was to investigate how high-wavenumber Raman 
spectroscopy can be used as an IOG tool for assessment of soft tissue and bone 
resection margins in head and neck surgical oncology. 
In chapter 2, a review on the oncological Raman spectroscopy applications 
developed in the last 10 years is presented. The published Raman studies aim to: 
detect pre-malignant lesions, detect cancer in less invasive stages, reduce the number 
of unnecessary biopsies and guide the surgery towards the complete removal of the 
tumor with adequate resection margins. Also, in chapter 2, the actual clinical needs 
in oncology that can be, and are being, addressed by Raman spectroscopy are 
summarized. Moreover, the status and the main hurdles of translation of these 
applications into clinical practice are discussed.  
In chapter 3, the potential of high-wavenumber Raman spectroscopy to distinguish 
tumor from the healthy soft tissue of ex-vivo tongue resection specimens from 
patients that underwent surgical treatment for squamous cell carcinoma of the oral 
cavity was investigated using a confocal Raman microscope. Based on water 
concentration, calculated using the high-wavenumber Raman spectra, tumor and 
healthy tongue tissue could be discriminated with high sensitivity and specificity. 
Based on the experience acquired during the experiments performed in chapter 3, it 
was noted that, even though the high-wavenumber region shows less tissue 
luminescence than the fingerprint region, the luminescence signal can still be orders 
of magnitude stronger than the Raman signal. There are not many software solutions 
to remove luminescence background in the high-wavenumber region. Therefore, in 
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chapter 4, the luminescence background signals of ex-vivo high-wavenumber region 
spectra of oral tissue were characterized, and the performance of two algorithms for 
correction of these background signals were compared. This was a major step 
towards a selection of the best method for non-supervised and automatic correction 
of fluorescence background signals. 
In chapter 5, the difference in water concentration found between tumor and healthy 
surrounding tissue (chapter 3) was used to localize the border in soft tissue of oral 
cavity squamous cell carcinoma specimens. In chapter 5, The usefulness of high-
wavenumber Raman spectroscopy as an objective tool for assessment of the 
resection margins in oral cavity squamous cell carcinoma specimens was 
demonstrated.  
In chapter 6, the potential of high-wavenumber Raman spectroscopy for detection of 
OCSCC in bone resection surfaces during mandibulectomy was investigated. This 
chapter is a crucial step towards the use of Raman spectroscopy not only for intra-
operative assessment of soft tissue resection margins, but also for bone resection 
margins. 
In chapter 7, the first steps toward the development of IOG Raman tool for assessing 
the entire tumor resection surface are shown. The IOG Raman tool uses a single-
fiber-optic needle probe for discriminating oral cavity squamous cell carcinoma 
from healthy tissue based on water concentration. The IOG Raman needle probe can 
be used to inspect the resection surface and the deep tissue layers, which may allow 
an oncological radical surgery and thereby improvement of patient outcome. 
Chapter 8 contains a general discussion and the future perspectives of the application 
of the IOG Raman tool for assessment of the resection margins in OCSCC. 
In chapter 9, a summary of this thesis is presented. 
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Abstract 
Oncological applications of Raman spectroscopy have been contemplated, pursued, 
and developed at academic level for at least 25 years. Published studies aim to detect 
pre-malignant lesions, detect cancer in less invasive stages, reduce the number of 
unnecessary biopsies and guide surgery towards the complete removal of the tumor 
with adequate tumor resection margins. This review summarizes actual clinical 
needs in oncology that can be addressed by spontaneous Raman spectroscopy and it 
provides an overview over the results that have been published between 2007 and 
2017. An analysis is made of the current status of translation of these results into 
clinical practice. Despite many promising results, most of the applications addressed 
in scientific studies are still far from clinical adoption and commercialization. The 
main hurdles are identified, which need to be overcome to ensure that in the near 
future we will see the first Raman spectroscopy-based solutions being used in 
routine oncologic diagnostic and surgical procedures.  
General introduction 
In 2012 the World Health Organization (WHO) reported 14.1 million new cancer 
cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 
years of diagnosis). These numbers are increasing, which motivates development of 
cancer treatment possibilities and technology for early detection of (pre-) 
malignancies (1). The high mortality rate of cancer can be reduced by early and 
accurate diagnosis, and by adequate surgical treatment (2). The reference standard 
for cancer diagnosis is histopathologic assessment of biopsies or diagnostic 
excisions of suspicious tissue. After biopsy/excision the tissue specimen is fixed, 
micro-sectioned and routinely stained with haematoxylin and eosin (H&E). The 
pathologist makes a diagnosis based on microscopic examination of the H&E 
stained section. Because only small portions of the lesional tissue are biopsied or 
excised for histopathological examination, there is the risk of sampling error and the 
pathology report remains a subjective assessment (with its inter and intra operator 
variability) (3). Studies have demonstrated that most tumor types develop through 
pre-malignant stages (4,5). Therefore, the treatment of premalignant tissue can 
prevent the further development of cancer. Because the distinction between early-
stage malignant, premalignant and benign tumors can be difficult to make, repeated 
biopsies/excisions are often taken. For sampling of tissue, literature reports positive 
predictive values as low as 22% for prostate cancer diagnosis (6), 14% for breast 
cancer (7), 18.5% in lung cancer screenings (8) and 7-23% for melanoma diagnosis 
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(9). Despite the risk of these unnecessary biopsies/excisions, a substantial number of 
early stage tumors are still missed, which increases the risk of progression to a 
metastatic stage.   
Introduction – early diagnosis/guided biopsy 
A technique that helps to achieve representative biopsies and that would enable 
accurate and early in-vivo diagnosis is needed. This tool should detect lesions in pre-
malignant/early stages and assess large tissue areas in real-time to decrease sampling 
errors. Several techniques have been tested for biopsy guidance, such as optical 
coherence tomography (OCT), white light reflectance (WLR), auto-fluorescence and 
Raman spectroscopy (10–14). OCT and WLR rely on the visualization of changes in 
tissue structure. These techniques provide little or no information about the 
molecular tissue composition and, therefore, generally have a low specificity 
(10,12).  Auto-fluorescence imaging is an optical technique that detects natural 
fluorescence emitted by fluorophores present in the tissues (e.g. flavins, collagen or 
hemoglobin), after excitation by a short-wavelength light source. This emission can 
be captured in real-time, for example during endoscopy, and can be used for lesion 
detection or characterization (13,14). Auto-fluorescence imaging has shown to 
improve the sensitivity of detection of early cancer, like epithelial neoplasia in 
esophagus and colon (sensitivities are 90% and 99%, respectively) (14). It also 
improves the diagnostic sensitivity (from 67% to 89%) for pre-malignant stages of 
lung cancer (e.g., dysplasia and carcinoma in situ). It also improves the diagnostic 
sensitivity compared to white-light endoscopic imaging (from 67% to 89%) for pre-
malignant stages of lung cancer. However, the specificity of this technique is low; a 
specificity of 64% for diagnosing pre-malignant stages of lung cancer, a specificity 
of 81% for detecting high-grade dysplasia and early cancer in Barrett's esophagus 
and a specificity of 35% for detection of pre-malignant colon polyps were reported 
(14-16). Optical vibrational spectroscopic techniques, such as Raman spectroscopy 
(RS), can provide high molecular specificity. The gradual changes from healthy 
tissue to tumor are reflected by their Raman spectra (2,17–19). Raman spectroscopy 
is a technique for characterizing biological tissue in-vivo, ex-vivo or in-vitro and for 
non-invasive detection of the molecular differences between tumor and healthy 
tissue. It does not require any labelling, reagents or other preparation of the tissue, 
which facilitates translation to the clinic. With the use of optical fibers many 
anatomical locations can be assessed in-vivo (20). Raman spectroscopy–based 
biopsy guidance can reduce the number of false positive biopsies and increase the 
accuracy of cancer diagnosis, with reported overall sensitivities and specificities 
between 73% - 100% and 66% - 100%, respectively (18,21). 
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 Introduction – guided surgery  
After diagnosis the primary treatment for solid tumors is often surgery. The 
objective of surgical treatment is resection of all malignant tissue with adequate 
resection margins while preserving important healthy structures. Achieving adequate 
surgical margins is important for disease control and survival. Residual tumor after 
surgery is associated with poor survival and the need for additional surgery, adjuvant 
chemotherapy, radiation therapy, or a combination of these (22–25). A number of 
studies have shown that the 5-year survival decreases significantly when tumor is 
not completely removed (22–25). Intra-operative guidance tools can help to achieve 
adequate surgery. However, there are no widely used intra-operative guidance tools 
available yet. Current surgical resection techniques are based on subjective methods, 
such as palpation and visual inspection, to judge the border between normal and 
cancerous tissue. In order to support the intra-operative assessment of resection 
margins, frozen sections can be used (26–28). A small piece of suspicious tissue is 
usually sampled from the wound bed (i.e. wound-driven assessment) by the surgeon.  
A microscopic evaluation of the frozen section is performed by the pathologist, 
directing operative management (28). It has been reported that the frozen section 
procedure increases the rate of adequate resections and thereby decreases local 
recurrence and improves the survival rate (29). Even though this procedure is 
successful for intra-operative assessment of the resection margins, it has its 
limitations: 1) it is time consuming, extending the duration of surgery and anesthesia 
(30); 2) it is likely prone to sampling errors because only a small fraction of the 
resection margin can be investigated, and 3) it can introduce histologic disruption 
caused by rapid freezing, which makes the analysis more difficult (31). Rosenthal et 
al, reported that at most 5% to 10% of the wound bed can be sampled and assessed 
with frozen section (32). These limitations can lead to false negative results 
(23,27,33–35). Consequently, there is much room for improvement in performing 
intra-operative assessment of the resection margins.  In order to guide oncological 
surgery, techniques like intra-operative real-time MRI, intra-operative ultrasound, 
intra-operative OCT, fluorescence and Raman spectroscopy have been investigated 
in operating room environments.   
Real-time intra-operative MRI has been tested during surgical resection of brain 
cancer (i.e. glioma). Several studies have demonstrated that this modality can be 
used for surgery guidance and improves the extent of the tumor resection without 
increasing neurological deficits. This also has a positive impact on survival (36–42). 
Some drawbacks of intra-operative MRI include: 1) operative defects that can affect 
the MRI image and decrease its accuracy (43); 2) interpretation of the image by the 
surgeon and his capability to correlate the location of the lesion to the brain anatomy 
(17,43); 3) significant surgical disruptions that prolong the operation time; 4) it 
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requires a considerable investment to implement MRI-capable operating rooms; and 
5) there is a need for contrast agents (43).   
Intra-operative ultrasound has been used to localize the tumor, guide the resection 
especially among highly vascular tumors (breast, e.g.), using probes that enhance 
contrast (43,44). However, it is less sensitive for tumor margins and has shown 
lower resolution and accuracy compared to intra-operative MRI. Besides, its 
accuracy is affected by previous surgery, as almost any imaging modality (43,45). A 
portable label-free optical coherent tomography (OCT) imaging system has been 
tested intra-operatively to assess breast resection margins and lymph nodes ex-vivo 
(46). The study showed promising results for real-time microscopic image-guide 
breast cancer surgery.  Structural-based imaging techniques (like OCT and intra-
operative MRI) show promising results. Unfortunately, they lack chemical disease-
specific information, which is essential for adequate tumor removal.   
Fluorescence imaging is another technique that has been applied to assess surgical 
resection margins. The technique requires administration of fluorescence agents and 
is based on the detection of fluorescently labelled structures during surgery. Various 
studies have reported that complete resection was achieved in a significantly higher 
percentage when fluorescence imaging was used, as compared to only regular white 
light (47–50). The major disadvantages of fluorescence imaging are: 1) the need for 
fluorescence agents, and 2) the need to switch off the room lighting to maximize the 
detection of the weak fluorescence (46). In addition, translational problems have 
been identified, related to the need of consistent manufacturing, to costs related with 
toxicology studies, and to the strict procedures for submission of a new 
investigational drug (51). An interesting alternative would be a label-free imaging 
method, which avoids the risks associated with dye/drug reactions and the 
challenges associated with specific tumor targeting and non-specific binding.   
Raman spectroscopy has also been implemented to guide oncological surgery. 
Several studies have demonstrated that this technique can be used for surgical 
guidance. For example, in brain cancer surgery, an intra-operative Raman system 
that measures directly brain tissue in the patient, has proven to distinguish dense and 
low-density cancer infiltration from benign brain tissue with a sensitivity of 93% and 
a specificity of 91% (52). In another study, a real-time Raman intra-operative system 
was used during breast cancer surgery for assessment of freshly resected specimens. 
This study has demonstrated that Raman spectroscopy could discriminate cancerous 
tissue from normal breast tissue with a sensitivity of 83% and a specificity of 93% 
(53).  Implementing Raman spectroscopy in the clinical setting can have important 
benefits: 1) it can enable representative sampling for correct pathological diagnosis 
(biopsy guidance); 2) it can accurately assist in defining adequate resection margins 
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during surgery; 3) it can reduce the sampling problem, during intra-operative 
assessment; 4) it can introduce a more objective assessment and 5) it can reduce the 
need for adjuvant therapies (20).  In the last years, several review articles reported 
the advances of Raman spectroscopy with the ultimate goal the clinical application 
for cancer diagnosis in different anatomical locations (17,18,20,21,54–57). In these 
reviews the latest developments of technology adaptations for Raman cancer 
diagnostic applications are described. The latest clinical outcomes of Raman 
spectroscopy on (early) cancer detection at different sites in-vitro, ex-vivo and in-
vivo have been also reported. However, specifically the translation of Raman 
spectroscopic developments into oncological applications has not been addressed 
extensively before. 
The scope of this article is to provide an analysis of the translation of R&D results, 
obtained in oncological applications of Raman spectroscopy, into clinical practice. 
We discuss problems that still need to be solved in order to bring the technique 
successfully to the end-users in the hospital setting. The importance of defining the 
clinical needs and requirements, for different applications, is also explored in this 
review. We have limited our review to spontaneous Raman spectroscopy 
applications on ex-vivo and/or in-vivo human tissue samples. We refer to the other 
recent review articles for biomedical applications of non-linear Raman spectroscopy, 
such as coherent and surface-enhanced Raman scattering (55,58,59).  
 
Methods  
 Literature search   
A search was carried out using the Web of ScienceTM library. Web of ScienceTM 
comprises the following databases: Web of ScienceTM Core Collection, KCI-
Korean Journal Database, MEDLINE, Russian Science Citation Index and SciELO 
Citation INdex. For research articles the included period was from 2006 to 2017. For 
review articles the included period was from 2011 to 2017. The date of the final 
search was on 16th of January 2017. The search filter comprehended a combination 
of the keyword “Raman” with two of the following keywords: "tumo(u)r", "patient", 
"biopsy", "carcinoma", "assessment", "intra-operative", "cancer", "guidance", 
"surgery", "human", "diagnostics" and "translation". These keywords were searched 
as a topic in the article. Articles that had at least three of the topic words were 
considered for inclusion. Commentaries and opinion articles were excluded. 
Furthermore, studies on non-human samples and performed in-vitro were not 
selected. Studies that used non-linear Raman spectroscopy were excluded. 
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Cytological screening methods based on Raman Spectroscopy are also being 
developed (60,61), however to limit the scope we have chosen not to include such 
studies in this review. Articles that were not written in English were also discarded.  
  Definition of the clinical need  
The clinical needs (clinical problems and their relevance) that could be solved by 
Raman spectroscopy applications were defined per cancer type as reported by the 
studies selected in this review. Furthermore, the information on clinical needs from 
current (inter)national guidelines and clinical articles (PubMed) were included. For 
clinical articles the included period from 1990 to 2017 was regarded. Moreover, 
opinion from pathologists and surgeons was obtained based on personal interviews.  
During the interviews clinical needs for other types of cancer than those addressed in 
the included studies were identified and discussed.  
  Raman spectroscopy applications  
All the eligible Raman application studies were included, regardless the cancer type 
addressed. The included studies were divided considering two major oncological 
applications of Raman spectroscopy: (A) biopsy guidance/early diagnosis and (B) 
surgery guidance.   
 Progress of the companies  
To address the progress of the companies that are developing/ have developed 
commercial Raman spectroscopy oncological applications towards implementation 
in the clinics, we have contacted leading companies in Raman spectroscopy to 
collect information. The contacted companies were: Tokyo Instruments Inc., 
Princeton Instruments Inc., Verisante Inc., ODS Medical Inc., Endofotonics Pte. 
Ltd., RiverD International B.V., EmVision LLC, Invenio Imaging Inc., Artphotonics 
GmbH., Carl Zeiss GmbH., Kaiser Optical systems Inc., Lambda solutions Inc., 
Horiba Jobin-Yvon Inc., B&W Tek Inc., Snowy Range instruments Inc., Wasatch 
Photonics Inc., Witec GmbH., Avantes B.V., Photonetc Inc. and Renishaw Plc.. A 
questionnaire was sent to the companies with the following questions: 1) “Are you 
actively developing or collaborating in the development of oncological Raman in-
vivo and/or ex-vivo tools for the clinics?”; 2) “Can you indicate what is the 
application?”; 3) “Do you have any scientific publication, or can you share with us 
more information about the subject?”; 4) “When do you think that it will be 
available in the market? What is the prognosis?”, and 5) “About the translation to 
the clinics, what hurdles have you encountered?”.  
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 Technology readiness level (TRL) classification of the 
studies  
In order to provide an overview of the current status of the technology towards 
clinical translation we classified all the included studies based on the Technology 
Readiness Level (TRL).  The TRL is an index used to measure the maturity and 
usability of an evolving technology (62). There are 10 levels (TRL 0 to TRL 9): at 
TRL 0 there is just an idea, but the concept is not yet proven or not yet tested; TRL 1 
is related to basic research, when the principles are observed and postulated, but not 
experimentally proven; TRL 2 is associated with technology development, when the 
concept and application have been formulated; TRL 3 consists of applied research/ 
proof of concept, when the first laboratory tests are completed; at TRL 4 a small 
scale prototype has been realized, which is still working in a laboratory 
environment; at TRL 5 the prototype has been tested in intended environment; at 
TRL 6 the prototype system has been tested in the intended environment close to the 
expected performance; at TRL 7 use of the system has been demonstrated in an 
operational environment at a precommercial scale; TRL 8 is characterized by the 
first version of a commercial system, when manufacturing issues are solved; finally, 
at TRL 9, the technology is available for end users.  We have grouped the TRL 
levels of the Raman applications into 4 main categories: (A) the proof of concept has 
been tested in the laboratory (TLR 0-3), (B) first hardware and software have been 
developed, including the algorithms for detection of (pre-) malignant lesions, and 
experiments have been performed close to the intended environment (TLR 4), (C) 
the developed hardware and software were tested with an independent dataset in the 
intended environment and preferably at different centers (TLR 5-7), and (D) the first 
of a kind commercial system(s) are/will be available soon for end users (TLR 8-9).  
 
Results 
 Clinical need and Raman applications  
Definition of the clinical need. Prior to the development of technological tools 
aiming to improve diagnosis and/or treatment of cancer, it is important to define the 
actual clinical needs, because various clinical problems have different needs and 
solutions.  Currently, two main oncological clinical needs, which could be fulfilled 
by Raman spectroscopy, have been identified: (A) diagnostic tools for biopsy 
guidance for early diagnosis of (pre-) malignant, and (B) tools for surgery guidance, 
which can be used for intra-operative assessment of resection margins to achieve 
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adequate tumor resection.  In this section we review several clinical problems in the 
process of diagnosis and surgical treatment of cancer.   
Literature search for Raman spectroscopy applications. Raman 
spectroscopy has been explored for oncological applications in numerous studies, 
employing various types of measurement systems, and targeting various types of 
cancers. This section also provides a review of the use of Raman spectroscopy ex-
vivo and in-vivo for early diagnosis, biopsy guidance and surgery guidance of 
different types of cancer. Based on the search terms, 42 research papers on 
oncological applications of Raman spectroscopy were included. From those, 36 
studies regarded early diagnosis and biopsy guidance applications and 6 studies 
regarded surgery guidance applications.  
 Breast Cancer  
Clinical need: The second leading cause of cancer-related deaths in women 
worldwide is breast cancer with a worldwide incidence rate of more than 1,670,000 
and a mortality rate of 522,000 (1). Presently, screening mammography is used to 
identify breast lesions. When suspicious lesions are found histopathological 
diagnosis is the next step, based on fine-needle aspiration cytology and/or 
histological biopsy (63). High sensitivity for fine-needle aspiration cytology (82-
99.7%) and for biopsy (90.1-93%) is reported (64-68).  The treatment of choice for 
ductal carcinoma in situ and early stage invasive cancer is breast conserving surgery. 
The surgery aims to preserve as much healthy tissue as possible while achieving 
negative resection margins (69). This procedure is performed in 58-70% of the 
patients (70,71). As a standard of treatment, patients receive adjuvant radiotherapy 
after surgery. In the Netherlands, resection margins are considered adequate when 
‘no tumor touches ink’ (72). Concerning pure DCIS resection margins of 2 mm are 
considered adequate. It is proven that patients with more than focal tumor positive 
resection margins have higher risk of developing recurrent disease (73,74).  When 
final histopathology shows a more than focal positive margin (concerning pure 
ductal carcinoma in situ) an additional resection is performed. Reresection rates 
varying between 7%-73% have been reported by different institutes (73). Therefore, 
an intra-operative guidance with an objective and rapid tool is needed to achieve 
high adequate resection rates.  
Raman applications for early diagnosis/biopsy guidance: Saha et al, 
developed a Raman spectroscopic tool for detecting microcalcifications, as an 
adverse sign, in breast tissue. An ex-vivo study was conducted, and Raman spectra 
were acquired in fresh stereotactic breast needle biopsies from 33 patients using a 
portable compact clinical multi-fiber Raman spectroscopy probe system. This first 
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study resulted in a positive predictive value of 97% for detecting microcalcifications, 
demonstrating potential of Raman spectroscopy as real-time feedback tool for 
radiologists and to reduce unnecessary biopsies (75).   
Raman applications for surgery guidance: Barman et al, looked at the 
utility of Raman spectroscopy as a guidance tool for mastectomy procedures. 
Spectra were acquired ex-vivo on freshly excised specimen from a total of 33 
patients. The Raman instrument was a portable clinical fiber probe system. A 
classification algorithm was developed to differentiate breast cancer from healthy 
tissue. The reported sensitivity was 62.5% with a specificity of 100%. The accuracy 
obtained for differentiation between normal, fibrocystic change, fibroadenoma, and 
breast cancer was 82.2% (76).   
 Skin Cancer   
Clinical Need: The clinical diagnosis of skin cancer is conventionally based on 
visual inspection of morphologic characteristics of the lesions, usually supported by 
a dermoscope. This manner of diagnosing cancer is subjective and largely depends 
on the experience of the clinician.   
Keratinocytic cancers: Keratinocytic cancers, such as the basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC), are two of the most common cancers in 
fair-skinned populations (77). Only in the United Stated of America, about 3 million 
people are diagnosed with keratinocytic cancers per year.  Although keratinocytic 
cancers are associated with low mortality rates both, BCC and SCC, can destruct 
surrounding tissue, recur and/or metastasize (78).  SCC can be locally aggressive, 
difficult to treat and it is associated with a 0.5% - 5% risk of metastasis. An effective 
management can be challenging in cases of patients with multiple lesions, or patients 
that in the past were diagnosed with keratinocytic cancers, demonstrating the need 
for early diagnosis (79).   Standard type of treatment for keratinocytic cancers is 
complete removal of the lesion by 1) standard surgical excision or 2) Mohs 
micrographic surgery (MMS). In standard surgical excision, resection margins are 
examined by the pathologist after the procedure. In low risk BCC a tumor free 
resection margin of 3 mm is recommended, and in high risk BCC a margin of 5 mm 
is advised (78,80).  In MMS, complete resection margins are examined by the 
specifically trained dermatologist and/or pathologist during the procedure, aiming to 
spare healthy tissue while removing completely the cancer cells. MMS leads to 
fewer recurrences; however, this procedure is labour-intensive and time consuming 
(81). Therefore, a tool that could quickly detect the cancer cells at the resection 
margins, could guide the excision towards an adequate surgical margin and 
accelerate the surgical procedure (21,82).   
15432-Barroso_BNW.indd   49 05-04-18   08:55
50 
Melanoma: Melanoma is the most commonly fatal form of skin cancer with a 
worldwide incidence of 232,130 and mortality rate as high as 55,488 (1). Melanoma 
is preferably diagnosed at an early stage because of its metastatic disease. The 
vertical depth of growth in a primary melanoma, the Breslow thickness, is 
significantly correlated with metastatic propensity and thus prognosis. Melanoma 
with < 1mm thickness can be treated surgically with a high cure rate without 
reducing life expectancy (5year survival is approximately 97%) (83,84). Once the 
melanoma is diagnosed at an invasive stage, the survival rate decreases enormously 
to approximately 40% for melanomas with a Breslow thickness >4 mm (83,85). 
Patients with thick melanomas and signs of distant metastasis are submitted to 
surgery and/or immunotherapy, which places a high burden on the patient’s quality 
of life. Moreover, the effect of current treatments on patient survival is very limited. 
Even with the use of a dermoscope by an experienced clinician, the sensitivity in 
diagnosing melanoma is between only 68% and 96% and it is very much depending 
on the clinician’s experience (9,86,87). Despite the large number of excised benign 
pigmented lesions (false positive suspicious lesions), 30% of early stage melanomas 
is still missed at the first clinical presentation and thereby present a risk to progress 
to a metastatic stage (88). Because of the severe consequences when a melanoma is 
missed, many suspicious pigmented skin lesions are surgically removed. The clinical 
positive predictive values are as low as 7% to 23% for melanoma diagnosis by 
dermatologists in a specialized pigmented lesion clinic (9,89). Therefore, a rapid, 
objective, real-time tool for clinical diagnosis could reduce the number of 
unnecessary excisions, guarantee early detection of melanoma, and, at the same 
time, could be used for lesions surveillance.   
Raman applications for early diagnosis/biopsy guidance: Investigations 
of Raman spectroscopy for skin cancer focus primarily on (early) detection of skin 
cancer and discrimination of benign from malignant and pre-malignant skin tumors 
(2,18,79,90-95). In 2008, Raman experiments were performed in-vivo by Zhao et al, 
on 289 patients using a single fiber Raman probe; Raman spectra were measured 
from 9 different types of lesions, including BCC and SCC. The authors report a 
sensitivity of 91% and a specificity of 75% in differentiating malignant lesions from 
benign lesions. Malignant melanoma could be distinguished from pigmented benign 
lesions with reported sensitivity of 97% and specificity of 78% (96). In the same 
year, Lieber et al, used a portable Raman system with handheld probe for non-
melanoma skin cancer diagnosis (97). Lieber et al, performed an in-vivo study on 19 
patients. Using the same handheld probe, Lieber et al, report classification of the 
BCC, SCC, inflamed scar tissues and normal tissues with sensitivity of 100% and 
specificity of 91%. The reported overall classification accuracy was 95% (98). In 
2012, Lui et al, measured 518 in-vivo skin lesions from 453 patients. Malignant and 
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pre-malignant lesions could be separated from benign skin lesions using a single 
fiber Raman probe with a reported sensitivity of 90% and a specificity of 64%. 
Benign pigmented lesions could be distinguished from melanoma with reported 
sensitivity of 90% and specificity of 68%. Melanomas could be separated from 
seborrheic keratosis with a reported sensitivity of 90% and specificity of 68% (90). 
The specificities were 15%, 17% and 25% for a sensitivity of 99%, when three 
distinct discrimination tasks were investigated: melanoma vs pigmented benign 
lesions, all cancers vs benign lesions and melanoma vs seborrheic keratosis, 
respectively.  In 2012, Silveira et al, reported an in-vivo study using a Raman fiber 
probe in which they demonstrated differentiation of BCC from normal skin with an 
accuracy of 85% (99). Lim et al, determined the diagnostic capability of a 
multimodal spectral diagnosis for in-vivo non-invasive disease diagnosis of 
melanoma and non-melanoma skin cancers. Measurements were performed with a 
custom-built clinical system that combines three fiber optic-based optical 
spectroscopy modalities: diffuse optical spectroscopy, laser-induced fluorescence 
spectroscopy, and Raman spectroscopy. Raman, fluorescence and reflectance spectra 
were acquired from 137 lesions in 76 patients. From the measured set, the number of 
lesions considered for the study were 100 (12 melanomas, 19 BCC, 38 SCC, 14 
actinic keratosis and 17 nonmelanoma pigmented lesions). When combining the 
three modalities, they reported a sensitivity of 100% and specificity of 100% for 
classifying melanoma vs non-melanoma pigmented lesions. BCC and SCC vs actinic 
keratosis were classified with a sensitivity of 95% and specificity of 71% also when 
combining the three modalities (100). In 2015, using a multi-fiber Raman probe, 
Schleusener et al, performed in-vivo measurements on 104 subjects with lesions 
clinically suspected of being skin cancer (36 melanomas, 39 BCC and 29 SCC). 
Additionally, 67 measurements on benign pigmented nevi from 33 subjects were 
also included. Sensitivity and specificity for discriminating histopathologically 
confirmed melanoma from lesions clinically suspected of being melanoma (not 
histopathologically confirmed) were 52% and 67%, respectively.  For discriminating 
histopathologically confirmed BCC from lesions clinically suspected of being BCC 
(not histopathologically confirmed) the sensitivity was 54% and specificity was 
48%.  The results for discriminating histopathologically confirmed SCC from 
lesions clinically suspected of being SCC (not histopathologically confirmed) were 
sensitivity of 52% and specificity of 27%. Discriminating histopathologically 
confirmed malignant lesions from lesions clinically suspected of being skin cancer, 
but not histopathologically confirmed, was not successful (93). Zhao et al, in 2015, 
performed an independent clinical test on a total of 645 lesions from 409 patients. 
The sensitivity and specificity for discriminating skin cancers and pre-cancers 
(including melanoma, BCC, SCC, and actinic keratoses) from benign skin disorders 
were 99% and 24%, respectively. This study provided an independent confirmation 
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of in-vivo skin cancer diagnosis by Raman spectroscopy (92). Santos et al, measured 
82 freshly excised melanocytic lesions suspected of melanoma (89). The 
measurements were performed using an in-house built Raman micro spectrometer 
optimized for measurements on pigmented skin lesions (101). All 24 melanomas 
were correctly identified with a specificity of 45%. The authors indicated that 
Raman spectroscopy might lead to a 3-fold reduction of the ratio of unnecessary skin 
excisions and that their results should encourage the use of Raman spectroscopy in-
vivo systems by general practitioners and non-experienced dermatologists to 
discriminate melanoma from suspicious lesions and reduce unnecessary skin 
excisions (89). In 2017, Bratchenko et al, tested a combination of Raman 
spectroscopy with auto-fluorescence for melanoma and BCC diagnosis. They 
performed ex-vivo measurements on 39 melanomas, 40 BCC’s and respective 
healthy skin within the excised samples. The authors show that the combination of 
Raman spectroscopy with auto-fluorescence has an accuracy of 97.3% in 
discriminating BCC’s from melanoma, whereas the determined accuracy for each 
modality separately is 79% (102).  
 Raman applications for surgery guidance: Kong et al, combined auto-
fluorescence with Raman spectroscopy for intra-operative detection of BCC in skin. 
This approach was developed to reduce the measuring time of whole tissue sections 
during the Mohs surgery procedure. First, the auto-fluorescence images, which were 
taken at excitation wavelengths of 377 nm and 292 nm (corresponding to collagen 
and tryptophan excitation) were segmented. In this way, the normal dermis, which is 
dominated by collagen, was discarded and only the suspicious segments were 
sampled by Raman spectroscopy. Based on this approach, Kong et al, demonstrated 
that BCC could be automatically detected with a sensitivity of 95% and a specificity 
of 94% (94).   
 Lung Cancer  
Clinical need: Lung cancer is one of the leading causes of cancer-related deaths 
in the world, with an incidence of 1,824,701 and mortality rate of 1,589,925. 
Reasons for the high mortality rate are the fact that patients tend to be diagnosed at 
an advanced stage and a lack of effective treatments. Part of the diagnostic process is 
white light bronchoscopy (whether or not combined with auto-fluorescence) 
combined with tissue biopsy for definitive pathology. A problem with this technique 
is that it suffers from either low sensitivity or specificity (103) and it is mainly 
accessible for centrally located lesions. Moreover, the representativeness and quality 
of the transbronchial and endobronchial biopsies is difficult to assess during the 
procedure (104).  Cytologic evaluation also plays an important role in the initial 
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evaluation and diagnosis of patients with lung cancer, especially in the evaluation of 
suspicious lymph nodes (105). Sampling errors and numerous mimics are the main 
pitfalls of the technique (105).  An objective optical tool that could be adapted to 
bronchoscopy or incorporated in a biopsy needle would be beneficial for biopsy 
guidance and early diagnosis of lung cancer. In early stage disease, surgical 
management is the treatment of choice. Several studies showed better 5-year 
survival rate for lobectomy (complete removal of the pulmonary lobe where the 
tumor is situated) than for sublobar resection, where less than an entire pulmonary 
lobe is removed (106-108).  The sublobar resection procedure has been adopted in a 
number of centers. This procedure has been used for diagnosis and is considered 
sufficient for early stage disease and for non-cancerous lesions. Technical 
limitations that preclude negative surgical margins are a more challenging issue for 
sublobar resection than conventional lobectomy (108). Ideally, complete tumor 
resection with resection margins of ≥ 2cm by sublobar resection would be favorable, 
maintaining lung volume and function (108) while reducing the risk of local 
recurrence. Intra-operative frozen section has traditionally been the sole modality for 
achieving negative resection margins. However, in some cases, frozen sections are 
not representative enough to predict the final pathology. Thus, the histopathological 
evaluation of the frozen section is difficult, especially between non-invasive stage of 
the disease and minimally invasive stage (109). The difficulty to predict the 
predominant pattern based on frozen section has been reported to be due mostly to 
sampling errors (110). Moreover, the intra-operative assessment of margins is 
challenging owing to an underestimation of the margin distance in lung tissue. If the 
tumor is peripheral, it is easier to guarantee a large resection margin. However, when 
the tumor is centrally located it is more challenging to assure that adequate resection 
margins are achieved. Improvement of intra-operative assessment of resection 
margins is essential to amend sublobar surgery and reduce the local recurrence rate.  
Raman applications for early diagnosis/biopsy guidance: The first study 
that demonstrated the technical feasibility of measuring in-vivo lung lesions using 
Raman spectroscopy was conducted in 2008 by Short et al, (111). A multi-fiber 
Raman probe was implemented to complement white light and auto-fluorescence 
bronchoscopy for in-vivo detection of lung cancer. Preliminary research on 26 
patients demonstrated that the combination of Raman spectroscopy with white light 
bronchoscopy and auto-fluorescence bronchoscopy can improve the diagnostic 
specificity of lung cancer (reducing the number of unnecessary biopsies). With these 
combined technologies, the sensitivity and specificity achieved were above 90% for 
detection of lung cancer and high-grade dysplasia lesions. The authors stated that the 
use of Raman spectroscopy has potential for substantially reducing the number of 
false-positive biopsies associated with white light bronchoscopy and auto-
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fluorescence bronchoscopy (112).  Recently, the same group used the bronchoscopic 
Raman spectroscopy in-vivo in 80 patients (280 samples), using signal acquisition 
times of 1s. The detection of high grade dysplasia and malignant lung lesions 
resulted in a reported sensitivity of 90% at a specificity of 65% (113). 
 Esophageal Cancer  
Clinical need: Esophageal cancer has a worldwide incidence rate of 455,784 and 
mortality rate of 400,169 (114). There are two main types of esophageal cancer: 
squamous cell carcinoma and adenocarcinoma. Diagnosis is established with 
endoscopic guided biopsy. Esophageal adenocarcinoma develops in sequential 
stages of change in the mucosa. Firstly, there is a change from a normal squamous 
epithelium to a columnar cell epithelium (i.e. intestinal metaplasia), known as 
"Barrett's esophagus". The "Barrett's esophagus" is considered a pre-malignant stage 
because it is associated with 100 times higher risk of developing esophageal cancer 
(115). Endoscopic identification of this pre-cancerous stage may enable early, 
minimally invasive therapeutic intervention (i.e.  endomucosal resection). The 
greater the number of biopsies taken from the border of the lesion (at least six), the 
higher the diagnostic accuracy (116,117). However, the increase in the number of 
biopsies performed may cause an increased risk of complications, such as 
gastrointestinal bleeding. Furthermore, still 11.3 % of upper gastrointestinal tract 
cancers are missed with this technique (118).  Therefore, an objective, real-time tool 
for biopsy guidance could reduce the number of unnecessary biopsies and improve 
the diagnostic accuracy.  Surgical resection is the treatment of choice in early staged 
esophageal cancer. The optimal extent of esophageal resections is still controversial, 
but completeness of surgical resection is an important determinant for a better 
outcome. There are recommendations for clearance of tumor from proximal and 
distal margins, but this may vary depending upon the type of tumor (119,120). The 
presence of tumor at a distance ≤1 mm of the circumferential resection appears to be 
a significant cause of local tumor recurrence and decreased survival (121,122). An 
intra-operative assessment of the resection margins of esophageal excisions is 
essential to reduce the local recurrence rate and increase the survival rate.  
 Raman applications for early diagnosis/biopsy guidance: Teh et al, 
studied 21 dysplastic gastric lesions and 44 normal samples from 44 patients using 
in-vivo multi-fiber Raman probe system. A sensitivity of 95% and specificity of 
91%, between dysplastic and healthy stomach tissue was found (123).  Bergholt et 
al, measured 924 Raman spectra in-vivo from normal tissue and 111 from benign 
ulcers from 71 patients with an endoscopic multi-fiber Raman probe system. 
Malignant ulcers were correctly classified with a sensitivity of 82.1% and a 
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specificity of 95.3% (124). An endoscopic multi-fiber Raman probe system for in-
vivo and online diagnosis of gastric cancer was developed by the group of Huang 
(125). Using this system, they obtained a total of 2748 in-vivo gastric tissue spectra 
from 305 patients: 2465 diagnosed as normal and 283 as cancer. The reported 
diagnostic accuracy for gastric cancer was 85.6% (sensitivity of 80.5% and 
specificity of 86.2%). Gastric cancer detection algorithms were further applied on 10 
patients undergoing gastroscopy (Figure 1). The authors report a predictive accuracy 
of 80.0% (sensitivity of 90.0% and specificity of 73.3%) (125). In 2014, Bergholt et 
al, performed an in-vivo study for diagnosis of gastric dysplasia in Barrett’s 
esophagus. A total of 450 patients underwent endoscopy in the upper gastrointestinal 
tract, Raman measurements were performed, biopsies were taken and submitted for 
histopathological evaluation. High grade dysplasia in Barrett’s esophagus, non-
dysplastic Barrett’s esophagus and normal columnar lined epithelium could be 
discriminated with a reported sensitivity of 87% and a specificity of 84.7% (126).  
Wang et al, demonstrated that, using the in-vivo endoscopic multifiber Raman probe 
system and acquisition times of 0.1-0.5s esophageal squamous cell carcinoma can be 
detected with sensitivity of 97% and specificity of 97%, based on the results from 48 
patients (127). 
Ishigaki et al, used a micro Raman probe system to examine ex-vivo early-stage 
(stages 0 and I) esophageal cancer samples from 15 patients. They demonstrated a 
sensitivity of 81% and a specificity of 94% using leave-one-out cross validation 
(128).  Using a Raman endoscopic multi-fiber probe during routine endoscopy 
examination, Lin et al, demonstrated in-vivo that simultaneous use of the fingerprint 
and high-wavenumber part of the Raman spectrum can improve early diagnosis of 
gastric precancers (sensitivity of 93% and specificity of 94%) in an independent 
dataset. 
 
Figure 1. (a) Photograph of Raman endoscopy system in clinic; (b) insertion of the 1.8 
mm Raman endoscopic probe into the working channel of an endoscope during 
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gastroscopy; and (c) routine Raman endoscopy procedure in clinic (125). From 
Duraipandian et al, (125). Reprinted with permission from SPIE. 
A total of 48 patients were included. From this dataset, 80% of the spectra were used 
for training and 20% for testing. Using exclusively either the fingerprint or the high-
wavenumber part, the area under the ROC curve was 0.972 and 0.928, respectively. 
When combining fingerprint spectral range and high-wavenumber range, the area 
under the ROC curve was 0.995 (129).  
 Head and Neck Cancer   
Clinical need: Head and neck cancer includes cancer of the oral cavity, 
nasopharynx, oropharynx, hypopharynx, and the larynx. Head and neck cancer has 
an overall incidence rate of 686,328 and a mortality rate of 375,665 (114). The most 
frequent type of cancer in head and neck region is oral cavity squamous cell 
carcinoma (OCSCC). When a patient is suspected for a tumor in the head and neck 
region, all subsites will be examined to screen for a synchronous second primary 
tumor. Biopsies are taken for tissue diagnosis and for staging purposes. Surgery is 
the mainstay of treatment for most oral cancers and for early stages in the other 
subsite. Advanced disease usually requires multimodality treatment consisting of 
surgery, radiation and/or chemo/biotherapy. Very recently immunotherapy was 
added as a promising option. An acceptable balance between remaining function and 
physical appearance on one side and clear margins on the other, is the main goal of 
surgery. Inadequate resection margins influence negatively local control and 
prognosis (130,131). In head and neck cancer, clear resection margins impact on 
disease control and survival (132,133). Achieving adequate resection margins is 
challenging. The lack of reliable intra-operative guidance and the proximity of 
tumors to vital structures are common causes of inadequate tumor resection. Recent 
studies show poor surgical success rates with inadequate tumor resection in oral 
cavity cancer surgery from 30% up to 85% (23,33,134). Intra-operative assessment 
by means of frozen-section is the standard procedure. However, these can only be 
used for soft tissue and not for bone. Additionally, only a small proportion of the 
resection margins can be investigated by this procedure and the selection of 
suspicious tissue depends on the surgeon’s and/or the pathologist’s experience. 
These factors also contribute to a high recurrence rate of oral cancer (21,135). The 
two primary clinical needs are early diagnosis of OCSCC and intra-operative 
assessment of the complete resection margins, not only for soft tissue but also for 
bone margins.   
Raman applications for early diagnosis/biopsy guidance: In 2014, Krishna et al, 
created an in-vivo multi-fiber Raman probe system and measured a total of 28 
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healthy volunteers and 171 patients with oral lesions. Spectra were annotated, based 
on histology or by clinical assessment, as oral squamous cell carcinoma (OSCC), 
oral submucosa fibrosis (OSMF), oral leukoplakia (OLK) and normal mucosa. Each 
group (OSCC, OSMF, OLK and normal) was correctly classified, when applying the 
developed diagnostic algorithm, in 89%, 85%, 82% and 85% of the cases, 
respectively (136).  In 2015, Guze et al, conducted an in-vivo pilot study with a 
Raman probe and measured oral diseases from 18 patients. Benign and malignant 
oral lesions were classified correctly with sensitivity of 100% and specificity of 77% 
using a multi-fiber Raman probe. Although, a larger study group was preferable, the 
results indicate that Raman spectroscopy is a promising diagnostic tool (137).   
 Raman applications for surgery guidance: In 2015, the feasibility of 
identifying oral cancer tumor based on water concentration was demonstrated ex-
vivo, using high-wavenumber Raman spectra obtained from freshly excised 
resection specimens from oral cavity (135). Barroso et al, investigated how the water 
concentration changes across the border between tumor and the healthy surrounding 
tissue on ex-vivo specimens from patients that underwent surgery for oral cavity 
squamous cell carcinoma. Measurements were performed on 20 patients using a 
confocal Raman microscope system. The results revealed consistent changes in the 
water concentration across the tumor border. Over distances of 4 to 6 mm across the 
tumor border, water concentrations changed from 76% ±8% in the tumor to 
54%±24% in the healthy surrounding tissue (138). 
 Brain cancer   
Clinical need: The estimated incidence of brain cancer in the developed world is 
7.1/100,000 with a high mortality of 5.3/100,000 (1). Neuroradiology is usually 
sufficient as the initial diagnostic modality for brain cancer. In some cases, 
stereotactic biopsy is needed to decide for primary resection versus chemo- 
radiation. For accurate histopathological diagnosis multiple tissue samples are 
obtained (139). Brain biopsy may be complicated by sampling error and cerebral 
hemorrhage (140,141). Therefore, a rapid and objective tool is needed for optimal 
biopsy guidance to provide one representative brain tumor tissue sample, thus 
minimizing the risk of cerebral hemorrhage. Treatment of choice for most primary 
brain cancer is surgery (17). In low-grade gliomas the extent of tumor tissue 
resection is associated with improved patient outcome (141-143). Three-dimensional 
stereotactic navigation, 5-ALA-fluorescence and intra-operative magnetic resonance 
imaging (MRI) are currently used to achieve optimal surgical results (141,144). 
Unfortunately, distinguishing cancer from healthy tissue during surgery still is a 
challenge (140,145). Generally, postoperative MRI demonstrates residual tumor in 
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69.6% of the cases (145). The accuracy of navigation is influenced by the intent to 
preserve vital brain structures, inter-observer disagreement on the tumor 
transformation zone, and brain edema (146). In the current practice, adoption of 
navigation techniques is limited owing to high costs and hampered by low evidence 
of survival benefit (147). An optical, intra-operative tool to guide the surgeon 
towards tumor tissue in stereotactic biopsy and to identify adequate resections while 
preserving function brain structures with resection may improve patient outcome.  
 Raman applications for surgery guidance: Jermyn et al, in Montreal have 
developed a Raman system with a hand-held probe for intra-operative use during 
brain tumor resection. In an in-vivo study, spectra were obtained from 17 patients 
with 0.2s acquisition time (Figure 2). Patients with grade 2 to 4 gliomas were 
included (66 normal spectra and 92 cancer spectra). They reported a sensitivity of 
93% and a specificity of 91% in distinguishing normal brain tissue from dense 
cancer and normal brain invaded by cancer cells (148).   
 
Figure 2. The handheld contact fiber-optic probe for Raman spectroscopy. The probe 
(Emvision, LLC) was used to interrogate brain tissue during surgery. A schematic 
diagram illustrated the excitation of different molecular species, such as cholesterol and 
DNA, to produce Raman spectra of cancer versus normal brain tissue (52). From 
Jermyn et al, (52). Reprinted with permission from the authors and AAAS. 
  
Colorectal Cancer  
Clinical need: Colorectal cancer (CRC) has a worldwide incidence rate of 
1,360,602 and mortality rate of almost 700,000 (1). CRC is diagnosed after onset of 
symptoms or through screening by colonoscopy (149). Screening detects early-stage 
malignancies or premalignant polyps (adenomas) and improves prognosis for the 
patient (149). Colonoscopy miss rates are 2-6% for CRC and 20-26% for adenomas 
(150,151). Additionally, many polyps with minimal malignant potential are removed 
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without benefit to the patient (149,152). Despite its contribution to the effectiveness 
of colonoscopy, polypectomy is associated with increased risk of major 
complications (perforation, hemorrhage) (153). An objective biopsy guidance tool is 
therefore of clinical importance to reduce these limitations.  Surgery is the only 
curative modality for localized colon cancer. Proximal and distal resection margins 
should be at least 5 cm from the tumor (154). Satisfyingly, positive margins in colon 
cancer resections are rare (155). The most important indicator of outcome following 
resection of colon cancer is the tumor pathologic stage (156).  
 Raman applications for early diagnosis/biopsy guidance: In 2008, 
Widjaja et al, measured 105 colon specimens ex-vivo with an inhouse built Raman 
probe (157). From the 105 colon specimens 41 were normal, 18 were hyperplastic 
polyps and 46 were adenocarcinomas. In this study, the diagnostic accuracy was 
98% (157).  Short et al, conducted a study using Raman spectroscopy on ex-vivo 
colon tissue from 18 patients, measuring both the fingerprint and high-wavenumber 
spectral regions. The results indicated that, using the high-wavenumber region, the 
non-malignant and the malignant groups could be classified correctly with a 
specificity of 89%. The authors referred that high-wavenumber region could be used 
in-vivo to improve the identification of neoplastic lesions (158). Bergholt et al, 
tested the same approach in-vivo (combined fingerprint and high-wavenumber 
spectral regions) on adenomatous polyps measured from 50 patients using an 
endoscopic multi-fiber Raman probe. Adenomatous polyps were separated from 
hyperplastic polyps with a sensitivity of 91% and specificity of 83%. The authors 
demonstrated that the analysis based on the combination of fingerprint and high-
wavenumber spectral regions is superior to considering either region alone (12).  
  Cervical Cancer   
Clinical need: Cervical cancer has a worldwide yearly incidence of 528,000 
women and mortality of 266,000 (1), In recent years incidence and mortality rates 
have decreased because of the emergence of screening (159). The primary method of 
screening is by cervical cytology with the Papanicolaou test (PAP). This has a high 
specificity (95–98%) but a low sensitivity (<50%) (160). This sensitivity of 
screening is increased by testing for Human Papilloma Virus (HPV) in the cervical 
swab (161). Final diagnosis of cervical cancer is based on histopathology. For this 
colposcopy guided biopsy is recommended, with a sensitivity of 92% and specificity 
of 67% (73). In low resource settings visual inspection of the cervix with biopsies is 
used with a specificity and sensitivity of 88-92% and 10-84% (162,163). Treatment 
of cervical cancer is based on stage. Small tumors will be treated by surgery, and 
higher stages with chemoradiation. It is not to be expected that Raman spectroscopy 
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has any value in the diagnostic or treatment of cervical cancer since the diagnostic 
accuracy of colposcopy guided biopsies will not be improved and precision 
treatment is not applicable for cervical cancer.  
 Raman applications for early diagnosis/biopsy guidance: Mo et al, 
measured Raman spectra from 46 patients in-vivo with high-wavenumber Raman 
spectroscopy, to investigate cervical precancer diagnosis. The Raman instrument 
used a ball-lens fiber-optic Raman probe. Cervical dysplasia could be distinguished 
from normal tissue with a reported sensitivity of 94% and specificity of 98% (164).  
Kanter et al, performed a clinical study on a total of 43 patients that underwent 
colposcopy-guided biopsy to investigate dysplasia. Using a portable Raman system 
with a fiber-optic probe spectra were acquired of low grade squamous intraepithelial 
lesions, high grade squamous intraepithelial lesions, metaplastic lesions and normal 
tissue. The classification accuracy for discriminating diseased from normal tissue 
was 88%, the sensitivity was 86% and the specificity was 97% (165). The same 
group reported, in 2011, a sensitivity of 70% and a specificity of 83% for cervical 
pre-cancer diagnosis. In this study a total of 29 patients were included. 
Measurements were done in-vivo using fiber-optic Raman probe with a ball-lens 
(166). To improve diagnostic accuracy, Duraipandian et al, combined high-
wavenumber and fingerprint Raman spectroscopy for cervical and pre-neoplasia 
detection. The obtained sensitivity and specificity were 85% and 81.7%, respectively 
(167). Rubina et al, performed ex-vivo Raman measurements on 49 abnormal 
cervical specimens and 45 negative control cytology samples using a fiber-optic 
Raman microprobe system. Abnormal lesions were classified correctly in 84.5% of 
the cases. The authors suggested that presence of blood in abnormal specimens was 
a major cause of discrimination (168,169). 
 Vulvar Cancer 
Clinical need: Vulvar cancer has a worldwide incidence of 1,300 women and 
mortality of 450 women per year (170). This malignancy has a high curability in 
early-stage disease, but a poor prognosis for advanced-stage disease and recurrent 
disease. Diagnosis is based on histopathology of a biopsy of the vulva at the 
peripheral edge of the lesion (171), whereby underlying stroma is included, and 
possible necrotic tissue avoided (172).  In-vivo diagnosis and biopsy guidance can 
be of great value for accurate diagnosis. Surgery is the main choice of treatment. In 
recent years surgical management has changed, were large radical and disfiguring 
resections make place for conservative surgery (172). The multifocality of this type 
of cancer, the presence of dysplasia and/or small resection margins result in local 
recurrence rates of 23-50% (173,174). Surgical management of vulvar carcinoma 
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aims to achieve a fine balance between adequate resection margins and preservation 
of sexual and urinary function (172,175). An intra-operative tool for surgery 
guidance is therefore needed.  
Raman applications for early diagnosis/biopsy guidance: During the 
literature search we have noticed that Raman applications have not been greatly 
developed for vulvar cancer. The most recent study, was developed by Frost et al, 
(176). They have evaluated the diagnostic performance of Raman Spectroscopy for 
differentiating a pre-malignant vulvar lesion (lichen sclerosus, LS) from other 
inflammatory vulvar conditions in fresh vulvar biopsies from 27 women. Biopsies 
resulted in circular discs o skin 3-4 mm in diameter (full thickness of the epidermis 
with underlying dermal tissue). Spectra were measured with a Raman micro-
spectrometer (modified Renishaw system 1000 dispersion), which was coupled to a 
diode laser of 830nm excitation wavelength and had a spot size of 15x17µm. A 
classification model was created using principal components and multivariate linear 
discriminant analysis. Leave one sample out cross validation was used to validate 
the model. The model was able to correctly differentiate LS from other 
inflammatory vulvar conditions with a sensitivity of 91% and specificity of 80%. 
The authors suggested that the study demonstrates that Raman spectroscopy has 
potential for in-vivo non-invasive diagnosis of vulvar skin conditions and when 
applied in the clinical setting may reduce the need for invasive tissue biopsy (177).  
 Bladder Cancer  
Clinical need: The global incidence rate for bladder cancer is 430,000 and 
mortality is 165,000 (1). The standard for diagnosis is cystoscopy, with biopsies of 
suspicious lesions, and transurethral resection (TUR) to confirm the diagnosis (178). 
Unfortunately, small papillary bladder tumors and flat urothelial carcinoma-in-situ 
(CIS) can easily be overlooked (179). This contributes to increased residual rates 
and a recurrence rate of 50% within 18 months. TUR is the standard of treatment for 
small (Ta) bladder tumors. Incomplete resection results in a second operation and/or 
increased recurrence rate, resulting in poor long-term prognosis (180-183). Thereby, 
high risk tumors grow fast with a mortality rate of 50%, despite treatment. Urinary 
markers are emerging but not able to outperform cystoscopy. These findings suggest 
that in-vivo biopsy, biopsy guidance and surgery guidance is needed for early 
detection, accurate diagnosis and adequate resections, to improve patient outcome.  
Raman applications for early diagnosis/biopsy guidance: The first in-
vivo Raman probe that was used in bladder was an Emvision® probe with a filtered 
six-around-one fiber configuration. The excitation wavelength was 785nm. The 
probe used had a large measurement volume (~1cm3) and did not have any lenses. 
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As a result, the probe collected Raman spectra not only from the upper urothelium 
surface of the bladder (where transitional cell carcinoma has its origin) but also from 
deeper layers. During the procedure of transurethral resection of bladder tumors 
(TURBT), spectra were collected from suspicious and non-suspicious locations 
(collection times of 1 to 5s). Bladder cancer could be distinguished from normal 
bladder with a reported sensitivity of 85% and a specificity of 79%. Even though the 
results show the possibility of discerning normal from malignant bladder tissue 
using Raman spectroscopy, the authors suggest that using a Raman probe that 
collects shallower signal from the urothelium surface of the bladder would be ideal 
for early diagnosis. Also, the combination of auto-fluorescence with Raman 
spectroscopy could potentially improve the diagnostic capability, by using the 
sensitive auto-fluorescence modality to indicate suspicious regions for “optical 
biopsy” by the highly specific Raman spectroscopy modality (184,185). In 2012, a 
confocal Raman probe was designed by Barman et al, and it was used ex-vivo for 
bladder cancer diagnosis in 14 patients. The confocal probe had depth of field of 
approximately 280μm. The result of the confocal system had a significantly higher 
specificity with respect to large-volume Raman spectral data, with a sensitivity that 
was comparable to the large-volume Raman system (60,177).  
 Prostate Cancer  
Clinical need: Prostate cancer is among the most common cancers in men 
worldwide, with an incidence of 1,094,916 and mortality rate of 307,481 (1). The 
diagnosis of prostate cancer is often made through transrectal ultrasound guided 
prostatic biopsy (186). Ten to twelve core biopsies are recommended, with > 12 
biopsies not being significantly more conclusive (187,188).  While the majority of 
prostate cancer patients are treated by radical prostatectomy or radiation therapy, an 
increasing number of men are actively surveyed for their disease without immediate 
treatment. In a significant number of men, radical prostatectomy is complicated by 
urinary and/ or erectile dysfunctions, which is related to eradication of the 
neurovascular bundles (NVB) localized in the dorsolateral peri-prostatic fat tissue. 
Operative removal of the prostate leaving the NBV intact can reduce post-operative 
complications. Decision making on nerve-sparing surgery can be optimized by intra-
operative assessment of the prostatic surgical margins. In practice, the urologist can 
only remove the prostate initially leaving the NVB in situ. In case intra-operative 
assessment of the prostatic surgical margin is negative, the NVB will remain intact; 
in case the margin is positive the urologist can remove the NVB at a second term. 
Although intra-operative frozen-section assessment is able to increase nerve-sparing 
surgery from 81% to 97%, it is labor-intensive requiring an optimized work-flow for 
the fast throughput of a large number of frozen sections 189. Intra-operative 
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assessment of surgical margins using Raman spectroscopy might be a good 
alternative for extensive pathologic frozen sections and could be implemented at 
large scale in operation theatres or departments of pathology.  
Raman spectroscopy applications: Spontaneous Raman spectroscopy has not 
been explored yet in-vivo and/or ex-vivo using human prostate cancer material. 
Raman-based studies were developed in the last years in-vitro, using cell cultures 
and, more recently, ex-vivo using peripheral nerves of rats (177,190,191).   
 
Instrumentation  
When developing instrumentation for in-vivo and ex-vivo applications, the main 
technical problems are: speed of measurement, adaptation in clinical workflow, 
interference of background from tissue auto-fluorescence and high instrumentation 
costs.  In the last years we consider that the major technological advances in Raman 
spectroscopic systems for clinical applications have been in: 1) detector technology, 
2) fiber-optic probe design, 3) combination with other techniques, and 4) new laser 
opportunities for low-cost systems.   
 1) InGaAs detectors for short-wave infrared Raman 
spectroscopy 
Until now the detection of Raman signals in the short-wave infrared (SWIR) region 
(>1100 nm) was constrained by limitations of the state-of-the-art detector 
technology for visible to NIR excitation (CCDs). An alternative in this spectral 
range is the Indium-GalliumArsenide (InGaAs) detector, which enables detection at 
wavelengths well above 1100nm. Several companies have recently moved towards 
the SWIR range, and have introduced InGaAs-based Raman devices (e.g. Andor™, 
Anton Paar™, Horiba™, B&W Tek™). Xenics™ introduced an InGaAs camera that 
has a read-out noise at comparable levels as a CCD detector, and that consequently 
can achieve shot-noise limited Raman spectra in clinically acceptable integration 
times (101). This development in detector technology enabled the use of longer 
excitation wavelengths for clinical applications on tissues with would otherwise 
suffer from strong laser-induced fluorescence of fluorophore-containing tissues. 
Santos et al, could measure melanocytic skin lesions without overwhelming tissue 
auto-fluorescence interference using a SWIR Raman system, with NIR 967nm laser 
and an extreme low-noise InGaAs detector (Figure 3) (89).  
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Figure 3. Implementation of SWIR Raman system in the dermatology out-patient clinic 
of Leiden University Medical Center for in-vivo measurements (a). Photograph of a 
pigmented skin lesion (b). This was measured using a 976-nm laser excitation, the SWIR 
Raman instrument and a single fiber probe. The corresponding Raman spectrum 
measured in-vivo is shown in (c). Exposure time: 30 s. 
Also, Patil et al, and Pence et al, have reported dispersive Raman spectroscopy of 
tissues with strong auto-fluorescence (liver and kidney human tissues) using 1064 
nm excitation in combination with an InGaAs detector array (192,193). Laser-
induced tissue fluorescence was significantly reduced compared to excitation with 
lasers in the visible wavelength range.   
 2) Fiber-optic probes  
Fiber-optic probes for early diagnosis: Fiber-optic probes have enabled the 
use of Raman spectroscopy for in-vivo clinical applications. The integration of 
Raman spectroscopy with other diagnostic techniques has been a major step in the 
development towards improved efficiency in biopsy guidance and early cancer 
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diagnosis. Fiber probes that could be inserted into endoscopic channels enabled in-
vivo measurements in hollow organs or surface assessment of solid organs: oral 
cavity (136,137), lung (111,113), upper gastrointestinal tract (123-127,129), 
colorectal (12,158), bladder (185), and cervical cancers (164-167,194). Also, 
handheld fiber-based systems have been used for in-vivo assessment of skin cancer 
(88,90,91,94–96), and of brain cancers (148,195).  In the last years numerous Raman 
probe designs have been developed, optimized and tested for clinical purposes. 
There has been an increased effort to tailor Raman probes to clinical needs and 
constraints defined by the specific clinical targets, specific pathophysiology of 
diseases, and specific anatomies of the region of interest (e.g. accessibility of the 
tissue, sample size, sampling depth).   
Stevens et al, and Wang et al, have reviewed Raman fiber-optic probe designs and 
construction concerns, considering different oncological applications and respective 
clinical needs (18,196).  Depth-selective fiber-optic Raman probes have been 
investigated for use in epithelial tissue associated with dysplasia (197). Wang et al, 
developed a confocal fiber-optic Raman probe coupled with a ball lens to enhance 
in-vivo Raman measurements from gastric premalignant epithelial tissue during 
endoscopy (197,198). With a beveled fiber-optic probe coupled with a ball lens, the 
authors could limit their collection depth to 300 µm. Since gastric dysplasia initially 
evolves in the epithelial tissue layer (~300 μm), it is especially relevant for selective 
interrogation of the gastric epithelium. Further work from the same group, featured a 
fully automated real-time Raman spectral diagnostics framework integrated with a 
multimodal image-guided Raman technique that enabled real-time in-vivo cancer 
detection at routine endoscopy procedure, as shown in Figure 1 (199). The same 
fingerprint/high-wavenumber fiber-optic Raman endoscopic system was developed 
further by Bergholt et al, for routine clinical colonoscopy diagnosis, making use of a 
foot pedal control switch and an auditory feedback to the gastroenterologist (199). 
Using a similar probe in a hand-held confocal design, Duraipandian et al, measured 
in-vivo fingerprint and high-wavenumber Raman spectra during colposcopy (167). 
Agenant et al, used a novel clinical Raman probe for sampling superficial tissue to 
improve in-vivo diagnosis of (superficial) urothelial carcinoma. This probe had a 
measurement depth of 0-200µm, which corresponds to the average urothelium 
depth. The probe is comprehended by 7 collection fibers, 1 excitation fiber and two 
component front lens (200).  
Fiber-optic probes for guided surgery: In the field of brain cancer, Jermyn 
et al, preformed in-vivo Raman measurements during human brain cancer surgery 
for real-time identification of invasive cancer, using a handheld contact Raman 
spectroscopy probe (52,195). Each measurement covered a 0.5mm diameter tissue 
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area with a depth sampling up to ~1 mm in 0.2s. During the tumor resection, Raman 
signals were measured in the surgical cavity.  
The probe is comprehended by filters that were placed directly at the tip of the 
optical fibers. The spectra acquired with the handheld Raman probe (Figure 2) do 
indicate that there are still some challenges in developing probes and methods for 
correcting for spectral distortions mainly caused by the filter characteristics of the 
probes and subtraction of fluorescence signal backgrounds (201).  A Raman system 
comprehended by a single fiber needle probe is currently being tested ex-vivo by 
Head and Neck surgeons and pathologists from Erasmus University Medical Center 
Rotterdam, The Netherlands. This probe aims intra-operative inspection of the entire 
resection margin of specimens from patients that underwent surgery for oral cavity 
SCC (Figure 4).   
 3) Combined Raman systems for guided surgery 
In the field of dermatology, Kong et al, developed a scanning device that combines 
auto-fluorescence imaging and Raman spectroscopy to guide Mohs micrographic 
surgery in the excision/treatment of high-risk skin basal cell carcinoma (94). 
Although Mohs micrographic surgery provides the highest cure rates, it is a time-
consuming technique (1 - 3 hours) needing highly trained personnel.  
With the purpose of reducing the duration of scanning large areas of tissue, tissue 
auto-fluorescence imaging is used to determine the main spatial histological features 
of the sample, and this information is used to select and prioritize the sampling 
points for Raman spectroscopy (Figure 5) (94,202).   
 4) New lasers 
Recent developments in vertical-external-cavity surface-emitting laser (VECSEL) 
technology have brought their characteristics in the realm of Raman spectroscopy, 
with special interest for low-cost hand-held devices (203). VECSELs are 
semiconductor lasers based on a vertical-cavity surface-emitting geometry.  
These types of lasers achieve a combination of high continuous wave output power, 
due to a large gain area, and a low- divergence near-diffraction-limited beam, due to 
the transverse mode control of the extended cavity. The advantages of VECSELs 
over edge emitting semiconductor lasers are circular output beam, easy array 
fabrication, small size, and low cost at mass production (56,203-205).  
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Transferability  
The Raman applications described above demonstrate potential of Raman 
spectroscopy to affect patient care. The major requirements for translation of a 
Raman equipment into clinical practice are: 1) well defined clinical need, 2) patient 
benefit proven and/or cost benefit, 3) equipment changes clinical practice, 4) 
demonstrated safety, reproducibility, robustness, and reliability (e.g. large clinical 
trials) and 5) regulatory approval. First, it is important to verify beforehand that the 
developed Raman application addresses an actual clinical need and that the 
application can provide results of clinical relevance. This does not mean that the 
Raman instrument needs to give perfect results, as long as it can bring about 
measurable and cost-effective improvements in patient care. Moreover, it is required 
that the instrument is introduced in the clinical workflow and is used/tested by 
clinicians. 
 
Figure 4. Single fiber needle probe for intra-operative assessment of the oral cavity SCC 
resection margins, developed by Artphotonics GmbH in collaboration with RiverD 
International B. V. and Erasmus University Medical Center, Rotterdam. a) Close up of 
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the single fiber needle probe. b-c) Testing the single fiber needle probe for inspection of 
the freshly excised oral cavity specimens. 
Second, it is essential to demonstrate the safety, reproducibility, robustness, and 
reliability of the developed application in large clinical trials, to the end-users. And 
finally, receive approval from regulatory agencies. Many of these aspects are now 
increasingly being addressed, which is a good sign of progress in the field towards 
clinical translation. However, for this translation continued effort is needed by 
searching for close collaboration and input from the medical community. 
 
Figure 5. Multimodal spectral histopathological diagnosis of BCC in unsectioned tissue 
blocks as received from surgery. H&E histopathology images for adjacent sections are 
included for comparison (Scale bars: 2 mm) (94). Reprinted with permission from the 
authors and PNAS. 
 Additionally, to gain the confidence of clinicians to the potential value of Raman-
based applications, it is essential to expose the results of Raman technologies over or 
in line with existing medical devices (2,206). This should be done in large cohorts’ 
studies based on patient outcomes and in direct comparison with the current gold 
standards.  Multidisciplinary networks are now being developed, such as the 
International Society for Clinical Spectroscopy (ClirSpec), European Photonics 
Industry Consortium (EPIC) and Raman4Clinics (EU COST Action BM1401), 
which target especially these translational aspects. ClirSpec is a society, 
comprehended by spectroscopists and clinicians, that facilitates and promotes the 
translation of spectroscopy into the clinical environment, for the general benefit of 
patients (clirspec.org). Raman4Clinics (EU COST Action BM1401) is a platform for 
scientific communication, exchange, collaboration and for new research activities, 
combining the partners’ expertise in technology, component, system and 
methodology development and medical application (www.raman4clinics.eu).  EPIC 
is a network that promotes awareness of opportunities for the European photonic 
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industry in healthcare (www.epic-assoc.com). To provide an overview of the current 
status of the technology towards clinical translation, we classified all reviewed R&D 
results, based on the TRL. Figure 6 (2008-2017) shows the result from the 
technology readiness classification of the different Raman studies mentioned in the 
Raman applications section. From this figure, it is immediately clear that the 
majority of the developed applications appears to get stuck in category B (TRL 4). 
These studies presented results of algorithms for (pre-) malignant tissue detection 
with data either collected in-vivo or ex-vivo with prototype Raman systems. 
However, validation of algorithms with an independent large dataset has not been 
proven yet. Some of the systems used in the analyzed studies are already further 
towards actual clinical use, and were classified as C, such as Zhao et al., Wang et 
al., Kong et al., and Duraipandian et al. (92,94,125,127).   
 Development of commercial instruments for oncological 
applications  
We realized that most of the studies do not report a fully commercial product (ready 
to be used in the clinic). We therefore contacted the companies that are collaborating 
directly with the research groups presented in the Raman applications section. We 
also investigated the progress/potential interest of the companies which are 
developing or have developed commercial Raman spectroscopic systems for 
oncological applications. We received information from the following leading 
companies in Raman spectroscopy: Avantes B.V., B&W Tek, EmVision LLC, 
Invenio B.V., Horiba Jobin-Yvon Inc. (HORIBA Scientific), ODS Medical Inc., 
Renishaw, RiverD International B.V., Verisante Technology Inc., and WITec B.V.. 
Based on the information received we have created a future perspective of clinical 
translation, which is presented in figure 6 (2017-2021). 
Progress reported by companies: B&W Tek has developed a Raman 
spectroscopic system, for the identification and qualification of cytostatics (in-vitro). 
B&W Tek is a company that provides instruments looking for R&D partners. 
Invenio Imaging Inc. is developing a stimulated Raman scattering microscope for 
histological examination of fresh tissue. The most recent publication was in Nature 
Biomedical Engineering, early 2017 (207). The perspective of the company is to 
have the equipment ready to be commercialized later this year. EmVision LLC does 
not manufacture or develop clinical systems, but the company is active in selling 
components, such as fiber-optic probes, to companies that are pursuing clinical 
systems. HORIBA Scientific is an active member of Raman4Clinics European 
project and provides research and analytical Raman instruments for all kind of 
applications, including oncology. ODS Medical Inc. is developing an in-vivo Raman 
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tool for surgical brain tumor resection (148,208-211). The company predicts that the 
system will be commercialized within approximately 3 years (in 2020) following 
approval by regulatory bodies, including FDA. Renishaw has been actively 
developing a Raman system for ex-vivo analysis of tissue cells and bio fluids for 
clinical use. The company is upgrading fiber-optic probe designs for clinical use 
during oncological surgery. This company has an ex-vivo Raman spectroscopy 
platform (InVia series, Renishaw, Gloucestershire, U.K.) for a number of life-
science and clinical applications including tissue pathology, neurobiology, stem cell 
research. Renishaw is currently developing a fast tissue imaging platform, which is 
based on the RA802 Pharmaceutical Analyser, for measuring uneven tissue surfaces 
with a minimum of sample preparation (212-214). The new fast tissue imaging 
platform should be available in the summer of 2017. 
RiverD International B.V. collaborates with the University of Nottingham in the 
development of an auto-fluorescence/Raman system for Mohs’ micrographic surgery 
of basal cell carcinoma. Two prototype systems are currently being tested at the 
University of Nottingham, in UK, and at Erasmus MC University Medical Center 
Rotterdam, in the Netherlands. The systems are based on the concept described by 
the Nottingham group (94). RiverD International B.V. is developing a Raman tool 
for surgical guidance of Head and Neck tumor resection, which they predict to be 
ready for clinical trials in 2019. Currently, an ex-vivo fiber-optic probe system is 
being developed for intra-operative inspection of resection margins of excised tissue. 
The company is also collaborating in an R&D project that aims to the development 
of a Raman spectroscopic device for use by dermatologists and general practitioners 
for objective assessment of pigmented skin lesions clinically suspected of melanoma 
(89,101). 
Verisante Technology Inc. is developing in-vivo Raman technology for clinical 
oncology applications focused on: 1) in-vivo non-invasive detection of skin cancers 
including melanoma and non-melanoma skin cancers; 2) endoscopy detection of 
cancers of internal organs such as lung cancers and gastro-intestinal cancers 
(90,111,113,215-217). Currently, Verisante Technology Inc. is commercializing a 
skin cancer detection device (Verisante Aura, see Figure 7) in Canada, Europe and 
Australia. Aura systems are being in use in several clinics in Canada. In figure 6, 
Verisante Aura is identified by [*]. WITec B.V. develops and commercializes 
confocal Raman microscope systems. The company is not actively involved in 
development of applications in the clinical oncology field. However, various users 
of the confocal Raman microscopes have applied their instruments in oncology-
relevant research (218-221).   
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Figure 6. Illustration of the result from the technology readiness classification of the 
different Raman studies, mentioned in the Raman applications section. Verisante 
Technology Inc. is commercializing a device (Verisante Aura) for skin cancer detection 
[*]. In the graph is also plotted the prognosis (2017-2021) of further 
development/commercialization given by the companies RiverD International B.V. [**] 
and ODS Medical Inc. [***]. 
Hurdles in translation reported by companies: Some of the companies 
have indicated what hurdles they have encountered when translating Raman systems 
into the clinics. One important issue can be assuring that high-quality data can be 
acquired consistently and robustly under intra-operative conditions, with minimal 
disruption of the surgical workflow (210). It is also important to ensure that real-
time high-accuracy tissue classification is provided to surgeons in an intuitive way 
and by simple metrics (user-friendliness). 
Another referred problem is to find funding/investors that can help to bring the 
product into the market. The fact that Raman spectroscopy is still a relatively 
unknown technique for most clinicians, was yet another hurdle mentioned. This can 
be partially explained by the fact that from all the scientific studies reviewed in this 
article only approximately 30% were published in medical oriented journals. 
Another explanation for Raman spectroscopy to be relatively unknown might be also 
partly due to this technique not being widely incorporated in the curriculum of 
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clinicians or clinical researchers. To resolve this, more effort should be done towards 
publication of clinical Raman studies in medical oriented journals. Additionally, 
current academic leaders in the medical field, who have knowledge of clinical 
spectroscopy, should encourage the introduction of this subject in medical school 
curriculums alongside other medical imaging and diagnostic topics.   
 
Figure 7 - Verisante Aura system for skin detection. Courtesy of Verisante Technology, 
Inc. (http://www.verisante.com/aura/medical_professional/) 
 
Discussion  
In the last decade a strong effort has been made towards clinical implementation of 
Raman spectroscopy as an adjunct technique for early diagnosis, biopsy guidance 
and oncologic surgery guidance. The most recent studies aim to: 1) detect pre-
malignant lesions (113,125,126,136,164,222), 2) detect cancer in less advanced 
stages (101,113,125,157,158), 3) reduce the number of unnecessary biopsies 
(91,96,112,113), and 4) guide surgery towards complete removal of the tumor 
(76,94,138,148,206). This means that Raman spectroscopy is used to detect (pre-
)malignant lesions for guidance of clinical procedures. A next step would be to use 
Raman spectroscopy in diagnosis of (pre-)malignant lesions; i.e. differentiating 
between different types of cancer and grading (pre-)malignant lesions (e.g., 
differentiating high-grade from low-grade dysplasia) (12,111,126,127,136). Raman 
spectroscopy may address all the clinical needs mentioned, because, in fact, all show 
the same fundamental problem: lack of pre- and intra-operative methods with 
sufficient or clinically relevant sensitivity and specificity. Raman spectroscopy is an 
objective technique that can add biochemical information, can be performed in-vivo 
and can be used in real-time. Raman spectroscopy can help pathologists and 
surgeons to assure adequate resection margins intra-operatively (2,20,21,82,148). 
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Consequently, the use of this technique may help to improve the surgical outcome of 
the patients and to decrease the need for adjuvant therapy.  Raman spectroscopy can 
also give an objective and reliable decision about malignancy and early malignant 
stages (2,20,21,82,223). This technique could help medical professionals in 
assessing with a clinically relevant specificity and sensitivity the location for most 
representative biopsies (2,21,223). In-vivo and ex-vivo trials that aim for detection 
of malignant tissue have achieved sensitivities varying between 77% and 100% and 
specificities varying between 45% and 100%. Studies that aimed for detection of 
pre-malignant lesions presented specificities (ranging between 63% and 97.8%) and 
sensitivities (ranging between 70% and 93.5%). Although these numbers are not 
perfect they demonstrate that Raman spectroscopy can help to improve current 
clinical practice.  In the past, a disadvantage of Raman spectroscopy was the low 
measurement speed. One way to overcome this is to complement Raman 
spectroscopy with other techniques, such as auto-fluorescence imaging. For instance, 
Kong et al. and McGregor et al, (94,113,224) have used auto-fluorescence imaging 
to quickly scan large areas of tissue for selection of the measurement locations for 
Raman spectroscopy, thereby reducing the time spent on redundant or non-relevant 
Raman measurements (94,202). Although spontaneous Raman spectroscopy is a 
mature technology there is still considerable development in instrumentation that 
further enable development towards clinical applications, in particular 1) advances 
in the detector technology, 2) in-vivo miniature fiber-optic probes to be used as an 
adjunct device to conventional endoscopes for biopsy targeting or for surgery 
guidance, 3) combined fluorescence microscopy and Raman spectroscopy systems 
for guided surgery, and 4) new lasers for low-cost Raman devices. The number of 
scientific groups that are working towards implementation of Raman spectroscopy 
devices in clinical procedures is remarkable. Most of the studies (89%) still take 
place at the same technology readiness level (TRL-4, or class B). In these studies, 
algorithms have been developed for detection of (pre-) malignant tissue based on in-
vivo or ex-vivo measurements, under conditions that approach the intended clinical 
environment. Validation of these algorithms based on large independent datasets 
obtained in the actual clinical workflow still needs to happen. We have observed that 
approximately 30% of the reviewed studies were published in medical journals. In 
order to raise awareness and increase acceptance of Raman technologies among 
clinicians and clinical researchers results of Raman cancer diagnostic studies should 
be presented at medical conferences and published in medical journals. Better 
communication between clinicians and spectroscopists will facilitate understanding 
of the clinical requirements and challenges. The gap between technology developers 
and clinicians is narrowing due to the contribution of multidisciplinary networks like 
ClirSpec, Raman4Clinics (EU COST Action BM1401) and EPIC. These networks 
also actively pursue standardization of sample preparation, measurements, data 
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analysis protocols, which will help to form a basis for transferability and thereby 
accelerate the developments discussed in this review. These networks can also play 
an important role in presenting Raman spectroscopy as a technology that can 
complement and facilitate the work of the clinicians and improve patient outcome.  
In summary, based on the expectation given by the companies, we believe that 
within 5 years Raman-based oncological products will advance into routine clinical 
settings. 
 
  
15432-Barroso_BNW.indd   74 05-04-18   08:55
2Chapter 2 
 
75 
References 
1. World Health Organization, 
GLOBOCAN 2012: Estimated Cancer 
Incidence, Mortality and Prevalence 
Worldwide in 2012, 
http://globocan.iarc.fr, (accessed 22 
March 2017). 
2. Çulha M., Bioanalysis, 2015; 7, 2813–
2824. 
3. Mendoza P., Lacambra M., Tan P.-H., 
Patholog. Res. Int.. 2011; 2011, 1–8. 
4. Quail D. and Joyce J., Nat. Med.. 2013; 
19, 1423–1437. 
5. Menakuru S. R., Brown N. J., Staton C. 
A., Br. J. Cancer. 2008; 99, 1961–
1966. 
6. Bokhorst L. P., Zhu X., Bul M., BJU 
Int.. 2012; 110, 1654–1660. 
7. Rominger M., Wisgickl C. and 
Timmesfeld N., RoFo. 2012; 184, 
1144–1152. 
8. McWilliams A., Tammemagi M. C., 
Mayo J. R., N. Engl. J. Med.. 2013; 
369, 910–9. 
9. Carli P., Mannone F., De Giorgi V., 
Melanoma Res, 2003; 2, 179–182. 
10.  Kuo W.-C., Kim J., Shemonski N. 
D., Biomed. Opt. Express. 2012; 3, 
1149–61. 
11.  Hariri L. P., Mino-Kenudson M., 
Applegate M. B., Chest. 2013; 144, 
1261–1268. 
12.  Bergholt M. S., Lin K., Wang J., J. 
Biophotonics. 2016; 9, 333–342. 
13.  Shin D., Vigneswaran N., 
Gillenwater A., Future Oncol.. 2010; 
6, 1143–54. 
14.  Wong Kee Song L. M., Banerjee S., 
Desilets D., Gastrointest. Endosc.. 
2011; 73, 647–650. 
15.  Wang Y., Wang Q., Feng J., Patient 
Prefer. Adherence. 2013; 7, 621–631. 
16.  Nijssen A., Koljenović S., Bakker 
Schut T. C., J. Biophotonics. 2009; 2, 
29–36. 
17.  Broadbent B., Tseng J., Kast R., J. 
Neurooncol.. 2016, 130; 1–9. 
18.  Wang W., Zhao J., Short M., J. 
Biophotonics. 2015; 8, 527–545. 
19.  Li X., Wang Y., Zhang X., Conf. 
Proc. IEEE Eng. Med. Biol. Soc.. 
2005; 2, 1453–6. 
20.  Kallaway C., Almond L. M., Barr H., 
Photodiagnosis Photodyn. Ther.. 
2013; 10, 207–219. 
21.  McGregor H., Wang W., Short M., 
Adv. Heal. Care Technol.. 2016; 2, 
13. 
22.  Binahmed A., Nason R. W. and 
Abdoh A. A.. Oral Oncol.. 2007; 43, 
780–784. 
23.  Smits R. W. H., Koljenović S., 
Hardillo J. A., Head Neck. 2016; 38, 
E2197–E2203. 
15432-Barroso_BNW.indd   75 05-04-18   08:55
76 
24.  Dillon J. K., Brown C. B., McDonald 
T. M., J. Oral Maxillofac. Surg.. 
2015; 73, 1182–1188. 
25.  Neuzillet Y., Soulie M., Larre S., 
BJU Int.. 2013; 111, 1253–1260. 
26.  Gokavarapu S., Rao L. M. C., 
Mahajan M., Br. J. Oral Maxillofac. 
Surg.. 2015; 53, 875–879. 
27.  Williams M. D.. Curr. Oncol. Rep.. 
2016; 18, 54. 
28.  Miedema J. R. and Hunt H. V. J. 
Gastrointestin. Liver Dis.. 2010; 19, 
181–5. 
29.  Olson T. P., Harter J., Muñoz A., 
Ann. Surg. Oncol.. 2007; 14, 2953–
2960. 
30.  Emmadi R. and Wiley E. L.. Int. J. 
Surg. Oncol.. 2012; 2012, 1–9. 
31.  Trejo Bittar H. E., Incharoen P., 
Althouse A. D., Mod. Pathol.. 2015; 
28, 1058–63. 
32.  Rosenthal E. L., Warram J. M., 
Bland K. I., Ann. Surg.. 2015; 261, 
46–55. 
33.  Varvares M. A., Poti S., Kenyon B., 
Laryngoscope. 2015; 125, 2298–
2307. 
34.  Magee N. D., Beattie J. R., Carland 
C., J. Biomed. Opt.. 2010; 15, 
026015(1-8). 
35.  McIntosh E. R., Harada S., Drwiega 
J., Ann. Diagn. Pathol.. 2015; 19, 
326–329. 
36.  Senft C., Bink A., Franz K., Lancet 
Oncol.. 2011; 12, 997–1003. 
37.  Senft C., Schoenes B., Gasser T., J. 
Neurosurg. Anesthesiol.. 2011; 23, 
241–6. 
38.  Wong J. M., Panchmatia J. R., 
Ziewacz J. E., Neurosurg. Focus. 
2012; 33, E16. 
39. Wu J.-S., Mao Y., Zhou L.-F., 
Neurosusrgery. 2007; 61, 935–949. 
40.  Claus E. B., Horlacher A., Hsu L., 
Cancer. 2005; 103, 1227–1233. 
41.  Kuhnt D., Becker A., Ganslandt O., 
Neuro. Oncol.. 2011; 13, 1339–1348. 
42. Kubben P. L., ter Meulen K. J., 
Schijns O. E. M. G., Lancet Oncol.. 
2011; 12, 1062–1070. 
43.  Visgauss J. D., Eward W. C. and 
Brigman B. E.. Orthop. Clin. North 
Am.. 2016; 47, 253–264. 
44.  Prada F., Perin A., Martegani A., 
Neurosurgery. 2014; 74, 542–552. 
45.  Selbekk T., Jakola A. S., Solheim O., 
Acta Neurochir. (Wien).. 2013; 155, 
973–980. 
46. Erickson-Bhatt S. J., Nolan R. M., 
Shemonski N. D., Cancer Res.. 2015; 
75, 3706–3712. 
47.  Stummer W., Pichlmeier U., Meinel 
T., Lancet Oncol.. 2006; 7, 392–401. 
48.  Widhalm G., Kiesel B., Woehrer A., 
PLoS One, 
DOI:10.1371/journal.pone.0076988. 
49.  Stummer W., Tonn J.-C., Mehdorn 
H. M., J. Neurosurg.. 2011; 114, 613–
623. 
15432-Barroso_BNW.indd   76 05-04-18   08:55
2Chapter 2 
 
77 
50.  Roberts D. W., Valdés P. A., Harris 
B. T., J. Neuroserg.. 2011; 114, 595–
603. 
51. Agdeppa E. D. and Spilker M. E., 
AAPS J.. 2009; 11, 286–299. 
52.  Jermyn M., Mok K., Mercier J., Sci. 
Transl. Med.. 2015; 7, 274ra19-
274ra19. 
53.  Haka A. S., Volynskaya Z., Gardecki 
J., J. Biomed. Opt.. 2009; 14, 54023. 
54. Kourkoumelis N., Balatsoukas I., 
Moulia V., Int. J. Mol. Sci.. 2015; 16, 
14554–14570. 
55. Austin L. A., Osseiran S.and Evans C. 
L., Analyst. 2016; 141, 476–503. 
56.  Pence I.and Mahadevan-Jansen A., 
Chem. Soc. Rev.. 2016; 45, 1958–
1979. 
57. Shipp D. W., Sinjab F. and Notingher 
I., Adv. Opt. Photon. 2017; 9, 315-
428. 
 58. Krafft C., Schie I. W., Meyer T., 
Chem. Soc. Rev.. 2016; 45, 1819–
1849. 
59.  Camp Jr C. H. and Cicerone M. T., 
Nat. Photonics. 2015; 9, 295–305. 
60.  Kerr L. T., Lynn T. M., Cullen I. M., 
Anal. Methods. 2016; 8, 4991–5000. 
61.  Isabelle M., Stone N., Barr H., 
Spectr.. 2008; 22, 97-104. 
62.  European Commission, Horizon 
2020; Work programme. 2014-2015, 
2014. 
63. Johnson J. M., Dalton R. R., Wester 
S. M., Arch Surg. 1999; 134, 712–
716. 
64.  Wang M., He X., Chang Y., The 
Breast. 2017; 31, 157–166. 
65.  Sun W., Li A., Abreo F., Diagn. 
Cytopathol.. 2001; 24, 421–5. 
66.  Lieske B., Ravichandran D. and 
Wright D., Br. J. Cancer. 2006; 95, 
62–66. 
67.  Yu Y.-H., Wei W., Liu J.-L., BMC 
Cancer. 2012; 12, 41. 
68.  Kazi M., Suhani, Parshad R., World 
J. Surg.. 2017; 41, 1528–1533. 
69.  van Maaren M. C., de Munck L., 
Jobsen J. J., Breast Cancer Res. 
Treat.. 2016; 160, 511–521. 
70. Onitilo A. A., Engel J. M., 
Stankowski R. V., Clin. Med. Res.. 
2015; 13, 65–73. 
71.  Agarwal S., Pappas L., Neumayer L., 
JAMA Surg.. 2014; 149, 267. 
72.  Ellis I. O., Carder P., Hales S., 
Pathology reporting of breast disease 
in surgical excision specimens 
incorporating the dataset for 
histological reporting of breast 
cancer. 2016. 
73.  Vos E. L., Siesling S., Baaijens M. 
H. A., Breast Cancer Res. Treat., 
DOI:10.1007/s10549-017-4232-6. 
74. Jacobs L., Ann. Surg. Oncol.. 2008; 
15, 1271–1272. 
75.  Saha A., Barman I., Dingari N. C., 
Biomed. Opt. Express. 2011; 2, 2792. 
15432-Barroso_BNW.indd   77 05-04-18   08:55
78 
76. Barman I., Dingari N. C., Saha A., 
Cancer Res.. 2013; 73, 3206–3215. 
77. Lomas A., Leonardi-Bee J. and Bath-
Hextall F.. Br. J. Dermatol.. 2012; 
166, 1069–1080. 
78.  Lewis K. G. and Weinstock M. A., 
Arch Dermatol. 2004; 140, 837–842. 
79.  Drakaki E., Vergou T., Dessinioti C., 
J. Biomed. Opt.. 2013; 18, 61221. 
80.  Basaalcercarcinoom-Klinische 
marges BCC,  
https://richtlijnendatabase.nl/richtlijn/basa
alcelcarcinoom/conventionele_chirur
gische_excisie_bcc/klinische_marges
_bcc.html, (accessed 25 April 2017). 
81.  van Loo E., Mosterd K., Krekels G. 
A. M., Eur. J. Cancer. 2014; 50, 
3011–3020. 
82.  Jermyn M., Desroches J., Aubertin 
K., Phys. Med. Biol.. 2016; 61, R370–
R400. 
83.  Siegel R., Ma J., Zou Z., CA. Cancer 
J. Clin.. 2014; 64, 9–29. 
84.  Balch C. M., Gershenwald J. E., 
Soong S. J., J. Clin. Oncol.. 2009; 27, 
6199–6206. 
85.  Dickson P. V. and Gershenwald J. E., 
Surg. Oncol. Clin. N. Am.. 2011; 20, 
1–17. 
86.  Kittler H., Pehamberger H., Wolff 
K., Lancet Oncol.. 2002; 3, 159–65. 
87.  Morton C. A. and Mackie R. M., Br. 
J. Dermatol.. 1998; 138, 283–7. 
88.  van der Rhee J. I., Bergman W. and 
Kukutsch N., Acta Derm. Venereol.. 
2011; 91, 428–31. 
89. Santos I. P., Caspers P. J., Bakker 
Schut T. C., Anal. Chem.. 2016; 88, 
7683–7688. 
90.  Lui H., Zhao J., McLean D., Cancer 
Res.. 2012; 72, 2491–2500. 
91.  Lieber C., Majumder S. K., 
Billheimer D., J. Biomed. Opt.. 2008; 
13, 24013. 
92. Zhao J., Lui H., Kalia S., Anal. 
Bioanal. Chem.. 2015; 407, 8373–
8379. 
93.  Schleusener J., Gluszczynska P., 
Reble C., Exp. Dermatol.. 2015; 24, 
767–772. 
94.  Kong K., Rowlands C. J., Varma S., 
Proc. Natl. Acad. Sci. U. S. A.. 2013; 
110, 15189–94. 
95.  Eberhardt K., Stiebing C., Matthäus 
C., Expert Rev. Mol. Diagn.. 2015; 
15, 773–87. 
96.  Zhao J., Lui H., McLea D. I., Conf. 
Proc. IEEE Eng. Med. Biol. Soc.. 
2008; 2008, 3107–3109. 
97.  Lieber C. and Mahadevan-Jansen A.. 
Opt. Express. 2007; 15, 11874–
11882. 
98. Lieber C. A., Majumder S. K., Ellis 
D. L., Lasers Surg Med. 2008; 40, 
461–467. 
99. Silveira L., Silveira F. L., Bodanese 
B., Proc. SPIE. 2012; 8207, 82070X–
1–7. 
100. Lim L., Nichols B., Migden M. R., J. 
15432-Barroso_BNW.indd   78 05-04-18   08:55
2Chapter 2 
 
79 
Biomed. Opt.. 2014; 19, 117003. 
101. Santos I. P., Caspers P. J., Bakker 
Schut T., J. Raman Spectrosc.. 2015; 
652–660. 
102. Bratchenko I. A., Artemyev D. N., 
Myakinin O. O., J. Biomed. Opt.. 
2017; 22, 27005. 
103. Sun J., Garfield D. H., Lam B., J 
Thorac Oncol.. 2011; 6, 1336–1344. 
104. Jain P., Hadique S. and Mehta A. C.. 
Interventional Bronchoscopy, 
Humana Press, Totowa, NJ, 2013; 
vol. 100, pp. 15–44. 
105. Idowu M. O. and Powers C. N.. Int. 
J. Clin. Exp. Pathol.. 2010; 3, 367–
385. 
106. Ginsberg R. J. and Rubinstein L. V.. 
Ann. Thorac. Surg.. 1995; 60, 615–
623. 
107. Landreneau R. J., Sugarbaker D. J., 
Mack M. J., J. Thorac. Cardiovasc. 
Surg.. 1997; 113, 691–700. 
108. Blasberg J. D., Pass H. I. and 
Donington J. S., J Thorac Oncol.. 
2010; 5, 1583–1593. 
109. Liu S., Wang R., Zhang Y., J. Clin. 
Oncol.. 2016; 34, 307–313. 
110. Yeh Y.-C., Nitadori J., Kadota K., 
Histopathology. 2015; 66, 922–938. 
111. Short M. A., Lam S., McWilliams 
A., Opt. Lett.. 2008; 33, 711–3. 
112. Short M. A., Lam S., McWilliams A. 
M., J. Thorac. Oncol.. 2011; 6, 1206–
1214. 
113. McGregor H. C., Short M. A., 
McWilliams A., J. Biophotonics. 
2016; 13, n/a-n/a. 
114. Ferlay J., Soerjomataram I., Dikshit 
R., Int. J. Cancer. 2015; 136, E359–
E386. 
115. Rees J., Lao-Sirieix P., Wong A., 
Cochrane Database Syst. Rev.. 2011; 
2010–2012. 
116. Lal N., Bhasin D. K., Malik K., Gut. 
1992; 33, 724–6. 
117. Choi Y., Choi H. S., Jeon W. K., J. 
Korean Med. Sci.. 2012; 27, 36–39. 
118. Menon S. and Trudgill N., Endosc. 
Int. Open. 2014; 2, E46–E50. 
119. Tsutsui S., Kuwano H., Watanabe 
M., Ann. Surg.. 1995; 222, 193–202. 
120. Casson A. G., Darnton S. J., 
Subramanian S., Ann. Thorac. Surg.. 
2000; 69, 205–209. 
121. Sagar P. M., Johnston D., McMahon 
M. J., Br. J. Surg.. 1993; 80, 1386–
1388. 
122. Dexter S. P., Sue-Ling H., McMahon 
M. J., Gut. 2001; 48, 667–670. 
123. Teh S. K., Zheng W., Ho K. Y., Br. 
J. Cancer. 2008; 98, 457–65. 
124. Bergholt M. S., Zheng W., Lin K., 
Analyst. 2010; 135, 3162–3168. 
125. Duraipandian S., Bergholt M. S., 
Zheng W., J. Biomed. Opt.. 2012; 17, 
81418. 
126. Bergholt M. S., Zheng W., Ho K. Y., 
Proc. SPIE. 2014; 8939, 89390M. 
15432-Barroso_BNW.indd   79 05-04-18   08:55
80 
127. Lin K., Wang J., Sylvest Bergholt 
M., Proc. of SPIE, eds. M. J. Suter, S. 
Lam, M. Brenner, G. J. Tearney and 
T. D. Wang, Nature Publishing 
Group, 2015; vol. 9304, p. 93040V. 
128. Ishigaki M., Maeda Y., Taketani A., 
Analyst. 2015; 141, 1027–33. 
129. Wang J., Lin K., Zheng W., Sci. 
Rep.. 2015; 5, 12957. 
130. Slootweg P. J., Hordijk G. J., Schade 
Y., Oral Oncol.. 2002; 38, 500–503. 
131. Al-Rajhi N., Khafaga Y., El-
Husseiny J., Oral Oncol.. 2000; 36, 
508–514. 
132. Helliwell T. and Woolgar J.. Dataset 
for histopathology reporting of 
mucosal malignancies of the nasal 
cavities and paranasal sinuses. 2013. 
133. Helliwell T.and Woolgar J.. Dataset 
for histopathology reporting of 
mucosal malignancies of the larynx. 
2013. 
134. Hoffmannová J., Foltán R., Vlk M., 
Int. J. Oral Maxillofac. Surg.. 2010; 
39, 561–567. 
135. Barroso E. M., Smits R. W. H., 
Schut T. C. B., Anal. Chem.. 2015; 
87, 2419–2426. 
136. Krishna H., Majumder S. K., 
Chaturvedi P., J. Biophotonics. 2014; 
7, 690–702. 
137. Guze K., Pawluk H. C., Short M., 
Head Neck. 2015; 37, 511–517. 
138. Barroso E. M., Smits R. W. H., Van 
Lanschot C. G. F., Cancer Res.. 2016; 
76, 5945–5953. 
139. Wong E. T. and Wu J. K.. Clinical 
presentation and diagnosis of brain 
tumors, 
https://www.uptodate.com/contents/cl
inical-presentation-and-diagnosis-of-
brain-
tumors?source=search_result&search
=brain 
cancer&selectedTitle=1~150#H22, 
(accessed 12 May 2017). 
140. Hollon T., Lewis S., Freudiger C. 
W., Neurosurg. Focus, 2016; 40, E9. 
141. Koljenović S., Choo-Smith L.-P., 
Bakker Schut T. C., Lab. Investig.. 
2002; 82, 1265–1277. 
142. Marko N. F., Weil R. J., Schroeder J. 
L., J. Clin. Oncol.. 2014; 32, 774–
782. 
143. Sanai N., Chang S. and Berger M., J 
Neurosurg. 2011; 115, 945–947. 
144. Lu F. K., Calligaris D., Olubiyi O. I., 
Cancer Res.. 2016; 76, 3451–3462. 
145. Albert F., Forsting M., Sartor K., 
Neurosurgery. 1994; 34, 45–61. 
146. Ulmer S., World J. Radiol.. 2014; 6, 
538–43. 
147. Ji M., Lewis S., Camelo-Piragua S., 
Sci. Transl. Med.. 2015; 7, 309ra163-
309ra163. 
148. Jermyn M., Mok K., Mercier J., 
Science Translational Medicine, eds. 
R. R. Alfano and S. G. Demos, 2015; 
vol. 7, p. 93180D. 
149. Wallace M. B. and Keisslich R., 
Gastroenterology. 2010; 138, 2140–
2150. 
15432-Barroso_BNW.indd   80 05-04-18   08:55
2Chapter 2 
 
81 
150. Bressler B., Paszat L. F., Chen Z., 
Gastroenterology. 2007; 132, 96–102. 
151. Quintero E., Hassan C., Senore C., 
Gastroenterol. Res. Pract.. 
DOI:10.1155/2012/846985. 
152. Stallmach A., Schmidt C., Watson 
A., J. Biophotonics. 2011; 4, 482–
489. 
153. Kessler W. R., Imperiale T. F., Klein 
R. W., Endoscopy. 2011; 43, 683–
691. 
154. Nelson H., Petrelli N., Carlin A., J 
Natl Cancer Inst. 2001; 93, 591. 
155. Amri R., Bordeianou L. G., Sylla P., 
JAMA Surg.. 2015; 150, 890–8. 
156. O’Connell J. B., Maggard M. and Ko 
C. Y., J. Natl. Cancer Inst.. 2004; 96, 
1420–1425. 
157. Widjaja E., Zheng W. and Huang Z., 
Int. J. Oncol.. 2008; 32, 653–662. 
158. Short M. A., Tai I. T., Owen D., Opt. 
Express. 2013; 21, 5025–34. 
159. Peirson L., Fitzpatrick-Lewis D., 
Ciliska D., Syst. Rev., 2013; 2, 35. 
160. Nanda K., Mccrory D. C., Myers E. 
R., Ann Intern Med.. 2000; 132, 810–
819. 
161. Cuzick J., Clavel C., Petry K.-U., 
Int. J. Cancer. 2006; 119, 1095–1101. 
162. Mustafa R. A., Santesso N., Khatib 
R., Int. J. Gynecol. Obstet.. 2016; 
132, 259–265. 
163. Eftekhar Z., Rahimi-Moghaddam P., 
Yarandi F., Asian Pac. J. Cancer 
Prev.. 2005; 6, 69–71. 
164. Mo J., Zheng W., Low J. J. H., Anal. 
Chem.. 2009; 81, 8908–15. 
165. Kanter E. M., Vargis E., Majumder 
S., J. Biophotonics. 2009; 2, 81–90. 
166. Duraipandian S., Zheng W., Ng J., 
Analyst. 2011; 136, 4328. 
167. Duraipandian S., Zheng W., Ng J., 
Anal. Chem.. 2012; 84, 5913–5919. 
168. Ramos I. R. M., Malkin A. and Lyng 
F. M., Biomed Res. Int.. 2015; 2015, 
1–9. 
169. Rubina S., Amita M., Kedar K. D., 
Vib. Spectrosc.. 2013; 68, 115–121. 
170. Vulval cancer mortality statistics, 
(accessed 4 April 2017), 
http://www.cancerresearchuk.org/heal
th-professional/cancer-
statistics/statistics-by-cancer-
type/vulval-
cancer/mortality#heading-Zero. 
171. Wessels R., de Bruin D. M., Faber 
D. J., J. Biomed. Opt.. 2012; 17, 
116022. 
172. Dellinger T. H., Hakim A. A., Lee S. 
J., 1999; 15, 1–5. 
173. Heaps J. M., Fu Y. S., Montz F. J., 
Gynecol. Oncol.. 1990; 38, 309–314. 
174. Chan J. K., Sugiyama V., Pham H., 
Gynecol. Oncol.; 2007, 104, 636–641. 
175. Wessels R., van Beurden M., de 
Bruin D. M., Int. J. Gynecol. Cancer. 
2015; 25, 112–118. 
176. Frost J., Ludeman L., Hillaby K., 
15432-Barroso_BNW.indd   81 05-04-18   08:55
82 
Analyst. 2017; 142, 1200–1206. 
177. Minamikawa T., Harada Y. and 
Takamatsu T., Sci. Rep.. 2015; 5, 
17165. 
178. Clark P. E., Agarwal N., Biagioli M. 
C., J. Natl. Compr. Cancer Netw.. 
2013; 11, 446–75. 
179. Barman I., Dingari N. C., Singh G. 
P., Anal. Bioanal. Chem.. 2012; 404, 
3091–3099. 
180. Jocham D., Stepp H.and Waidelich 
R., Eur. Urol.. 2008; 53, 1138–1150. 
181. Seltz L. M. and Herrell S. D., Curr. 
Opin. Urol.. 2016; 26, 259–263. 
182. Dotan Z. A., Kavanagh K., 
Yossepowitch O., J. Urol.. 2007; 178, 
2308–2313. 
183. Novara G., Svatek R. S., 
Karakiewicz P. I.,. Urol.. 2010; 183, 
2165–2170. 
184. Grimbergen M. C. M., van Swol C. 
F. P., Draga R. O. P., 2009; vol. 7161, 
p. 716114. 
185. Draga R. O. P., Grimbergen M. C. 
M., Vijverberg P. L. M., Anal. Chem.. 
2010; 82, 5993–5999. 
186. Ruijter E., Van De Kaa C., Miller 
G., Endocr. Rev.. 1999; 20, 22–45. 
187. Eichler K., Hempel S., Wilby J., J. 
Urol.. 2006; 175, 1605–1612. 
188. Mottet N., Bellmunt J., Bolla M., 
Eur. Urol.. 2016; 71, 1–12. 
189. Schlomm T., Tennstedt P., Huxhold 
C., Eur. Urol.. 2012; 62, 333–340. 
190. Li M., Banerjee S. R., Zheng C., 
Chem. Sci.. 2016; 7, 6779–6785. 
191. Kast R. E., Tucker S. C., Killian K., 
Cancer Metastasis Rev.. 2014; 33, 
673–693. 
192. Patil C. A., Pence I. J., Lieber C. A., 
Opt. Lett.. 2014; 39, 303–306. 
193. Pence I. J., Patil C. A., Lieber C. A., 
Biomed. Opt. Express. 2015; 6, 2724–
37. 
194. Duraipandian S., Zheng W., Ng J., J. 
Biomed. Opt.. 2013; 18, 67007. 
195. Desroches J., Jermyn M., Mok K., 
Biomed. Opt. Express. 2015; 6, 2380–
97. 
196. Stevens O., Iping Petterson I. E., 
Day J. C. C., Chem. Soc. Rev.. 2016; 
45, 1919–1934. 
197. Wang J., Bergholt M. S., Zheng W., 
Opt. Lett.. 2013; 38, 2321–3. 
198. Wang J., Lin K., Zheng W., Anal. 
Bioanal. Chem.. 2015; 407, 8303–
8310. 
199. Duraipandian S., Bergholt M. S., 
Zheng W., J. Biomed. Opt.. 2012; 17, 
81418. 
200. Agenant M., Grimbergen M., Draga 
R., Biomed. Opt. Express. 2014; 5, 
1203–16. 
201. Puppels G. J., Cancer Res.. 2017; 77, 
2775-2778. 
202. Takamori S., Kong K., Varma S., 
Biomed. Opt. Express. 2015; 6, 98. 
203. Santos I. P., van der Lee A., Gu X., 
15432-Barroso_BNW.indd   82 05-04-18   08:55
2Chapter 2 
 
83 
J. Raman Spectrosc.. 
DOI:10.1002/jrs.5124. 
204. Kuznetsov M.. in Semiconductor 
Disk Lasers. Physics and Technology, 
ed. O. G. Okhotnikov, WILEY-VCH, 
Weinheim, 2010. 
205. Pallmann W. P., Zaugg C. A., 
Mangold M., Opt. Express. 2012; 20, 
24791. 
206. Nguyen J. Q., Gowani Z. S., 
O’Connor M., Lasers Surg. Med.. 
2016; 48, 774–781. 
207. Orringer D. A., Pandian B., Niknafs 
Y. S., Nat. Biomed. Eng.. 2017; 1, 27. 
208. St-Arnaud K., Aubertin K., Strupler 
M., Opt. Lett.. 2016; 41, 4692–4695. 
209. Jermyn M., Desroches J., Mercier J., 
Biomed. Opt. Express. 2016; 7, 247–
248. 
210. Desroches J., Laurence A., Jermyn 
M., Analyst. 2017; 142, 1185–1191. 
211. Jermyn M., Desroches J., Mercier J., 
J. Biomed. Opt.. 2016; 21, 94002. 
212. Isabelle M., Dorney J., Lewis A., 
Faraday Discuss.. 2016; 187, 87–103. 
213. Gaifulina R., Maher A. T., Kendall 
C., Int. J. Exp. Pathol.. 2016; 97, 
337–350. 
214. Lau K., Isabelle M., Lloyd G. R., 
Biomedical Vibrational Spectroscopy, 
eds. A. Mahadevan-Jansen and W. 
Petrich, 2016; vol. 9704, p. 97040B. 
215. Short M. A., Wang W., Tai I. T., J. 
Biophotonics. 2016; 9, 44–48. 
216. Zhao J., Lui H., McLean D. I., Appl. 
Spectrosc., 2007; 61, 1225–32. 
217. Zhao J., Lui H., McLean D. I., Skin 
Res. Technol., 2008; 14, 484–92. 
218. Abramczyk H., Brozek-Pluska B., 
Surmacki J., Analyst, 2014; 139, 
5547–59. 
219. Mavarani L., Petersen D., El-
Mashtoly S. F., Analyst, 2013; 138, 
4035–9. 
220. Tolstik T., Marquardt C., Matthäus 
C., Analyst. 2014; 139, 6036–43. 
221. Lech G., Słotwiński R., Słodkowski 
M. I., World J. Gastroenterol.. 2016; 
22, 1745–1755. 
222. Wang J., Lin K., Zheng W., Faraday 
Discuss.. 2015; 187, 377–392. 
223. Devpura S., Barton K. N., Brown S. 
L., Med. Phys.. 2014; 41, 50901. 
224. Kong K., Zabar F., Rakha E., Phys. 
Med. Biol.. 2014; 59, 6141-6152. 
15432-Barroso_BNW.indd   83 05-04-18   08:55
   
15432-Barroso_BNW.indd   84 05-04-18   08:55
  
 
 
 
 
 
 
 
 
CHAPTER 3 
 
 
Discrimination between oral cancer 
and healthy tissue based on water 
content determined by Raman 
spectroscopy 
 
E. M. Barroso†, R. W. H. Smits†, T. C. Bakker Schut, I. ten Hove, J. A. Hardillo, E. B. 
Wolvius, R. J. Baatenburg de Jong, S. Koljenović, and G. J. Puppels 
† These authors contributed equally to this work. 
Analytical Chemistry 2015;87(4):2419-2426 
15432-Barroso_BNW.indd   85 05-04-18   08:55
  
15432-Barroso_BNW.indd   86 05-04-18   08:55
3Chapter 3 
87 
Abstract  
Tumor-positive resection margins are a major problem in oral cancer surgery.  High-
wavenumber Raman spectroscopy is a reliable technique to determine the water 
content of tissues which may contribute to differentiate between tumor and healthy 
tissue. The aim of this study was to examine the use of Raman spectroscopy to 
differentiate tumor from surrounding healthy tissue in oral squamous cell carcinoma. 
From fourteen patients undergoing tongue resection for squamous cell carcinoma, 
the water content was determined at 170 locations on freshly excised tongue 
specimens using the Raman-bands of the OH-stretching vibrations (3350-3550cm-1) 
and of the CH-stretching vibrations (2910-2965cm-1). The results were correlated 
with histopathological assessment of hematoxylin and eosin stained thin tissue 
sections obtained from the Raman measurement locations. The water content values 
from squamous cell carcinoma measurements were significantly higher than from 
surrounding healthy tissue (p-value <0.0001). Tumor tissue could be detected with a 
sensitivity of 99% and a specificity of 92% using a cut-off water content value of 
69%. Because the Raman measurements are fast and can be carried out on freshly 
excised tissue without any tissue preparation, this finding signifies an important step 
towards the development of an intra-operative tool for tumor resection guidance 
with the aim of enabling oncological radical surgery and improvement of patient 
outcome. 
 
Introduction 
The primary goal of oncological surgery is the complete removal of cancerous 
tissue. However, in practice this goal is often not achieved. A recent retrospective 
study of oral cavity squamous cell carcinoma (OCSCC) surgery showed tumor-
positive resection margins in up to 43% of cases (1). Tumor-positive resection 
margins are well known to lead to a significantly worse clinical outcome after 
surgery for oral cancer (2,3). The most notable cause of tumor-positive resection 
margins is the surgeon’s inability to reliably differentiate between tumor and healthy 
tissue by ocular inspection and by palpation. Intra-operative histopathological 
assessment of suspicious tissue by means of frozen-section procedures have been 
shown to be unreliable and time-consuming (4-6). This is due to the fact that only a 
very small percentage of the resection margins can be investigated by this procedure 
and that the selection of apparently suspicious tissue still depends on the eyes and 
hands of the surgeon and/ or the pathologist. Intra-operative tools are needed which 
enable support to the surgeon in his assessment of the resection margin.   
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As early as 1971, water content was described as a possible discriminator between 
tumor and healthy tissue (7). Subsequently, tissue water content has been explored 
using several techniques, such as magnetic resonance imaging (MRI) (8-15) and 
terahertz imaging (16). Research on nuclear MRI showed that the main cause of the 
differences observed between the relaxation times of normal and malignant tissues is 
the higher water content in the latter (7,9,13-15). MRI is a standard imaging 
modality for localization of a tumor in the oral cavity and for estimating its relation 
to surrounding tissues and size prior to surgery. However, intra-operative application 
of these imaging technologies is unfeasible in oral cancer surgery for practical and 
financial reasons (17). 
Another promising technique is terahertz (THz) imaging, which is used to measure 
water concentration and water distribution in tissues. For breast cancer, cervical 
cancer, skin cancer and liver cirrhosis, high absorption coefficients were measured 
using this technique (16,18). These high absorption coefficients reflect high water 
content. THz imaging is a surface and/or a sub-dermal technique. For measuring the 
skin this technique can be used quite easily and without extensive preparation. 
Unfortunately, this technique is still in its infancy with only a few studies describing 
small numbers of measurements (19). Future research will determine whether THz 
imaging merits a place in the competitive world of cancer diagnostics. 
García-Flores et al. (2011), using Fourier-Transform (FT) Raman Spectroscopy, 
demonstrated that cancerous tissue in mammary gland tumors in rats shows a higher 
signal intensity in the OH-stretching region of water (3100-3500 cm-1) than normal 
mammary gland tissue. In that study a 1064nm laser was used for excitation and 
signal was detected in the 2800-3600 cm-1 spectral region (20). Philipsen et al. 
(2013), using near infrared Fourier Transform (NIR-FT) Raman spectroscopy, 
showed that the diagnosis of malignant and nonmalignant skin lesions is also 
possible due to significant differences found in the bands around 3250cm-1 (due to 
OH-stretching vibrations and N-H stretching vibrations) in combination with other 
specific proteins (21). Confocal Raman imaging and infra-red (IR) spectroscopy 
have also indicated that the amount of water in breast cancer is remarkably higher 
than in non-cancerous tissue (22).  
Abramczyk et. al. (2014) demonstrated that the vibration properties of water at the 
biological interfaces of human breast tissues, acquired from IR and Raman 
spectroscopy, are sensitive to the cellular environment of the human tissue. These 
differences in the vibrational properties allow distinguishing between malignant and 
normal human breast tissue (23).   
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Raman spectroscopy is very suitable for rapid quantitative (in-vivo) determination of 
the water concentration of tissue (24,25). In the current study, we have applied high-
wavenumber Raman spectroscopy (HWNRS) to quantify the water concentration in 
freshly excised tissue immediately after OCSCC surgery. The primary goal of this 
study was to assess the possibility to distinguish tumor from surrounding (healthy) 
tissue in fresh resection specimens immediately after the surgical procedure. 
 
Materials and Methods 
 Tissue Samples 
Resection material of patients undergoing surgery for squamous cell carcinoma 
(SCC) of the tongue was examined. Tongue resection specimens from 14 patients 
were included in this study. The resections were part of the normal therapeutic 
surgical procedures performed at the Erasmus MC Cancer Institute, University 
Medical Center Rotterdam. Informed consent was obtained prior to the operation 
according to the protocol approved by the Medical Ethics Committee (MEC-2013-
345) of the Erasmus MC Cancer Institute, University Medical Center Rotterdam. 
The maximum time allowed for the experimental procedure described below was 
fixed at 30 minutes, to keep tissue preservation optimal and to avoid interference 
with the routine histopathological examination of the resection specimen. 
Measurement locations were chosen by the surgeon and the pathologist aiming to 
obtain spectra of both tumor and normal tissue. Every chosen location was digitally 
noted with a number on a photograph of the specimen (figure 1.3). Immediately after 
a Raman measurement, each measured position was marked with a colored pin 
(exactly at the place of laser spot) and with the respective digital number. In this 
way, it was possible to relocate measurement positions after routine 
histopathological handling of the resection specimen.  
Raman Instrumentation 
Raman measurements were obtained using a confocal Raman microscope (CRM), 
built in-house.  
The instrument was placed in a room adjoining the examination room of the 
pathology department, enabling Raman measurements without delay. 
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Figure 1.  Overview of specimen handling and measurement protocol. 1.  Resection of 
SCC of the tongue in the surgery room with the orientation shown (anterior (A), 
posterior (P), superior (S), inferior (I). 2. Immediately after operation, the resection 
specimen was transferred to the pathology department in close proximity to the 
operating room. Here, blood was rinsed from the surface of the tissue using 
physiological salt solution. Under supervision of the pathologist an incision was made 
through the tumor and the surrounding healthy tissue In this way both tumor and 
normal tongue tissue were made accessible for Raman measurements (see also figure 
1.3). 3. Pins were used to fix the tongue specimen to a cork plate. The orientation of the 
specimen was indicated on the cork plate (Anterior (A), Posterior (P), Superior (S), 
Inferior (I)). Figures 1.3 and 1.4 also show the demarcation of the locations selected for 
Raman measurements by means of digital labels; red for locations presumed to be 
tumor and green for locations presumed to be surrounding normal tongue tissue. 4. 
Specimen is then transported to the adjoining Raman spectroscopy room. Raman 
spectra were obtained from the marked locations. 5. After the Raman measurements, 
the specimen was placed in formalin and processed for routine clinical histopathological 
evaluation as well as histopathological assessment of each of the locations marked for 
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Raman measurements. These assessments were used for definitive histopathological 
annotation of the measured spectra. 
The setup consisted of a multichannel Raman Module (HPRM 2500, RiverD 
International B.V, the Netherlands), equipped with a 671 nm laser (Crystal Laser, 
CL671-150-SO) and a Charge-Coupled Device (CCD-) camera, fitted with a back-
illuminated deep depletion CCD-chip, which was thermo-electrically cooled to -65 
ᵒC (Andor iDus 401, DU401A BR-DD, Andor Technology Ltd., UK). The Raman 
Module was coupled to a microscope (Leica DM RXA2, Leica Microsystems 
Wetzlar GmbH, Germany) and a computer-controlled sample stage (Leica DM 
STC). A 20x, 0.4 numerical aperture dry objective with a free working distance of 
1.1 mm (N PLAN 11566026, Leica Microsystems B.V, the Netherlands) was used to 
focus 30-80 mW of laser light to a spot of 4 µm in diameter. Spectral data were 
collected in the wavenumber interval from 2500 cm-1 to 4000 cm-1 with a resolution 
<5 cm-1. 
 Measurement Protocol 
Raman spectra were collected at the selected tissue locations. At each measurement 
location up to 30 measurements were carried out with a signal collection time of 1 
second to assure high signal to noise, until all the selected positions were measured, 
or the maximum period of 30 minutes available for this study had passed.  
After performing the Raman measurements, the specimen was immediately 
immersed in formalin according to the standard protocols of the pathology 
department.  
 Histological Examination 
Histopathological evaluation of the measurement locations (marked with pins) was 
performed by means of routine hematoxylin and eosin (H&E) stained thin tissue 
sections (figure 1.5). Each H&E-stained section was photographed and archived. 
 Data Analysis 
Calibration and preprocessing of spectra: 
After data acquisition, the spectra were calibrated to a relative wavenumber axis and 
corrected for the wavelength dependent detection efficiency of the setup according 
to the directions of the spectrometer supplier (RiverD International B.V., the 
Netherlands). Spectral preprocessing was applied comprising removal of cosmic ray 
events and subtraction of background signal generated in the optical path of the 
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setup itself. After pre-processing an average spectrum was calculated for each 
measurement point. 
Calculation of water concentration: 
The ratio of the Raman bands at 3390cm-1 and 2935cm-1 was used to determine the 
concentration of water from the average spectra of each measurement point, 
according to the method developed by Caspers et al. (2001).  
The method uses the background corrected bands of protein (P: 2910-2966 cm-1) and 
water (W: 3350-3550 cm-1), as illustrated in figure 2, to calculate the water 
concentration using the following equation: 
                         
 
 
 
 
  
      (3.1) 
In this equation   is the integrated Raman signal of water,   is the integrated 
Raman signal of protein and   is proportionality constant describing the ratio 
between the Raman bands of water and protein in a solution with a water 
concentration of 50 % (24).  
 
Figure 2. Example of a HWNR spectrum used to illustrate the factors W and P of 
equation 1. P is the Integrated Raman signal intensity of protein, represented by the 
gray bar located between 2910 and 2966 cm-1. W is the Integrated Raman signal 
intensity of water is represented the gray bar, located between 3350 and 3550 cm-1. 
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Signal background was estimated by a linear fit to the first 20 points (2600-2638 cm-
1) and the last 20 points (3762-3800 cm-1) of the signal. The CH-band intensity (P) 
and the OH-stretching band intensity (W) were calculated with respect to this linear 
signal background.   
The error in determining the water concentration is mainly caused by the error in 
estimating the linear background, represented by the red line in figure 2. The error is 
estimated by calculating the two most extreme possible baselines, one with the 
highest possible slope, and one with the lowest possible slope. The error in the water 
calculation is defined as half of the difference between the maximum and minimum 
water concentration values, calculated using these two extreme baselines (25).  
Statistical analysis: 
A Mann-Whitney U-test was used to determine if the water content of squamous cell 
carcinoma and the water content of healthy tissue showed a statistically significant 
difference.  
The power to discriminate between healthy tissue and SCC was determined using a 
ROC (Receiver Operating Characteristic) curve. The ROC curve was obtained by 
determining the number of correct and incorrect classifications as a function of the 
threshold water concentration value to discriminate between the two groups. The 
Youden Index (highest combined specificity and sensitivity) was used to determine 
an optimal threshold value for using the water concentration as a diagnostic marker 
(26). 
 
Results and Discussion 
One hundred and seventy Raman point measurements were performed on tongue 
resection specimens obtained from 14 patients. Each point measurement is 
represented by the average of acquisitions performed in the respective point. 
 Histology and Spectral Analysis 
Seventy one of the 170 Raman point measurements were labeled SCC and 99 were 
labeled normal tissue after histopathological assessment of H&E stained tissue 
sections obtained from the measurement locations. Normal tissue comprised muscle, 
fat, connective tissue, blood vessels, salivary glands and/or nerve. 
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After normalization of the intensity of the spectra to the signal in the CH-stretching 
band (2800 cm-1 to 3040 cm-1), the intensity of the OH-stretching vibration (3450 
cm-1) is seen to be higher in spectra of SCC than in spectra of normal tissue, as 
shown in figure 3.  The spectra in figure 3 were normalized with an extended 
multiplicative signal correction (emsc) to clearly illustrate the differences between 
normal and SCC measurements (27). This normalization was not used for 
calculation of the water concentrations, but only to better illustrate the intensity 
differences for the OH band. 
The Raman experiments did not lead to tissue degeneration and did not interfere 
with routine histopathological evaluation of the resection specimen. The H&E 
sections performed as routine histopathological work-up showed, for all the 
measured locations, tissue without degeneration and without any damages. 
 Statistical significance of water concentration to 
differentiate normal tissue and SCC 
For each spectrum the water concentration was calculated according to equation 3.1. 
Figure 4a shows a graphical representation of all water concentrations, arranged 
according to their histopathological annotation. For the majority of cases the water 
content of SCC was higher than that of normal tissue, as illustrated in figure 4a. The 
clear separation of data points indicates that the groups are significantly different, 
which was confirmed by a Mann-Whitney U-test confirming that the water 
concentration in SCC is significantly higher than in surrounding normal tissue 
(p<0.0001). This difference is illustrated in figure 5a, where a typical spectrum of 
SCC is shown together with the respective H&E stained tissue section. 
Based on the distribution of the water concentration we identified two groups within 
the normal tissue, one with very low water concentration (0-30%) and one with 
moderate water concentration (>30%). The spectrum of the tissue with low water 
concentration is shown in figure 5b, characterized by a high intensity of the CH 
symmetric stretch of lipids (2724 cm-1 and 2926 cm-1), CH2 symmetric stretch of 
lipids (2860 cm-1), CH2 asymmetric stretch of lipids and proteins (2900 cm-1) and 
unsaturated =CH stretch (3010 cm-1) (28). Histopathological correlation revealed 
adipose tissue at this measurement location, as shown in figure 5b1.  
This holds true in general. Whenever we encountered low water concentration this 
was in adipose tissue, which therefore is easy to distinguish from SCC (figure 4a). 
The second group of normal tissue is characterized by CH-stretching vibration 
typical for proteins, which corresponds to muscle and connective tissue based on 
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histopathological evaluation, as shown in figure 5c1 (28) and water concentration 
values higher than 30%. Figure 6c2 shows a representative spectrum of this group. 
In order to verify whether adipose tissue was of major influence on the statistical 
significance of the differences in water concentration between SCC and all normal 
tissues measured, a new calculation was made after removing the adipose tissue 
measurements from our dataset. The difference between the water concentration in 
healthy tissue and SCC remained statistically significant (p<0.0001).  
To investigate the use of the water concentration as a diagnostic marker during 
tumor resection surgery, a ROC curve was generated based on all measurements, 
where the true positive rate (sensitivity) was plotted against the false positive rate for 
different values of water concentration threshold (29). This is displayed in figure 4b. 
Figure 3. All 170 HWNR spectra normalized on the CH-stretching band (2800 cm-1 to 
3040 cm-1). Spectra are colored according to the histopathological evaluation. The green 
color represents spectra from healthy tissue and the red color represents spectra from 
SCC tissue.  
The area under the curve proved to be 0.98. This further illustrates the high 
discriminatory power of water content as a diagnostic marker for SCC detection. 
The Youden Index was used as the optimum cut-off value, since it represents the 
best combination of specificity and sensitivity (26). The Youden index is a water 
concentration of 69%, with a sensitivity of 99% and a specificity of 92%. 
The mean error in the estimation of the water concentration for healthy non-adipose 
tissue and SCC is 0.95%. For a cut-off of 69±0.95% the sensitivity stays 99% but the 
specificity ranges between 86 and 92%. Therefore, errors in determination of the 
water content will only affect the specificity of the discrimination between healthy 
tissue and SCC.  
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Figure 4. Scatter plot of the water concentration for all measurements (a) and the ROC-
curve for discriminating SCC from normal tissue (b). (a) - the red points present the 
water concentration values for measurements in SCC and the green points show the 
water concentration values measured in healthy tissue. The p(<0.0001) value was 
calculated according with the Mann-Whitney u test. The vertical broken line represents 
the position of the cut off value calculated as Youden Index. (b) - at the Youden Index 
(water concentration of 69%) the sensitivity is 0.99 and the specificity is 0.92. The 
calculated area under the curve (AUC), representative for the discriminative power, is 
0.98. 
In figure 4a the highlighted points labeled a.1 and a.2 represent a measured water 
concentration in SCC below the cut-off concentration of 69% and a water 
concentration in healthy tissue above this cut-off value, respectively. 
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Figure 5. Examples of HWNR spectra measured in: a.1) H&E stained thin tissue section 
of SCC a.2) typical Raman spectrum of SCC. b.1) H&E stained thin tissue section 
showing adipose tissue (arrow) b.2) Raman spectrum of adipose tissue. c.1) H&E stained 
thin tissue section showing muscle tissue (arrow) c.2) representative Raman spectrum of 
muscle. 
The SCC-measurement showing a water concentration below the cut-off value of 
69% is shown in figure 6. We cannot exclude that normal tissue is also present in the 
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measured region, however, histopathologically, this H&E stained section was 
identified as SCC.  
 
Figure 6. H&E stained thin tissue section from the SCC-measurement that has a water 
concentration below the cut-off value 69%. The area where the measured point is 
located is represented by a) and b) and histologically this area contains muscle cells (M), 
a blood vessel (BV), some connective tissue (CT), adipose tissue (A) and tumor cells 
(SCC). 
The eight measurements represented by label a.2 in figure 4a were of tissue locations 
with a mixture of connective tissue, muscle, blood vessels and nerves, showing 
water concentrations ranging between 71.4-78.4%. We do not have a clear 
explanation why the water concentration in these eight measurements is above the 
69% cut off value. 
The higher water concentration we found in SCC compared to healthy tissue was 
also found earlier in other tumors, such as melanoma, ductal carcinoma of the breast 
and basal cell carcinoma. However, these were qualitative observations (20-22). 
Garcia-Flores et al. (2011) have reported a higher water concentration in chemically 
induced breast tumors in rats, than in normal breast tissue. In this case the normal 
tissue measurements appear to have been obtained from subcutaneous adipose 
tissue, which contains very little water, different from the tumor which is rich in 
water (20). Philipsen et al. (2013) demonstrated by in-vivo FT Raman spectroscopy 
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a relatively stronger Raman signal contribution of water in skin lesions (including 
melanoma, basal cell carcinoma and benign pigmented lesions) than in normal skin. 
It should be noted that the spectral region assigned in this paper to water OH-
stretching vibrations (3175 to 3265 cm-1) strongly overlaps with NH-stretching 
vibrations from proteins and therefore is not the most suitable spectral region to 
assess water concentration in tissue (21). Surmacki et al. (2013) also reported a 
higher intensity of the water Raman signal water in human breast tumor than in 
normal (adipose) breast tissue, which is low in water content by nature (22). 
A first limitation of this study is related with the fact that the method to calculate the 
water concentration was devised for protein-water mixtures, and does not take the 
signals from lipids into account which also contribute to the 2910-2966 cm-1 band. 
The measurements with a high signal from lipids showed consistently low water 
contribution and were always associated with healthy tissue. For these reasons, we 
conclude that despite the fact that the determination of the water concentration is 
based on a protein model the signal contributions from lipids are unlikely to 
influence our discrimination results regarding discrimination of tumor and healthy 
tissue. 
Limitations of this study include the fact that we have a limited number of samples 
(fourteen). Future investigation will also target other subsides within the oral cavity 
to see if we can extrapolate our results. Also, one can imagine that measurements of 
the transition zone between tumor and healthy surrounding tissue could be valuable 
in understanding and explaining the underlying mechanism. This is why we will 
keep on performing measurements and will try to focus on this peritumoral zone as 
well.  
Another limitation could be the fact that it is still difficult to correlate the measured 
points with pathology. Even though we used pins to mark the measurement spots, 
the pathologists found it hard to find the exact measurement spot in some cases. 
Currently we are thinking of a different approach to mark the measurement spots 
after measuring, to overcome this problem. This technique could be integrated in a 
multi-fiber probe which can measure a bigger surface at once (30,31). 
Finally, this setup is not yet suitable for intra-operative use. Yet, these results can 
contribute to creating a method which can be used in an intra-operative system as 
well. Our ultimate goal would be the scanning of all resection margins, which is still 
far from the point measurements we describe in this study. Still, we believe that our 
results, promising as they are, could help to create a method to scan all resection 
margins.   
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Conclusions 
In this study, high-wavenumber Raman measurements of fresh SCC tongue 
resection tissue specimens have demonstrated that SCC has significantly higher 
water content than surrounding healthy tissue. HWNRS can therefore be used to 
differentiate tumor and surrounding healthy tissue based on water concentration. The 
specific spectral information obtained in this study can be used for the development 
of an in-vivo Raman spectroscopic method for border demarcation of SCC of head 
and neck. Raman spectroscopy is fast (measurements in the order of 1 second or less 
with real-time signal analysis) and can be applied through the use of hand-held fiber-
optic probes at virtually any location of the head and neck area. This enables the 
development of both ex-vivo and in-vivo intra-operative applications for the purpose 
of assisting and guiding oncological surgical procedures towards adequate resection 
margins. 
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Abstract  
Raman spectroscopy in the high-wavenumber spectral region (HWR) is particularly 
suited for fiber-optic in-vivo medical applications. The most-used fiber-optic 
materials have negligible Raman signal in the HWR. This enables the use of simple 
and cheap single-fiber-optic probes that can be fitted in endoscopes and needles. The 
HWR generally shows less tissue luminescence than the fingerprint region. 
However, the luminescence can still be stronger than the Raman signal.  
Hardware- and software-based strategies have been developed to correct for these 
luminescence signals. Typically, hardware-based strategies are more complex and 
expensive than software-based solutions. Effective software-strategies have almost 
exclusively been developed for the fingerprint region. First-order polynomial 
baseline fitting (PBF) is the most common background/luminescence estimation 
employed for the HWR. 
The goal of this study was to characterize the luminescence background signals of 
HW spectra of human oral tissue, and compare the performance of two algorithms 
for correction of these background signals: PBF and multiple regression fitting 
(MRF). In the MRF method, we introduce here, prior knowledge of the range of 
Raman signals that can be obtained from the tissues of interest is explicitly used.  
MRF is more robust than PBF because it does not require an a priori choice of the 
polynomial order for fitting the background signal. This is important because, as we 
show, no single polynomial order can optimally characterize all backgrounds that are 
encountered in HW tissue spectra. We conclude that MRF should be the preferred 
method for background subtraction in the HWR. 
 
Introduction 
Raman spectroscopy has been broadly explored for medical applications in oncology 
aiming at early diagnosis, biopsy guidance and surgery guidance (1-3). The 
technique can provide qualitative and quantitative molecular information about 
tissues and enables classification of tissues with high sensitivity and specificity. 
Raman spectroscopy is directly applicable for in-vivo and ex-vivo analysis of tissue, 
without the need for labels and/or reagents (4). Elimination of interference from 
laser-induced tissue luminescence is still a challenge for many medical applications 
of Raman spectroscopy. This intrinsic luminescence signal can be several orders of 
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magnitude more intense than the Raman signal, which limits the analysis (5). To 
overcome this, both hardware- and software-based strategies have been developed to 
reduce the interference from luminescence (3, 5-29). 
An example of a hardware-based strategy is the use of specific excitation 
wavelengths far from the visible range. For example, the intensity of a fluorophore is 
dependent on the excitation wavelength. With exception of porphyrins and melanin 
(17), the excitation and emission of most tissue fluorophores exhibit maxima at 
ultra-violet (UV) and visible (VIS) wavelengths (18). Thus, longer wavelengths are 
preferred over UV/VIS (5,6). The selection of appropriate NIR source is an 
optimization between competing factors. For example, while tissue luminescence 
decreases with increasing wavelength, also the Raman scattering cross section and 
the quantum efficiency of CCD detectors decrease. For CCD detectors the quantum 
efficiency drops below 15% at 1000 nm, and cannot be used at all above 1100nm. 
Detectors such as indium gallium arsenide (InGaAs), germanium, and indium 
phosphide can be used for wavelengths above 950 nm. Although these detectors 
have lower quantum efficiency, and exhibit much more detector noise in comparison 
to silicon detectors (5), new types of InGaAs detectors are emerging which have 
very good noise characteristics, approaching those of CCD detectors (6).  
Another hardware-based strategy for luminescence rejection is multi-excitation 
wavelength Raman spectroscopy, also called as shifted excitation Raman difference 
spectroscopy (SERDS) (29). Raman spectra shift with the excitation wavelength, 
and luminescence is invariant for small excitation-wavelength shifts. The use of 
multiple excitation frequencies can thus be employed to separate the Raman signal 
from the luminescence background. The efficiency of the rejection increases with 
the number of excitation frequencies, which adds significant complexity to this 
hardware solution (20). This technique has been mainly used on samples that have 
spectral bands with similar spectral widths (powders, crystalines proteins, etc). 
Recently, Cordero et al. (29) demonstrated that this technique may also be applicable 
for biological tissue, demonstrating SERDS to correct background from chicken 
meat. They concluded that SERDS could be a good choice for background 
correction when backgrounds are too complex to be estimated, and when signal-to-
noise of the spectra is not a limiting factor (29). 
Software-based strategies aim at algorithms to accurately subtract luminescence 
background signals from tissue spectra. Such algorithms have been widely 
developed and tested for the fingerprint region of the Raman spectrum (400 cm-1 to 
2000 cm-1), including methods based on wavelet transformation (21,22), iterative 
weighted least squares (23), geometric approach (24), polynomial baseline fitting (7-
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9,25), iterative morphological and mollifier-based baseline correction (26), auto-
adaptive background (27), and genetic algorithm based cubic spline smoothing (28). 
For the high-wavenumber region (2500 cm-1 to 4000 cm-1), these methods have 
shown limited value, mainly because of limited knowledge about the shape of the 
luminescence backgrounds of high-wavenumber Raman spectra of human tissues. 
The high-wavenumber region consists of a small number of relatively broad and 
overlapping bands, which makes the estimation of the background signals much 
more difficult than for the fingerprint region. Polynomial subtractions of 1st and 5th 
orders are the few and most common solutions mentioned for background correction 
in the high-wavenumber region (3,10-15). First order polynomial subtraction has 
been used on high-wavenumber Raman spectra acquired from oral cavity (gingiva, 
buccal, dorsal tongue, palate), adenomatous polyps, esophageal squamous cell 
carcinoma, nasopharyngeal tissues and breast tissue (3,10,12-15). The spectra in 
these studies were acquired with fiber-optic Raman probes and a confocal Raman 
microscope. The excitation laser wavelengths used were 785 nm and 1064 nm. A 5th 
order polynomial subtraction method has been reported for HW Raman spectra of 
urine samples, using a confocal Raman system with a 785 nm laser (11). 
Raman spectroscopy in the high-wavenumber region demonstrates significant 
advantages for ex-vivo and in-vivo medical applications when compared to the 
commonly used fingerprint region. The intensity of the signal is higher, and 
therefore measurements can be performed in shorter integrations times. 
Additionally, much used fiber-optic materials like fused silica do not have Raman 
signal at the high-wavenumber region of the Raman spectrum (30). This enables the 
use of simple and cheap single fiber optic probes that can be easily inserted in 
endoscopes and needles to perform in-vivo measurements in hollow organs or 
surface assessment of solid organs such as oral cavity (31,32), lung (33,34), upper 
gastrointestinal tract  (35-37) and colorectal (14,38).  
A study by Koljenović et al. showed that, for discriminating cancer from healthy 
tissue, essentially the same diagnostic information is obtained in either of the two 
spectral regions (fingerprint or high-wavenumber) (30). Although the high-
wavenumber spectra show considerably less interference from tissue luminescence 
compared to spectra in the fingerprint region, the background luminescence signal in 
the high-wavenumber can still be some orders of magnitude higher than the Raman 
signal itself.  
This study reports a more elaborate method for luminescence background 
subtraction from tissue spectra in the HWR. The method is based on a detailed 
characterization of the shapes of the luminescence background signals in ex-vivo 
15432-Barroso_BNW.indd   109 05-04-18   08:55
110 
high-wavenumber Raman spectra of freshly excised oral cavity tissue. The aim of 
this study was to characterize the luminescence background, and to compare the 
performance of two algorithms for correction of these backgrounds: the most used 
algorithm (polynomial baseline fitting) and a multiple regression fitting based 
method. 
 
Materials and Methods 
 Instrumentation and spectral pre-processing 
For all Raman experiments a confocal Raman microscope was used. The setup 
comprised a multichannel Raman Module (HPRM 2500, RiverD International B.V., 
The Netherlands), a 671nm laser (CL671-150-SO, CrystaLaser) and a charge-
coupled device (CCD) camera fitted with a back-illuminated deep depletion CDD-
chip (Andor 316, Andor Technology Ltd., UK). All the different parts of the 
instrument are described in detail in earlier work (39,40). All spectra acquired with 
this setup were calibrated to a relative wavenumber axis, and corrected for the 
wavelength dependent detection efficiency of the setup. The calibration was 
performed following the instructions of the spectrometer supplier (RiverD 
International B.V., The Netherlands). Spectral preprocessing was performed by 
removal of cosmic ray events and Raman signal generated in the instrument (caused 
by the passage of laser light through optical components), which was recorded by 
measuring a Raman spectrum without a sample being present.  
 Luminescence background signal 
Bleaching experiments were performed to evaluate the shapes of the luminescence 
background signals that are present in ex-vivo high-wavenumber human tissue 
spectra. The bleaching was induced by continuous exposure of the samples to the 
focused Raman excitation laser light. This produced spectra with an almost constant 
Raman contribution and decaying luminescence contributions. In this subsection, the 
bleaching experiments and the method used to extract the luminescence background 
signals from these experiments are described.  
Tissue samples 
Ex-vivo experiments were performed on fresh resection specimens from patients 
undergoing surgery for oral cavity squamous cell carcinoma. Informed consent was 
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obtained from the patients prior to the surgical procedure. The study protocol has 
been approved by the Medical Ethics Committee of the Erasmus MC, University 
Medical Center Rotterdam, The Netherlands (MEC-2013-345). The surgeon brought 
the specimen right after resection to the pathology department. The pathologist 
performed assessment of resection margins by cutting the specimen, perpendicularly 
to the resection surface, in about 5mm thick cross sections. After this intra-operative 
assessment, one of the cross sections was chosen by the pathologist for 
measurements and the remaining cross sections were immersed in formalin. Blood 
was rinsed with physiological salt solution (0.9% NaCl) and gently patted dry with 
gauze. The section was inserted in a cartridge with the tissue in contact with a fused 
silica window on one side of the cartridge. The window allowed scanning of a 3cm x 
3cm tissue area. Experiment time was limited to 60 minutes, after which the section 
was immersed in formalin and together with the rest of the resection specimen, and 
followed the standard pathology workflow. 
Bleaching Experiments to isolate luminescence background signals 
For bleaching experiments Raman spectra were collected from different tissue 
locations on the freshly excised oral cavity tissue sections. Approximately 80mW of 
laser light was focused to a spot of 4µm in diameter. Up to 120 spectra with 1 s 
exposure time were obtained at each measurement location.   
In the experiments breakdown of the luminescence molecules was induced by 
continuous exposure to the focused Raman excitation laser light. Time decay of the 
luminescence component of the signal and time invariance of the Raman component 
was determined by calculating difference spectra between consecutive spectra in a 
bleaching experiment. If difference spectra showed a broad background signal 
without observable Raman features, the difference between the first spectrum 
(spectrum with the highest background) and last spectrum (spectrum with the lowest 
background) was used to estimate the luminescence background signal. If Raman 
features were present in the difference spectra between the first spectrum and 
consecutive spectra the experiment was discarded. 
Optimization of plynomial approximation to the background 
The background signals estimated from each bleaching measurement were 
normalized, and polynomials of increasing orders from 1st to 10th order were fitted 
to the normalized backgrounds by the classical least-squares method (41). The norm 
of the residuals was plotted as a function of polynomial order. The optimal 
polynomial order was defined as the order after which there was no more significant 
decrease in residual (<5%). 
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 BSA reference spectra 
Bovine serum albumin (BSA) was purchased from Sigma-Aldrich (A9647, 66kDa). 
Eleven solutions of BSA and water were prepared with mass percentages from 5% 
to 40%. Per solution 60 spectra were acquired with an exposure time of 1s and then 
averaged, resulting in a set of reference spectra characterized by a low background 
signal and varying fractions of protein and water (CH3 stretching vibrations, 2910-
2965 cm-1, and OH stretching, 3350-3550cm-1). First order polynomial subtraction 
was used to subtract the little existing background signal. 
 Tissue reference spectra 
A total of 10147 tissue spectra, collected in Raman mapping experiments described 
earlier (40), were used to create a set of tissue reference spectra with low 
luminescence backgrounds and a high variance with respect to Raman content. 
Ratios between peak content and background content were calculated based on the 
2910 cm-1 - 2965 cm-1 CH3 stretching band. A first order polynomial baseline was 
fitted between the spectral points at 2910 cm-1 and 2965 cm-1. Peak content was 
calculated as the integrated area above this baseline. Background was calculated as 
the integrated area below the baseline. The spectra with the 25% highest CH3 
content to background ratio were selected for the reference set. These spectra were 
scaled on the mean of the data set by an extended multiplicative scatter correction 
(EMSC) algorithm (41,42). Hierarchical cluster analysis (HCA) was used to find the 
largest clusters in the group of the spectra with the 25% highest CH3 content to 
background ratio. Principal component analysis (PCA) was first used for data 
reduction (43). The clustering method was Ward’s agglomerative algorithm with 1- 
R2 as the distance metric, where R2 is the squared Pearson's correlation coefficient. 
The result of the HCA is a membership matrix NxN (N is the number of spectra) that 
represents the clustering at each level of agglomeration (44). The largest clusters, 
comprising 90% of the spectra (from the group of spectra with the 25% highest CH3 
content to background ratio), were selected as a representation of the most common 
tissue structures present in the oral cavity with the lowest luminescence background. 
Cluster averages were calculated, and the residual background subtracted by 1st 
order polynomial baseline fitting.  
 Algorithms for luminescence background subtraction 
Two algorithms were compared for characterization and subsequent subtraction of 
luminescence background signals: a polynomial baseline fitting (PBF) algorithm and 
an algorithm based on multiple regression fitting (MRF). 
15432-Barroso_BNW.indd   112 05-04-18   08:55
4Chapter 4 
   
 
 113
     
Polynomial baseline fitting algorithm 
The PBF algorithm used is an iterative function that fits a polynomial, of a user-
specified order, through a selected set of spectral points. In the first iteration, all 
points of the spectrum are used, and in each iteration the number spectral points are 
reduced by only including spectral points with lower intensity than the fitted 
polynomial at those points. In this way, the polynomial is iteratively adapted to fit 
the lowest points of the spectrum. The iteration is stopped when the number of 
points used for the baseline fit is below a threshold set by the user. Finally, the offset 
of fitted baseline polynomial is adapted to ensure that the value of the fitted baseline 
was never above the value the spectrum over the whole spectral range.  
Multiple regression fitting algorithm 
In the MRF method the spectra were fitted with a set of library spectra (independent 
variables), that have low background, and a polynomial, of a user-specified order, 
using a non-negative least squares method (constraining fit coefficients to greater or 
equal to zero).  
 Algorithm performance evaluation 
The performance of the PBF and MRF algorithms was evaluated using two artificial 
data test sets that were constructed from the extracted luminescence background 
spectra, BSA reference spectra, and tissue reference spectra described above. 
Different luminescence background spectra were digitally added to the reference 
sets, which resulted in test spectra for which the luminescence background 
component was exactly known. The result of the luminescence background 
correction methods was compared to the corresponding reference spectrum (without 
artificially added luminescence background). Performance of the two background 
correction algorithms was evaluated for different values of the polynomial order to 
define optimal values for both methods. Evaluation criteria were the similarity 
between the background corrected spectrum and the original spectrum using 
Pearson's correlation coefficient, and secondly, the influence of the background 
correction on the calculated water percentage. The water concentration was 
calculated from the ratio of the Raman bands at 3390 and 2935 cm-1, as described by 
Caspers et al (45).   
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Results 
 Luminescence background signal data set 
Tissue samples& Bleaching experiments 
Bleaching experiments were performed to isolate the luminescence background 
signals that are present in ex-vivo tissue spectra. Freshly excised oral cavity 
specimens from 6 patients were analyzed on a total of 35 different tissue locations. 
An example of a bleaching experiment is presented in the figure 1.a.  
Optimization of polynomial approximation to the background 
Table S1 (Supporting Information) shows the residuals of the polynomial fits to the 
35 different luminescence background spectra and the optimal polynomial order. 
The results for orders 1 to 7 are shown in the table. Three out of the 35 luminescence 
backgrounds were optimally approximated by a 1st order polynomial (8%), 22 
background signals were optimally approximated by a 2nd order polynomial (63%), 
8 by a 3rd order polynomial (23%), and 2 by 4th order polynomial (6%). An 
example of the polynomial approximation to the background can be seen in the 
figure 1.b-d.  
BSA test data set 
Figure 2 shows the reference set of a total of 11 spectra of BSA solutions with 
different mass-percentages (4.92%, 5.91%, 9.86%, 14.80%, 19.74%, 24.70%, 
29.66%, 31.65%, 34.64%, 37.62% and 39.61%). Eight spectra were used for testing 
of the PBF and MRF algorithms. The remaining 3 spectra were used as independent 
data in the MRF algorithm. Each of the 8 BSA reference spectra was combined with 
all 35 different background luminescence spectra, resulting in a total test set of 280 
spectra shown in figure 2.b. 
Tissue test data set 
A total of nineteen tissue reference spectra with low luminescence background were 
obtained, which are shown in figure 3.a. Thirteen spectra were used for testing of the 
PBF and MRF algorithms. 
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Table S1 - Residuals of the luminescent background approximations using increasing 
polynomial orders (1st to 7th order). OPO: optimal polynomial order, order at which 
the residual does not further decrease (<5%). 
 Residuals per polynomial approximation (%)  
Background 1st 2nd 3rd 4th 5th 6th 7th OPO 
1 2.0 0.5 0.5 0.5 0.5 0.5 0.5 2 
2 1.6 1.3 1.3 1.3 1.3 1.3 1.3 2 
3 1.5 0.6 0.6 0.6 0.6 0.6 0.6 2 
4 0.3 0.2 0.2 0.2 0.2 0.2 0.2 2 
5 0.9 0.8 0.7 0.7 0.7 0.7 0.7 3 
6 0.9 0.3 0.3 0.3 0.3 0.3 0.3 2 
7 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1 
8 1.9 1.7 1.7 1.7 1.7 1.6 1.6 2 
9 2.8 1.9 1.9 1.9 1.9 1.9 1.9 2 
10 2.7 1.5 1.3 1.3 1.3 1.3 1.3 3 
11 2.6 1.2 0.8 0.8 0.8 0.8 0.8 3 
12 3.4 2.3 1.7 1.6 1.6 1.6 1.6 4 
13 3.5 2.7 2.5 2.5 2.5 2.5 2.5 3 
14 4.3 3.5 3.1 3.0 3.0 3.0 3.0 4 
15 1.7 1.0 1.0 1.0 1.0 1.0 1.0 2 
16 6.5 6.3 6.3 6.3 6.3 6.3 6.3 2 
17 2.3 1.2 1.2 1.2 1.2 1.2 1.2 2 
18 1.7 1.2 1.2 1.2 1.2 1.2 1.2 2 
19 1.3 0.8 0.8 0.8 0.8 0.8 0.8 2 
20 1.8 1.0 1.0 1.0 1.0 1.0 1.0 2 
21 2.3 1.6 1.6 1.6 1.6 1.6 1.6 2 
22 2 1.3 1.3 1.3 1.3 1.3 1.3 2 
23 3.1 2.2 2.2 2.2 2.2 2.2 2.2 2 
24 2.9 1.2 1.0 1.0 1.0 1.0 1.0 3 
25 6.0 5.8 5.8 5.8 5.8 5.8 5.8 2 
26 1.2 0.3 0.3 0.3 0.3 0.3 0.3 2 
27 1.6 0.8 0.8 0.8 0.8 0.8 0.8 2 
28 0.8 0.7 0.7 0.7 0.7 0.7 0.7 2 
29 2.7 2.7 2.7 2.6 2.6 2.5 2.5 1 
30 1.5 0.2 0.2 0.2 0.2 0.2 0.2 2 
31 2.6 1.4 1.3 1.3 1.3 1.3 1.3 3 
32 2.1 1.0 1.0 1.0 0.9 0.9 0.9 2 
33 1.2 0.7 0.6 0.6 0.6 0.6 0.6 3 
34 1.7 1.3 1.1 1.1 1.1 1.1 1.1 3 
35 3.0 3.0 2.8 2.8 2.8 2.8 2.8 1 
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Figure 1. Example of background estimation from a bleaching experiment.  a) Bleaching 
time-series: first spectrum (dark blue), last spectrum (light blue) and the difference 
between the two as the estimated background (red). b) Residuals for different 
polynomial order fits to the estimated background. c) Estimated background (red), 
fitted 1st order polynomial (black), and residual (green). d) Estimated background (red), 
optimal (2nd order) polynomial (black), and residual (green). The optimal polynomial 
order is defined as the minimal order after which there was no more significant decrease 
in residual (<5%). 
The remaining 6 spectra were used as independent data in the MRF algorithm and. 
Each of the 13 tissue reference spectra was combined with all 35 different 
background luminescence spectra, resulting in a total test set of 455 spectra shown in 
figure 3.b.  
The mean and the standard deviation of the Pearson's correlation coefficients are 
shown per test data set and per algorithm used for testing. The table also shows the 
mean and the standard deviations of the differences in calculated water 
concentrations.  
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Figure 2. BSA reference spectra data set and BSA spectra test set. a) Averaged Raman 
high-wavenumber spectra from different albumin solutions. The mass percentage (m%) 
of the solutions varied between 5% and 40%. For better visualization of Raman signal 
the low intensity background was subtracted as a 1st order polynomial. b) BSA spectra 
test set: 280 Raman spectra with BSA signal and luminescence content. 
 
Figure 3. Ex-vivo high-wavenumber tissue reference spectra data set and high-
wavenumber tissue spectra test set. a) Nineteen ex-vivo high-wavenumber tissue 
reference spectra with low luminescence background were obtained after cluster 
analysis of the low luminescence spectra in the ex-vivo tissue spectra data set. For better 
visualization of Raman signal the low intensity background was subtracted as a 1st 
order polynomial. b) Ex-vivo high-wavenumber tissue spectra test set: 455 Raman 
spectra with known Raman and luminescence content. 
Algorithm performance evaluation 
BSA test data set   
For all 280 spectra of the BSA test data set, the background was estimated with the 
two algorithms using a 1st, 2nd, 3rd, 4th and 5th polynomial order and subtracted. 
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The similarity of the background-corrected data with the original data is listed in 
table 1. 
Examples for the PBF algorithm with 1st, 3rd and 4th polynomial order are shown in 
figure 4.a-4.c. The distributions of the corresponding Pearson's correlation 
coefficients are shown in figure 4.d. Examples for the MRF algorithm with 1st, 2nd 
and 4th polynomial order are shown in figure 4.e-4.g. The distributions of the 
corresponding Pearson's correlation coefficients are shown in figure 4.h. 
Table 1 - Evaluation of the performance of the PBF and PRF algorithms on BSA spectra 
and on ex-vivo high-wavenumber tissue spectra. Average +/- standard deviation of the 
Pearson’s correlation coefficient between background corrected spectra and their 
reference spectra for the two different correction algorithms (PBF and MRF) and 
different values of the algorithm background polynomial. Average and standard 
deviation of the absolute error in water concentration (%) between background 
corrected spectra and their reference spectra for the two different correction algorithms 
and different values of the algorithm background polynomial.  
Background 
Polynomial  
BSA Spectra 
 Pearson's Correlation Coefficient Absolute error in [H2O] (%) 
PBF MRF PBF MRF 
1st order 0.973±0.076 0.974±0.075 2.74±10.60 2.74±10.60 
2nd order 0.995±0.009 0.996±0.006 0.64±0.57 0.61±0.52 
3rd order 0.993±0.021 0.996±0.006 0.74±1.22 0.56±0.48 
4th order 0.747±0.136 0.996±0.007 29.24±34.10 0.58±0.54 
5th order 0.516±0.197 0.996±0.006 46.54±16.39 0.58±0.52 
Background 
Polynomial  
Tissue Spectra 
Pearson's Correlation Coefficient Absolute error in [H2O] (%) 
PBF MRF PBF MRF 
1st order 0.996±0.008 0.996±0.007 0.81±1.30 0.81±1.30 
2nd order 0.996±0.010 0.997±0.007 0.62±1.00 0.52±0.72 
3rd order 0.996±0.010 0.997±0.006 0.60±0.82 0.48±0.54 
4th order 0.728±0.140 0.997±0.007 12.99±22.30 0.48±0.53 
5th order 0.578±0.200 0.997±0.007 37.00±13.97 0.49±0.52 
 
15432-Barroso_BNW.indd   118 05-04-18   08:55
4Chapter 4 
   
 
 119
     
 
Figure 4. Luminescence background correction on BSA test data using the PBF and 
MRF algorithms. PBF results are shown in the left column, MRF results in the right 
column. a) Example of PBF 1st order polynomial background subtraction. b) PBF 2nd 
15432-Barroso_BNW.indd   119 05-04-18   08:55
120 
order polynomial. c) PBF 4th order polynomial. d) Box-plot of the Pearson's correlation 
coefficients for PBF with different polynomial orders. e) Example of MRF 1st order 
polynomial background subtraction. f) MRF 2nd order polynomial. g) MRF 4th order 
polynomial. Spectra displayed: test spectrum (red), estimated background (blue), 
corrected spectrum (green), corresponding reference spectrum (black).  
Tissue reference test data set 
For all 455 spectra of the tissue test data set, the background was estimated with the 
two algorithms using a 1st, 2nd, 3rd, 4th and 5th polynomial order. The similarity of 
the background-corrected data with the original data and the errors in calculated 
water concentration after background correction are listed in table 1. The figure 5 
shows tissue reference spectra that were used that were used as independent 
variables in the MRF algorithm. Two examples of the results obtained using PBF 
algorithm and MRF algorithm are shown in figure 6.a-6.d. 
 
Figure 5. The 6 ex-vivo high-wavenumber tissue reference spectra that were used as 
independent variables in the MRF algorithm. For better visualization of the differences 
in the Raman signal the spectra were normalized. 
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Figure 6. Luminescence background correction on tissue test data using the PBF and 
MRF algorithms. PBF results are shown in the left column, MRF results in the right 
column. a) Example of PBF 2nd order polynomial background subtraction. b) PBF 4th 
order polynomial. c) MRF 4th order polynomial. d) MRF 4th order polynomial. Test 
spectrum (red), estimated background (blue), corrected spectrum (green), 
corresponding reference spectrum (black). 
 
Discussion & Conclusions 
When measuring Raman spectra from biological tissue, high luminescence 
backgrounds can (almost) completely obscure the Raman signal. Both hardware- and 
software-based strategies have been developed to correct for these luminescence 
background signals.  
Hardware-based strategies can be efficient, but their implementation is associated 
with higher instrument complexity and associated higher costs. Software-based 
strategies are easier to implement and have lower costs. Most software-based 
strategies have been developed for the fingerprint region. In contrast to the 
fingerprint region, not many background subtraction algorithms have been 
developed for the high-wavenumber region of the Raman spectrum (7,9,21-28,47).  
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For high-wavenumber region spectra, polynomial baseline fitting (PBF) is the only 
solution mentioned for background correction, using either a 1st order (3,10,12-15), 
or a 5th order polynomial (11).  However, this method produced unsatisfactory 
results for our ex-vivo high-wavenumber spectra of human oral tissues. First, we 
experienced that not all luminescence backgrounds could be characterized by a first 
order polynomial, and the estimation of the background by higher order polynomials 
did not produce stable results. We observed that the polynomial fits have problems 
in distinguishing between luminescence background and the rather broad band 
Raman spectral features in the high-wavenumber region.  
Therefore, in this article, we present a new and effective method for correction of 
luminescence backgrounds in high-wavenumber region Raman spectra. The method 
is based on multiple regression fitting (MRF) and on high-wavenumber 
luminescence-free Raman signal. The goal of this study was to characterize the 
luminescence background signals of ex-vivo human oral tissue high-wavenumber 
region spectra, and to compare the performance of the MRF method with the more 
common polynomial background fitting (PBF).   
The luminescence background signals were measured in laser-induced bleaching 
experiments on freshly excised human oral tissue. The bleaching process was not 
complete for all the bleaching experiments performed, due to time constraints (fresh 
specimen(s) that needed to be sent to pathology department). Although the estimated 
backgrounds did not bleach completely, we do not believe that this affects the 
outcome of this study in any way. 
Polynomials of different order were required for optimal approximation of the 
luminescence backgrounds, ranging from 1st order (8% of the cases), 2nd order (63% 
of the cases), 3rd order (23%), to 4th order (6%). These results indicate that it is not 
possible to choose a single optimal polynomial order that will give the best 
background estimation for all cases. Hence operator-supervision is required, and 
inter-operator subjectivity may play a role. Moreover, the selection of a polynomial 
order that is not optimal can result in significant artifacts in the Raman spectrum 
from residual luminescence contributions or from removal of Raman signal by 
polynomial over-fitting. 
The luminescence background signals obtained from the bleaching experiments 
were used to generate test data sets of spectra with known luminescence and Raman 
contributions (figures 2-3). For the Raman contributions two different datasets were 
used: a set of spectra from pure BSA solutions with different concentrations, and 
fresh ex-vivo tissue spectra from oral cavity tissue with very low luminescence 
background. Because the luminescence backgrounds in the test data sets were 
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digitally added, the test data enabled accurate evaluation of the performance of the 
background subtraction algorithms (figures 4-6). Evaluation criteria were spectral 
correlation and error in the calculated water content after background correction, as 
compared to the corresponding reference spectra. The results in table 1 show that for 
both datasets MRF performs equally well or better than PBF for all the polynomial 
background orders evaluated. The results test show that the MRF is more robust and 
more effective than PBF in accurately estimating the luminescence background in 
HWR tissue and BSA spectra. Also, here, it is clear that the MRF algorithm gives 
significantly better results when higher order polynomials are used in the fitting 
process. For the tissue reference test data set the MRF algorithms gives better 
results, and again especially for the higher order polynomials.  
For the classical PBF method, the overall best results were obtained by fitting a 2nd 
order polynomial. This is mainly determined by the observation that the 
luminescence backgrounds obtained from the bleaching experiments predominantly 
had a 2nd order polynomial shape. Higher polynomial orders lead to large errors due 
to over-fitting artifacts. This is a common risk in polynomial background fitting of 
HWR Raman spectra of tissues because these spectra are characterized by broad 
partially overlapping bands, and because no reliable baseline points are available to 
anchor the central part of the spectrum around 2800-3800 cm-1. As a result, the 
broad high-wavenumber Raman bands are partly fitted as background by higher 
order polynomials (see figure 4.c).  
For MRF, 2nd order polynomials or higher gave the best results. This confirms that 
the MRF-method is robust and can be reliably used with higher order polynomials, 
because the Raman signal is fitted by the independent spectra included in the 
method. Thus, higher order polynomials do not result in fitting of the Raman signal 
as background. The MRF algorithm is not dependent of the shape of the Raman 
signal, provided that the independent data set of luminescence free Raman spectra is 
representative of the Raman signal variance measured. This effectively eliminates 
subjectivity in choosing an optimal polynomial order, as required by the PBF 
method, and the associated problem that a single optimal polynomial order does not 
exist for a variety of backgrounds, as shown in the results section.  
The results of this study were obtained on high-wavenumber region Raman spectra. 
However, we believe that the method may not be limited to this spectral region but 
may prove equally useful for luminescence background correction in the fingerprint 
region. Further studies will be conducted to prove the usefulness of MRF for 
luminescence background subtraction in the fingerprint region. 
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In conclusion, this study has demonstrated that MRF is a more accurate and robust 
solution than PBF for correction of luminescence backgrounds and can be used for 
unsupervised and automated background subtraction as needed in real time tissue 
diagnostic applications.  
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Abstract  
Adequate resection of oral cavity squamous cell carcinoma (OCSCC) means 
complete tumor removal with a clear margin of more than 5 mm. For OCSCC 85% 
of the surgical resections appear inadequate. Raman spectroscopy is an objective and 
fast tool that can provide real-time information about the molecular composition of 
tissue and has the potential to provide an objective and fast intra-operative 
assessment of the entire resection surface.  A previous study demonstrated that 
OCSCC can be discriminated from healthy surrounding tissue based on the higher 
water concentration in tumor.  
In this study we investigated how the water concentration changes across the tumor 
border towards the healthy surrounding tissue on freshly excised specimens from the 
oral cavity. Experiments were performed on tissue sections from 20 patients 
undergoing surgery for OCSCC. A transition from a high to a lower water 
concentration, from tumor (76% ± 8% of water) towards healthy surrounding tissue 
(54% ± 24% of water), takes place over a distance of ≈ 4 to 6 mm across the tumor 
border. This was accompanied by an increase of the heterogeneity of the water 
concentration in the surrounding healthy tissue. The water concentration 
distributions between the regions were significantly different (p-values<0.0001). 
This new finding highlights the potential of Raman spectroscopy for objective intra-
operative assessment of the resection margins.  
 
Introduction 
Oral cavity cancer is a major public health issue, with 300.000 new cases per year 
worldwide (1). Most oral cancers arise from the epithelium of the mucosal surface 
and are referred to as oral cavity squamous cell carcinoma (OCSCC). OCSCC 
mortality is high, with a 5-year survival of around 50% and 145,000 deaths per year 
worldwide (1,2). Despite advances in treatment modalities (surgery, radiotherapy 
and chemotherapy), these numbers have not shown significant improvement over the 
last decades (3,4). Important determinants of the clinical outcome of OCSCC 
patients are tumor subsite, TNM classification, age, comorbidity, and tumor 
histological characteristics (5-7). Surgery is the mainstay of treatment for OCSCC. 
Adequate tumor resection with acceptable remaining function and physical 
appearance is the main goal. At our institute, we follow the guidelines of the Royal 
College of Pathologists (United Kingdom). The distance between tumor and the 
nearest resection surface (DBTNRS) determines the adequacy of the surgical 
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procedure. This distance is histologically measured in mm. A resection margin can 
be classified as clear (>5 mm of DBTNRS), close (1 to 5 mm of DBTNRS) and 
positive (<1 mm of DBTNRS) (8). Clear margins are regarded as adequate, close 
and positive margins as inadequate. Adequate resection margins are crucial for 
disease control and survival (8-14). Patients with inadequate resection margins often 
receive adjuvant therapy (chemotherapy and/or radiation), or re-resection. However, 
these can have a negative effect on patient morbidity.  
Achieving adequate resection margins is challenging. The lack of reliable intra-
operative guidance and the proximity of tumors to vital structures are the common 
causes of inadequate tumor resection. Despite comprehensive preoperative imaging 
of the tumor (by CT scan, MRI etc.), the surgeon decides where to cut, based on 
visual inspection and palpation of the tumor during the operation. Earlier, we have 
reported the surgical results obtained in two Dutch centers (Erasmus Medical Center 
Rotterdam and Leiden University Medical Center). For OCSCC surgery adequate 
resection margins were obtained in only 15% of the cases (9).  A similar result was 
recently reported by the Harborview Medical Center and the University of 
Washington Medical Center in Seattle (USA) (11).  Clearly, visual inspection and 
palpation of the tumor and surrounding tissue by the surgeon are insufficient to 
warrant adequate tumor resection. 
Intra-operative assessment of resection margins by means of a frozen section 
procedure can be used (15). This procedure, in which the pathologist performs 
microscopic evaluation of a piece of suspicious tissue, is currently the gold standard 
of intra-operative diagnostics (15-17). The main limitation of the frozen section 
procedure is that only a fraction of the resection margins can be investigated. The 
method is prone to sampling error, which often leads to false negative results (9,18). 
As a result, the frozen section procedure is not very effective in improving surgical 
success rate. Ideally, the entire resection surface should be evaluated intra-
operatively, which requires an objective and fast technology.  
Intra-operative assessment of resection margins on the resection specimen (i.e. 
specimen driven approach) has been reported to be superior to assessment of the 
wound bed (i.e. defect driven approach) by different groups. Specimen driven intra-
operative assessment of resection margins leads to a higher surgical success rate and 
increase of patient survival than defect-driven or no intra-operative assessment at all 
(11,17-19).  
Various techniques like ultrasonography, imprint cytology, and various optical 
techniques are being explored for intra-operative use in surgical oncology (20-28). 
Some of these techniques are being applied for OCSCC, which were recently 
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reviewed by Ravi et al (2014). Optical techniques like high-resolution micro-
endoscopy (HRME), optical coherence tomography (OCT), fluorescence 
spectroscopy, elastic light scattering spectroscopy, and Raman spectroscopy are 
promising because of their ease of use, relatively low cost and high speed in 
screening large tissue areas (20-28).  
Raman spectroscopy is an optical technique that is being investigated for intra-
operative evaluation of the surgical margins. Raman spectroscopy can be applied to 
assess the mucosa, as well as, the deep soft tissue layers (29-34). It is an objective 
technique based on inelastic scattering of monochromatic light that provides detailed 
quantitative and qualitative information about the molecular composition of tissue. 
The technique is non-destructive and there is no need for reagents or labeling, which 
promotes easier translation to the clinics (35,36).  
The goal of our research is to develop a Raman spectroscopic technique for 
objective intra-operative assessment of the entire resection surface, with the ultimate 
goal to improve the success rate of OCSCC surgery. In a first pilot study we have 
demonstrated that Raman spectra of resection specimen discriminated tumor from 
healthy surrounding tissue with a sensitivity of 99% and a specificity of 92% (37). 
The primary discriminating factor of the Raman spectra proved to be the water 
concentration in the tissue. Raman spectroscopy is very suitable for rapid 
quantitative determination of the water concentration in tissue, as has been 
demonstrated by our group (38-40). The objectives of the current study were to 
investigate how the change in water concentration correlates with the border 
between tumor and surrounding healthy tissue and, consequently, to verify if this 
information can be used to assess resection margins. 
 
Material and Methods 
 Medical Ethical Approval 
This study was approved by the Medical Ethics Committee (MEC-2013-345) of the 
Erasmus MC Cancer Institute, University Medical Center Rotterdam. Prior to the 
operation, informed consent was obtained from the patients. Measurements were 
conducted ex-vivo on resection specimen of patients undergoing surgery for 
OCSCC. The allowed time for the experiments was 60 minutes, after which the 
resection specimen was put in formalin for routine histopathological evaluation. 
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 Tissue samples and handling 
Immediately after resection, the surgeon brought the specimen to the cutting room of 
the pathology department, which is in close proximity to the operating room. A 
dedicated pathologist and surgeon inspected the specimen together. This process 
included labeling of the anatomic sites and documentation of the specimen with 
diagrams and digital images (Figure 1.1). 
 
Figure 1. Overview of the experimental protocol. 1. Immediately after surgical resection, 
the specimen (excision of tongue SCC) was transferred to the pathology room and 
orientation was digitally recorded (anterior (A), posterior (P) and medial (M)). 2. The 
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specimen was cut perpendicular to the resection surface in three sections for intra-
operative assessment of the resection margins. Thereafter, a tissue section was chosen 
for the Raman experiment. 3. The Raman tissue section was inserted into a cartridge. 
The area to be measured was defined by the pathologist, containing tumor and >5 mm of 
surrounding healthy tissue, at least in one direction. 4. Raman mapping experiments 
were performed on a grid. The water concentration for each measured point was 
calculated. A two-dimensional image was obtained by using a nonlinear color scale to 
represent the water concentrations. 5. After Raman measurement, the specimen was 
routinely processed. H&E stained slide was made from the whole Raman tissue section 
within which pathologists identified the tissue area that was measured. The 
histopathological annotation of the tumor (T), healthy tissue (H) and of the tumor 
border (red line) was performed.6. Based on the annotated tumor border in the H&E 
image (red line), the position of the adequate surgical margin (>5 mm of distance to the 
tumor border) was determined within the water map (green line). 
After orienting and defining the resection margins, the pathologist and the surgeon 
surveyed all resection planes by visual inspection and palpation. After this, the 
pathologist cut the specimen in 3 - 5 cross sections (with a thickness of about 5 mm 
– 10 mm), perpendicular to the resection margin plane (Figure 1.2). For specimens 
comprising bone (i.e. mandibular resection specimens in patients with OCSCC 
invading the bone) the soft tissue was cut till the bone. The pathologist measured the 
distance between tumor and resection surface. Often, this macroscopic assessment 
only was sufficient to decide on the further course of the operation without the need 
for frozen sections. In case of an unclear tumor border the pathologist may decide to 
further refine the information by microscopic examination of frozen sections. 
Provided with this intra-operative information regarding inadequate margins the 
surgeon continues to harvest more tissue from the wound bed (e.g. immediate re-
resection) to achieve an adequate surgical result.  
After this intra-operative diagnostic procedure, one of the specimen cross sections 
was chosen for Raman experiments (further called “Raman tissue section”). The 
cross section was regarded suitable when containing tumor and >5 mm of healthy 
looking surrounding tissue (Figure 1.2).  The remaining specimen cross sections 
were immersed in formalin.  
Blood was rinsed from the Raman tissue section using physiological salt solution 
(0.9% NaCl) and gently patted dry with gauze. The area of interest (i.e. tumor and 
>5 mm of surrounding healthy tissue) was macroscopically chosen by the 
pathologist. The Raman tissue section was inserted in a closed cartridge to avoid 
drying of the tissue. The upper side of the cartridge consists of a fused silica 
window. This cartridge allows the scanning of a 3x3 cm tissue area. The Raman 
tissue section was placed in the cartridge with the surface to be measured in contact 
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with the fused silica window. Digital images of all handling steps were made, 
including images for the macroscopic representation of the tissue area measured 
(Figure 1.3). 
After the experiment, the Raman tissue section was removed from the cartridge and 
immersed in formalin, together with the rest of the specimen to follow the routine 
procedure for final pathological processing. 
 Raman instrumentation and mapping experiments 
Raman ex-vivo mapping experiments were performed using a confocal Raman 
microscope (CRM), built in-house. The equipment was placed in a laboratory close 
to the operating room. The setup, as explained in our previous work (37), comprised 
a multichannel Raman Module (HPRM 2500, RiverD International B.V., The 
Netherlands), a 671nm laser (CrystaLaser, CL671-150-SO) and a charge-coupled 
device (CCD) camera fitted with a back-illuminated deep depletion CDD-chip 
(Andor iDus 401, DU401A BR-DD, Andor Technology Ltd., UK). A microscope 
(Leica DM RXA2, Leica Microsystems Wetzlar GmbH, Germany) and a computer-
controlled sample stage (Leica DM STC) were coupled with the Raman Module. 
Eighty mW of laser light was focused in the tissue by means of a microscope 
objective (0.4 numerical aperture) with a free working distance of 1.1 mm (N PLAN 
11566026, Leica Microsystems B.V., The Netherlands). The depth resolution was 40 
µm, experimentally determined. Spectral information was collected in the 
wavenumber range 2500 to 4000 cm-1 with a resolution <5 cm-1. 
For each measurement the cartridge with the tissue section was fixed on the 
microscope stage. The selected area was measured point–by-point using a grid. The 
grid cell size was between 300 µm per 300 µm to 1000 µm per 1000 µm, depending 
on the size of the tissue section and on the allowed time of 60 minutes to perform the 
experiment. In some cases, more than one map per specimen was measured 
depending on the size of the tissue section and on the allowed time. The acquisition 
time per spectrum was 1 second. Laser light was focused in the tissue at about 50 
µm below the fused silica window surface.   
 Calibration and processing of spectra 
All spectra were calibrated on the relative wavenumber axis and corrected for the 
wavelength dependent detection efficiency of the setup, according to instructions of 
the spectrometer supplier (RiverD International B.V., The Netherlands). Pre-
processing of the spectral data was performed by removal of cosmic ray events and 
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subtraction of the signal background generated in the optical path of the setup itself 
(39). MATLAB R2014b was used for data processing and data visualization. 
The tissue Raman spectra showed varying levels of background signal originating 
from tissue autofluorescence. For the calculation of tissue water concentrations, the 
autofluorescent background signal was estimated by a 3rd order polynomial and 
subtracted from the measured spectra.  
Spectra with a relative intensity lower than 5% of the average intensity of all spectra 
measured from the sample were discarded. Intensity of the spectra was determined 
for the range 2700 to 3100 cm-1 in which almost all spectral signatures from lipids 
and proteins are localized. Low signal intensities were encountered in cases where 
the tissue was locally not fully in contact with the measurement window.  
The ratio of the Raman bands at 3390cm-1 and 2935cm-1 was used to determine the 
concentration of water per spectrum according to the method developed by Caspers 
et al. (2001) and described in detail in our previous study (38, 40).  
 Raman water maps 
Raman water maps were created by plotting the water concentration as a 2D map 
using pseudo colors to represent the water concentration range. A convolution of the 
water map with a 3x3 averaging filter was applied, as shown in figure 1.4, to obtain 
values that are more representative of the local water concentration (reducing noise 
in the image), and for better visualization of the difference in water concentration 
between tumor and the surgical margins (41).  
 Histopathology 
Histopathological evaluation of the measured areas was performed by two dedicated 
pathologists on routine hematoxylin and eosin (H&E) stained thin tissue sections. 
Subsequently, the H&E stained section was digitized, and the pathologists delineated 
healthy tissue, tumor and tumor border (Figure 1.5).  
 Data analysis 
Based on the projection of the tumor border in the H&E image (red line) onto the 
Raman water map, each pixel was labeled as either tumor border, tumor or healthy 
(Figure 1.6).  The precision with which the individual pixels could be annotated in 
this way is limited by the much lower resolution of the Raman map compared to the 
microscopic image. The error was estimated to be half of the Raman map pixel-size. 
Thereafter, the minimal Euclidean distance between each Raman map pixel and the 
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tumor border was calculated. Based on these distances, the position of the adequate 
surgical margin (all pixels with distance >5 mm to the tumor border) was obtained 
(Figure 1.6).  
For each map, the average and standard deviation of the water concentration were 
separately calculated for tumor, for the inadequate margin (i.e. distance from tumor 
border ≤ 5 mm), and for the adequate margin.  
The Mann-Whitney U-test was used to determine if the distribution of the water 
concentrations in tumor, in inadequate margins and in adequate margins are 
significantly different from each other.  
Next, we calculated the average water concentration of the tissue as a function of the 
distance to the tumor border. This was done by calculating the mean water 
concentration of pixels falling within a 0.5 mm distance interval and moving this 
interval from -15 mm (inside the tumor) to + 10 mm (in the healthy tissue). 
Likewise, the standard deviation in the water concentration was calculated as 
function of distance to the tumor border.  
 
Results 
Twenty-five ex-vivo Raman mapping experiments were performed on fresh 
resection specimens from 20 patients treated by surgery for OCSCC. Table 1, shows 
patient and tumor characteristics.  
Each map had an average of 406 spectra (range comprehended between 97 to1250 
spectra), and an average area of 240 mm2 (from 18.9 to 624 mm2). The average 
tumor area per map was 84mm2 (range was between 13 mm2 to 390 mm2), the 
average inadequate margin area per map was 85 mm2 (minimum value was 27.9 
mm2 and maximum value was 237 mm2), and the average adequate margin area per 
map was 71 mm2 (minimum and maximum values were respectively 4 mm2 and 
379.2 mm2).  
In total, 3526 Raman spectra from tumor were obtained. From the surrounding 
healthy tissue, 3620 spectra were obtained at a distance of less than 5mm from the 
tumor border (i.e. within the area of inadequate margin) and 3001 spectra were 
obtained at a distance greater than 5mm from the tumor border (i.e. from the area of 
adequate margins).  
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As an example, the results for three experiments performed on fresh resection 
specimens from three patients are shown in figure 2. The macroscopic images of the 
measured areas are shown in column A. Column B shows the water concentration 
maps.  
Table 1. Patient and tumor characteristics. Number of maps measured per patient 
(Maps). Primary tumor location and pathological TNM classification (pTNM) of 
malignant tumors (42). Tumor size varied from less than 1cm (T1) to more than 4cm. In 
some patients, tumor had extended into the mandible (T4a). N-stage varied from no 
regional metastasis in lymph nodes to multiple lymph nodes with metastasis of 6cm or 
less in greatest dimension (N0-N2b). Distant metastasis was not encountered (M0). 
Patient Age Gender Maps Primary Tumor location pTNM 
1 71 F 1 Lateral side of tongue T2N2bM0 
2 72 M 1 Floor of mouth T2N2bM0 
3 52 F 1 Floor of mouth T3N2bM0 
4 52 F 1 Lateral side of tongue T1N0M0 
5 54 M 1 Lateral side of tongue T1N0M0 
6 42 M 1 Lateral side of tongue T1N0M0 
7 59 F 1 Lateral side of tongue T2N0M0 
8 91 M 2 Lateral side of tongue T1N1M0 
9 52 F 1 Lateral side of tongue T1N0M0 
10 42 F 1 Lateral side of tongue T4aN2bM0 
11 67 M 2 Inferior alveolar process T4aN0M0 
12 60 F 1 Lateral side of tongue T1N0M0 
13 69 M 2 Lateral side of tongue T1N0M0 
14 61 M 1 Lateral side of tongue T1N0M0 
15 68 M 1 Lateral side of tongue T1N0M0 
16 79 M 2 Lateral side of tongue T1N0M0 
17 68 M 2 Retromolar trigone T4aN2bM0 
18 72 F 1 Tongue and floor of the mouth T3N1M0 
19 58 M 1 Lateral side of tongue T2N0M0 
20 61 F 1 Lateral side of tongue T2N0M0 
These maps were interpolated to a pixel size of 300 µm, which was the smallest step 
size used for mapping. In column C, the averaged water maps after interpolation to 
the same pixel size are presented. Column D shows the annotated H&E stained 
sections. Column E shows the average water concentration (blue line) and standard 
deviation (black line).  
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Figure 2.  1 – 3: Examples of the data obtained by means of mapping experiments on 3 
Raman tissue sections from 3 patients. Panels column A: Photograph of the measured 
fresh tissue surface. Panels column B: Raman water map with indication of tumor 
border (red; based on final histopathology shown in panels of column D) and adequate 
surgical margin (green). Panels column C: Averaged Raman water map with indication 
of tumor border (red; based on final histopathology shown in panels of column D) and 
adequate surgical margin (green). Panels column D: H&E stained section obtained from 
the measured tissue surface, with tumor border (red), tumor (T), healthy surrounding 
tissue (H) indicated by pathologist. Panels column E: Graphs showing water 
concentration as function of the distance to the tumor border. Blue line: Average water 
concentration calculated per 0.5 mm distance interval. Black line: Standard deviation of 
the water concentration, per 0.5 mm distance interval. The red line at 0 mm represents 
the tumor border and the green line represents a distance of 5 mm from tumor border. 
For each map the mean and standard deviation of the water concentration for tumor, 
inadequate and adequate margins were calculated (table 2). The average water 
concentration in tumor is 76 ± 8%, in the inadequate margin it is 59 ± 24%, and in 
the adequate margin it is 54 ± 24%.   
Mann-Whitney U-tests show that these difference in water concentration between 
tumor, inadequate margin, and adequate margin are all significantly different with p-
values < 0.0001.  
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Table 2 – Average water concentration and respective standard deviation for each map. 
The water concentration was calculated specifically for the tumor, inadequate margin 
and adequate margin. Maps were ordered according to the TNM classification of tumors 
(42). 
pTNM Map Patient 
Concentration of water (%) 
Tumor Inadequate Margins Adequate Margins 
mean std Mean std Mean std 
T1N0M0 1 4 71 5 66 12 55 14 
T1N0M0 2 5 71 5 65 20 62 19 
T1N0M0 3 6 76 8 62 24 61 25 
T1N0M0 4 12 76 6 54 28 58 24 
T1N0M0 5 13 75 14 53 30 61 24 
T1N0M0 6 13 76 11 49 30 57 31 
T1N0M0 7 14 81 5 62 25 69 16 
T1N0M0 8 15 77 4 66 21 61 26 
T1N0M0 9 16 81 5 59 26 44 30 
T1N0M0 10 16 77 12 57 26 43 32 
T1N0M0 11 9 79 6 69 21 61 24 
T1N1M0 12 8 73 10 55 26 46 33 
T1N1M0 13 8 75 10 46 31 37 30 
T2N0M0 14 7 78 5 60 24 55 24 
T2N0M0 15 19 69 18 63 21 62 25 
T2N0M0 16 20 81 3 70 23 62 24 
T2N2bM0 17 1 80 9 65 25 55 30 
T2N2bM0 18 2 76 6 54 20 60 22 
T3N1M0 19 18 77 9 56 27 49 26 
T3N2bM0 20 3 74 9 53 26 58 28 
T4aN0M0 21 11 77 5 58 27 61 27 
T4aN0M0 22 11 75 4 62 25 50 28 
T4aN2bM0 23 10 76 8 64 18 42 21 
T4aN2bM0 24 17 74 14 58 25 44 28 
T4aN2bM0 25 17 75 13 52 27 43 27 
In figure 3 the water concentration (blue line) is shown, calculated as the mean and 
standard deviation over all experiments, as a function of distance to the tumor 
border, using 0.5mm distance intervals. From the figure it is clear that, the water 
concentration in tumor is much higher than in the surrounding healthy tissue. The 
figure also shows that the drop-in water concentration coincides with the tumor 
border. The water concentration starts to decrease inside the tumor mass, close to the 
tumor border and continues to drop steeply until about 4 mm into the surrounding 
healthy tissue. From there the decline in water concentration continues with a 
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smaller gradient. Interestingly, the standard deviation in water concentration values 
also differs between tumor and surrounding healthy tissue; from less than 10% 
inside the tumor to more than 15% just outside the tumor. 
  
Figure 3. Water concentration profile from inside the tumor towards adequate margin. 
All individual water concentration percentages of the 25 maps were averaged per 
interval to calculate the mean (blue) and standard deviation (black) of the water 
concentration as a function of the distance to the tumor border. The red line at 0 mm 
indicates the tumor border. The green line at 5 mm indicates the beginning of the 
adequate surgical margin. 
 
Discussion 
The aim of our research is the development of a clinical tool for intra-operative 
guidance of surgical-oncological procedures motivated by the main goal of surgery: 
adequate tumor resection and preservation of function and physical appearance. Of 
the many factors that affect the clinical outcome of patients with OCSCC, only the 
resection margins, can be influenced by the surgeon and pathologist. The objective 
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intra-operative assessment of resection margins is the key to increase the number of 
adequate resections in surgical oncology, therefore, an objective tool for assessment 
and guidance is needed.  
Multiple techniques are being explored for intra-operative use in surgical oncology 
(20-28). Until now, fluorescence spectroscopy (20), diffuse reflectance spectroscopy 
(21), elastic light spectroscopy (22), HRME (23) and OCT (24) have explored in-
vivo delineation of the tumor at the mucosal surface, prior to surgery. However, 
eighty-seven percent of inadequate margins are found in the deeper (submucosal) 
soft tissue layers (43). Therefore, the design of these studies is not perfect to be 
applied at the submucosal layers of soft tissue, which is where the majority of 
inadequate margins are found. 
OCT is a promising technique that has been used to investigate OCSCC resection 
margins. A recent study published by Hamdoon et al (2015) concluded that OCT is a 
valuable tool in the assessment of surgical margins. This study reported that the 
diagnostic accuracy was about 85%. However, they mentioned that the use of OCT-
technology is limited, because the created image can be affected by the lack of 
normal tissue perfusion. Therefore, the resolution and contrast of the OCT images 
are influenced by the "ex-vivo nature" of the approach (44,45). Moreover, not only 
OCT but also HRME has as disadvantage that it requires complicated subjective 
image-interpretation (23,24,44,45).  
Raman spectroscopy has proved to be a reliable technique that can be applied to 
assess mucosa as well as the deep soft tissue layers (31,36-38). This objective and 
non-destructive technique was used in our first study, where it showed to be accurate 
in discriminating OCSCC from the surrounding healthy tissue. In this previous 
study, we showed, by means of high-wavenumber Raman spectroscopy, that water 
concentration within the tumor (OCSCC) is significantly higher than in the 
surrounding healthy tissue enabling discrimination between tumor and healthy tissue 
with 98% accuracy (37). The notion that certain tumors contain more water than 
surrounding healthy tissue was not new; already in 1971 water content was 
described as one of the discriminators between tumor and healthy tissue. Diagnostic 
instruments like MRI use the differences in water between the relaxation times of 
normal and malignant tissues to generate contrast between the two (46).  
In the current study, we investigated how the water concentration changes from 
inside the tumor towards the adequate surgical margin. The results show a clear 
correlation between the tumor border and the change in water concentration. The 
transition from a high-water concentration inside the tumor to a lower water 
concentration in the surrounding tissue takes place as a negative gradient over a 
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distance of about 4-6 mm across the border of the tumor. By analyzing this negative 
water concentration gradient (Figure 3) we observed that the decrease in water 
concentration from tumor towards the adequate margin is accompanied by an 
increase in the standard deviation of the water concentration, i.e. the heterogeneity 
increases. Inside the tumor, the water concentration was higher than 69%, with a 
relatively low standard deviation of less than 15%. This low standard deviation 
indicates that OCSCC is homogeneous concerning water concentration, regardless of 
pTNM classification (Table 2). Inside the tumor, at about 1.5 mm distance to the 
tumor border, the water concentration of the tumor starts to decrease, and the 
standard deviation starts to increase (Figure 3.A). The average precision with which 
the Raman image could be annotated with the image of the H&E-stained section was 
±0.38 mm (from ±0.15 mm to ±0.5 mm) and was determined by the resolution of the 
Raman measurements as explained in the materials and methods section. The 
increase in the standard deviation can indicate that close to the tumor border, the 
water concentration heterogeneity increases, possibly explained by the presence of 
stroma, blood vessels and lymphatic vessels (47). Another interesting finding is that 
at approximately 4 mm beyond the tumor border the standard deviation of the water 
concentration levels off at about 26%. This high variance of the water concentration 
in the surrounding healthy tissue is due to the heterogeneity in these areas 
comprising fat tissue, muscle (M) and vessels (Figure 4).  
In this study we show the water concentration distribution across the tumor border. 
The shape of the water profile from inside the tumor towards the adequate margin 
for OCSCC is a new finding, as well as, the increase in water concentration 
heterogeneity at the tumor border.  
 
Figure 4. H&E stained section obtained from a measured tissue surface, with tumor 
border (red line), tumor (T) and healthy surrounding tissue (H) indicated by pathologist. 
A representative region of the adequate margin was enlarged and the tissue structures 
annotated. Tissue structures present are muscle (M), adipose tissue (A) and blood vessels 
(B). 
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We are currently devising fiber optic probe configurations and fiber optic probe 
measurement strategies to capture this information in a way that can be implemented 
for rapid intra-operative assessment of resection specimens. 
We believe that Raman spectroscopy is a promising candidate for comprehensive 
intra-operative inspection of the surgical margins for OCSCC resection specimens, 
which will fit in the surgical workflow and can help to significantly improve the 
percentage of adequate resections. 
We expect that water concentration analysis will be proof equally useful in 
localizing the tumor border in other locations of the body and plan to expand this 
line of investigation accordingly. 
 
  
15432-Barroso_BNW.indd   145 05-04-18   08:55
146 
References 
1. Ferlay J., Soerjomataram I., Dikshit R., 
GLOBOCAN 2012. International Journal 
of Cancer. 2014;136: E359–E386. 
2. Karim-Kos H. E., de Vries E., 
Soerjomataram I., Eur. J. Cancer. 
2008;44:1345–89. 
3. Guntinas-Lichius O., Wendt T., 
Buentzel J., J Cancer Res Clin. Oncol. 
2010;136:55-63. 
4. Sant M., Allemani C., Santaquilani M., 
Eur J Cancer. 2009;45:931–91. 
5. Woolgar J. A.. Oral Oncol. 
2006;42:229–239. 
6. Datema F. R., Ferrier M. B., van der 
Schroeff M. P., Head & Neck. 
2009;32:728-736. 
7. Baatenburg de Jong R. J., Hermans J., 
Molenaar J., Head & Neck. 2001;23:718-
724. 
8. Helliwell T., Woolgar J., The Royal 
College of Pathologist. 2013. 
9. Smits R. W. H., Koljenović S., Hardillo 
J. A., Head & Neck. 2015; doi: 
10.1002/hed.24075. 
10. Dillon J. K., Brown C. B., McDonald 
T. M., J Oral Maxillofac Surg. 
2015;73:1182-8. 
11. Varvares M. A., Poti S., Kenyon B., 
Laryngoscope. 2015; doi: 
10.1002/lary.25397. 
12. Slootweg P. J., Hordijk G. J., Schade 
Y., Oral Oncol. 2002;38:500–503. 
13. Al-Rajhi N., Khafaga Y., El-Husseiny 
J., Oral Oncol. 2000;36:508–514. 
14. Binahmed A., Nason W. N., Abdoh 
A. A., Oral Oncol. 2007;43:780–784. 
15. Pathak K. A., Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod. 
2009;107:235-239. 
16. Gandour-Edwards R. F., Donald P. J., 
Wiese D. A., Head & Neck. 1993;15:33-
8. 
17. Hinni M. L., Ferlito A.,  Brandwein-
Gensler M. S., Head & Neck. 2013; 
35:1362–1370. 
18. Yahalom R., Dobriyan A., Vered M., 
J Surg Oncol. 2008;98:572–578. 
19. Chang A. M., Kim S. W., Duvvuri U., 
Oral Oncol. 2013;49:1077–1082. 
20. Francisco A. L., Oral Oncology. 
2014;50:593-599. 
21. Stephen M. M., Jayanthi J. L., Unni 
N. G., BMC Cancer. 2013;13:278.  
22. Sharwani A., Oral Oncology. 
2006;42:343-349. 
23. Vila P. M. Ann Surg. Oncol. 
2013;19(11):3534-3539. 
24. Lee A. M. D., Biomedical Optics 
Express. 2015;6(7):2664-2674. 
 25. Deshmukh A., J Biomed Opt. 
2011;16:127004. 
26. Ravi S. P., J. of Clinical and 
Diagnostic Research. 2014;8(9):ZE01-
ZE05. 
15432-Barroso_BNW.indd   146 05-04-18   08:55
5Chapter 5 
147 
27. Keereweer S., Kerrebijn J. D. F., Mol 
I. M., Head & Neck. 2012;34:1002:1008. 
28. Keereweer S., Mieog J. S. D., Mol I. 
M., Archives of Otolaryngology - Head 
and Neck Surgery 2011;137:609-615. 
29. Malini R, Biopolymers. 2006;81:179–
193. 
30. Oliveira A. P., Photomed Laser Surg. 
2006;24:348–353. 
31. Su L., Laser Phys. 2012;22:311–316.  
 32. Nijsen A., Koljenović S., Schut T. C. 
B., J Biophoton. 2009;2:29-36. 
33. Cals F. L. J. , Schut T. C. B., Hardillo 
J. A., Laboratory Investigation. 2015. 
34. Bergholt M. S., Lin K., Zheng W., J 
Biomed Opt. 2012;17:077002. 
35. Liu H., Cancer Res. 2012;72:2491-
2500. 
36. Barman I., Cancer Res. 
2013;73:3206:3215. 
37. Barroso E. M., Smits R. W. H., 
Bakker Schut T. C., Anal. Chem. 
2015;87:2419-2426. 
38. Wolthuis R., Van Aken M., Fountas 
K., Anal. Chem. 2001;73:3915-3920. 
39. Wolthuis R., Bakker Schut T. C., 
Caspers P. J., Fluorescent and 
Luminescent Probes for Biological 
Activity. 1999;433-455.   
40. Caspers P., Journal of Investigative 
Dermatology. 2001;116(3):434-442. 
41. Haralick, Sternberg, and Zhuang, 
IEEE Transactions on Pattern Analysis 
and Machine Intelligence. 1987;PAMI-
9:532-550. 
42. Sobin L. H.,Gospodarowicz M. 
K.,Wittekind Ch., eds., International 
Union Against Cancer (UICC) TNM 
Classification of Malignant Tumors. 7th 
ed. Oxford, UK: Wiley-Blackwell; 2009. 
43. Woolgar J. A., Triantafyllou A., Oral 
Oncol. 2005;41:1034-43. 
44. Hamdoon Z., Jerjes W., McKenzie G., 
Photodiagnosis and Photodynamic 
Therapy. 2016;13:211-217. 
45. Jung W., Boppart S. A., Anal Cell 
Pathol. 2012;35(3):129-143. 
46. Damadian R., Science. 
1971;171:1151-1153. 
47. Wenig B. M., Modern Pathology. 
2002;15(3):229-254.
15432-Barroso_BNW.indd   147 05-04-18   08:55
 15432-Barroso_BNW.indd   148 05-04-18   08:55
  
 
 
 
 
 
 
 
 
CHAPTER 6 
 
 
Raman spectroscopy for assessment 
of bone resection margins in 
mandibulectomy for oral cavity 
squamous cell carcinoma 
 
E. M. Barroso†, I. ten Hove†, T. C. Bakker Schut, H. Mast, C. G. F. van Lanschot, R. W. H. 
Smits, P. J. Caspers, R.  erdijk,  . Noordhoek Hegt, R. J. Baatenburg de Jong,  . B. Wolvius, 
G. J. Puppels, S. Koljenović 
† These authors contributed equally to this work. 
European Journal of Cancer 2018; 92:77-87 
15432-Barroso_BNW.indd   149 05-04-18   08:55
   
15432-Barroso_BNW.indd   150 05-04-18   08:55
6 Chapter 6 
151 
Abstract  
The aim of this study was to investigate the potential of Raman spectroscopy for 
detection of oral cavity squamous cell carcinoma (OCSCC) in bone resection 
surfaces during mandibulectomy. 
Raman mapping experiments were performed on fresh mandible resection 
specimens from patients treated with mandibulectomy for OCSCC. A tumor 
detection algorithm was created based on water concentration and the high-
wavenumber range (2800 cm-1 to 3050 cm-1) of the Raman spectra. 
Twenty-six ex-vivo Raman mapping experiments were performed on 26 fresh 
mandible resection specimens obtained from 22 patients.  
The algorithm was applied on an independent test set and showed an accuracy of 
95%, a sensitivity of 95%, and a specificity of 87%. 
These results form the basis for further development of a Raman spectroscopy tool 
as an objective method for intra-operative assessment of bone resection margins. 
 
Introduction 
Oral cavity squamous cell carcinoma (OCSCC) is the most frequent type of cancer 
in the head and neck region. The 5-year survival is around 50% (1,2). Every year, 
145.000 deaths are registered worldwide (3,4).  
The primary treatment for OCSCC is surgery aiming at complete removal of tumor 
with an adequate resection margin (5,6). During the operation, the surgeon decides 
where to cut based on preoperative imaging (CT, MRI), visual inspection and 
palpation of the tumor and surrounding tissues. 
For OCSCC surgery, results obtained from two Dutch centers (Erasmus MC, 
University Medical Center Rotterdam and Leiden University Medical Center) 
showed inadequate soft tissue resection margins in about 85% of the cases (7).  
Similar results were reported by the Harborview Medical Center and the University 
of Washington Medical Center in Seattle (USA) (8). With respect to bone resection 
margins, studies have reported tumor-positive bone resections in 2-20% of the cases 
(9-12). Additionally, a retrospective study performed by our group showed that 
tumor-positive bone resection margins were found in 21% of the patients (13).  
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Adequate resection margins are paramount for disease control and survival: a 
number of studies have shown that 5-year disease-free survival decreases 
significantly when the margins are inadequate (7,9,14-19). Ideally, all resection 
margins (soft- and bone tissue) should be controlled by intra-operative assessment. 
This would enable additional resection during the same surgical setting to ensure 
adequate tumor resection and a tumor-free wound bed for tissue transplants.  
For soft tissue resection margins the so-called frozen section procedure is available 
for intra-operative assessment (20-24). The surgeon samples a piece of suspicious 
tissue from the wound-bed and submits it for microscopic evaluation by the 
pathologist. 
In contrast to soft tissue, for bone resection margins the assessment by frozen 
sections is virtually impossible (25-29), while histopathological information on the 
presence of tumor or free of tumor in the bone margins is available only after a few 
weeks (7).  
The resection of advanced OCSCC with mandible involvement requires immediate 
reconstruction with microvascular free flaps. By that time the wound is healed, 
which makes a second surgery undesirable (25-29). Therefore, current 
histopathology does not contribute to more radical resections. During surgery, other 
than visual inspection, there is no routine intra-operative technique to evaluate the 
bone resection margins.  
Recently, Nieberler et al. (2014, 2016) showed that intra-operative cytological 
assessment of bone resection margins can be used. This intra-operative approach 
was established and validated to assess bone specimens, including the inferior 
alveolar nerve. The technique revealed a sensitivity of 94.4%, a specificity of 97.4%, 
a positive predictive value of 85% and a negative predictive value of 99.1%. 
Although these results are very promising, this approach is not widely used.  The 
authors mention a number of limitations of the technique. Desiccation of the bone 
margin caused altered cell morphologies, which led not only to false-positive results 
but also to false-negative results. Additionally, the authors mention that insufficient 
cellular material or excessive trabecular bone material and the interference by blood 
cells resulted in low quality cytological preparations (28,29).  
The use of Raman spectroscopy for intra-operative assessment of tumor resection 
margins is currently being investigated (30-32). This optical technique is based on 
inelastic scattering of light by the molecules in the tissue and provides detailed 
quantitative and qualitative information about its molecular composition (30-34). 
The technique can be used directly on tissue because it is non-destructive and there 
is no need for reagents or labeling (30-41).  
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In earlier work we showed that Raman spectroscopy can be used to discriminate 
OCSCC from surrounding healthy soft tissue with a sensitivity of 99% and a 
specificity of 92%, based on clear differences in tissue water concentration. The 
water concentration was found to be significantly higher in the tumor than in the 
surrounding healthy soft tissue (35). Furthermore, we demonstrated that the tumor 
border could be determined based on water concentration. The water concentration 
decreases from 76% (± 8%) inside the tumor to 54% (± 24%) at a distance of 5 mm 
from the tumor border, corresponding to the targeted tumor free margin in OCSCC 
resections (36).  
The goal of the current study was to investigate whether Raman spectroscopy can 
also be used to detect OCSCC in bone resection surfaces enabling surgeons and 
pathologists to use it as an objective intra-operative technique for assessment of the 
bone resection margins. 
 
Materials and Methods 
 Medical Ethical Approval 
This study was approved by the Medical Ethics Committee of the Erasmus MC, 
University Medical Center Rotterdam (MEC-2013-345). Before the surgical 
procedure, informed consent was obtained from all patients. Between October 2014 
and July 2016 experiments were performed on fresh resection specimens of patients 
undergoing mandibulectomy for OCSCC. The time for the Raman experiments was 
limited to 60 minutes for optimal preservation of the tissue.  
 Handling of resection specimen 
After the resection, the pathologist and the surgeon examined the specimen together. 
This examination comprised of recording the anatomical orientation of the specimen 
with drawings and photographs (Figure 1.a). Subsequently, the pathologist together 
with the surgeon examined all resection planes by visual inspection and palpation.  
After this assessment, without compromising the histopathological process, cross 
sections were taken from one or both mandible resection edges and from the center 
of the specimen (containing tumor) (Figure 1.a-e). The bone sections had a thickness 
of 5 mm. The complete bone resection surface was macroscopically inspected by the 
pathologist and surgeon. Regions within the resection surfaces were selected for 
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Raman measurements that either appeared to contain tumor, or, as controls, appeared 
to be free of tumor. 
Prior to Raman experiments the bone sections were rinsed with physiological salt 
solution (0.9% NaCl) and then gently patted dry with gauze. The bone section was 
placed in a cartridge with the surface to be measured in contact with a fused silica 
window (Figure 1.b-c). After the Raman experiments measurements, the specimen 
followed the routine procedure for final histopathological processing. An overview 
of the handling protocol of a mandible specimen is illustrated in Figure 1. 
 Raman instrumentation and mapping 
A confocal Raman microscope was used to perform Raman mapping experiments. 
The equipment is described in detail in earlier work (36). It comprises a 671nm laser 
(CrystaLaser, CL671-150-SO), a multichannel Raman Module (HPRM 2500, 
RiverD International B.V) and a charge-coupled device (CCD) camera fitted with a 
back-illuminated deep depletion CDD-chip (Andor iDus 401, DU401A BR-DD, 
Andor Technology Ltd.). The Raman Module was coupled to a microscope (Leica 
DM RXA2, Leica Microsystems Wetzlar GmbH) and a computer-controlled sample 
stage (Leica DM STC). By means of a microscope objective with 0.4 numerical 
aperture and 1.1mm working distance (N PLAN 11566026, Leica Microsystems 
B.V.) 80mW of laser light was focused in the bone tissue. Spectral information was 
collected in the high-wavenumber range of 2500 to 4000 cm-1 with a resolution 
<5cm-1. 
The depth resolution was 40µm. The laser light was focused in bone at about 70µm 
below the fused silica window of the cartridge. The cartridge was then fixed on the 
microscope stage and a selected surface area was mapped in a grid. The step size of 
the grid varied between 250µm by 250µm to 1000µm by 1000µm depending on the 
size of the bone section. The signal acquisition time per spectrum was 1 second. 
Each mapping experiment was performed in less than 30 minutes.  
 Calibration and pre-processing of spectra 
For data calibration and data pre-processing software was developed with MATLAB 
(R2014b). 
Spectra were calibrated on the relative wavenumber axis and corrected for the 
wavelength dependent detection efficiency of the setup (37).  
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The background signal due to tissue auto fluorescence was estimated using a method 
based on the multiple regression (42). The background was estimated as a 3rd order 
polynomial and subtracted from the pre-processed spectra.  
 
Figure 1. Overview of the handling protocol of a segmental mandibulectomy specimen. 
a) Specimen with recorded anatomical orientation (A for anterior and P for posterior). 
b) Section inserted in the cartridge. This section is from the edge of the specimen 
(without macroscopically visible tumor). c) Section inserted in the cartridge. This section 
is from the center of the specimen with the tumor invading the bone. d) Close up of the 
tissue section shown in b. e) Close up of the tissue section shown in c. f) H&E stained 
section obtained from the bone section b. g) H&E stained section obtained from the bone 
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section c. Healthy tissue (H) and tumor (T) are indicated. The red line demarcates the 
border between the tumor and healthy bone. 
For all spectra, the average intensity over the range of 2700 to 3100 cm-1 was used as 
a measure of signal intensity. The lowest quality spectra (with an average intensity 
lower than 5% of the overall average intensity) were excluded from the data 
analysis.  
 Histopathological annotation 
Histopathological annotation of tumor and healthy tissue in bone resection 
specimen, based on H&E stained sections, was performed by a dedicated pathologist 
(Figure 1. f-g).  
 Spectral Analysis 
Data processing and data analysis was also performed in MATLAB; R2014b. Data 
analysis consisted of two steps: 1) analysis of the water concentration and 2) 
analysis of the C-H stretching region by performing principal component analysis 
(PCA) and linear discriminant analysis (LDA). 
1) Analysis of the water concentration  
The water concentration in bone resection specimen was calculated for each 
measurement point according to the method developed by Caspers et al. (2001) and 
described in detail elsewhere (33-35).  
Raman water maps of the bone sections were created, using a color code to represent 
the water concentration range. The images of the H&E stained sections were 
projected onto the corresponding Raman water maps. This allowed histopathological 
annotation of each pixel as tumor, tumor border, or healthy bone.  
Additionally, for each Raman pixel the minimal Euclidean distance to the closest 
pixel belonging to the tumor border was calculated. The precision of the annotation 
of the individual pixels was limited by the resolution of the respective Raman water 
map (pixel size varying from 250 µm by 250 µm to 1000 µm by 1000 µm).  
After calculation of the water concentrations and histopathological annotation of the 
Raman water maps, the water concentrations were separated in two groups: water 
concentrations from samples only containing healthy bone (referred to as H-group), 
and water concentrations from bone containing tumor (referred as T-group). For the 
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T-group we only considered the spectra from the tumor region that were >3 mm 
away from the tumor border to ensure that only pure tumor spectra were analyzed.  
The Mann-Whitney u-test was used to determine if there was a significant difference 
between the water concentrations measured in tumor and the water concentrations 
measured in healthy bone. 
The discriminatory power of the water concentration analysis was determined using 
a Receiver Operating Characteristic (ROC) curve. The ROC curve was obtained by 
calculating the number of correct and incorrect classifications as function of the 
water concentration cut-off value used to discriminate between the T-group and the 
H-group. The water concentration percentage that discriminated the two groups with 
a sensitivity of 99% was used as a cut-off value in order to minimize the risk of 
misclassifying tumor as healthy tissue. Spectra with water concentrations lower than 
the cut-off were indicated as negative (bone without tumor). Spectra with water 
concentrations higher than this cut-off were indicated as positive (i.e. potentially 
tumor) and were further processed in step 2.  
2) Analysis of the C-H stretching region: PCA-LDA modeling  
The spectral region between 2800 and 3050 cm-1 was used for analysis of the C-H 
stretching Raman signal. The information obtained in this region is independent 
from, and complementary to, the water concentration information.  
First, all spectra were scaled using an extended multiplicative scatter correction 
(EMSC) procedure to eliminate the spectral interference of varying water 
contributions. This method has been used in earlier studies and in this study was 
used to ensure that the C-H stretching region analysis is independent from the water 
signal (40,43). After, PCA was performed to reduce the dimensionality of data prior 
to LDA modeling. The scores on the most significant principal components 
(determined by the highest confidence levels in a student t-test of group differences) 
were selected as input parameters to the LDA. LDA finds the direction in this PCA 
space that maximizes the ratio between inter-group and intra-group variance (44,45). 
The LDA discriminant score was used for classification. The discriminating 
parameter used as input for the LDA was a Boolean: tumor or non-tumor. 
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 Classification algorithm for detection of OCSCC in the 
bone 
An algorithm for detection of OCSCC in the bone was developed by combining the 
two previous analyses: 1) analysis of the water concentration and 2) PCA-LDA 
analysis of the C-H stretching region.  
After algorithm development, an independent data set was used for validation of the 
algorithm. Sixty-eight percent of the maps served for algorithm development, 32% 
of the maps were used as independent data set.  
Algorithm development 
The water concentration was calculated per spectrum (step 1). Only the spectra that 
yielded a water concentration higher than the cut-off were subjected to the PCA-
LDA model, labeled as suspicious of being tumor (step 2). Spectra with a water 
concentration lower than the cut-off were classified with a zero score (labeled as 
bone without tumor).  
The LDA discriminant score, obtained in step 2, was used for classification of the 
spectra with water concentrations higher than the cut-off, calculated in step 1).  
The discriminative power of this sequential model was determined by calculating the 
area under the curve (AUC) of the ROC curve that was generated by evaluating the 
leave one patient out prediction results for different discrimination threshold levels.  
The Youden Index was determined to find the cut-off level that best discriminates 
between the two groups (highest combined sensitivity and specificity) (46). This 
Youden index was used as the cut-off for the tumor detection algorithm.  
Algorithm Validation 
The tumor detection algorithm was tested on an independent data set, consisting of 
data obtained from tissue samples of patients that were not included in the data set 
used to create the classification model. The sensitivity and specificity of the 
algorithm were calculated. 
Due to the relatively large pixel-size in the Raman maps, the pixels on the tumor 
border could not be annotated as tumor or healthy. They were annotated as tumor 
border and were excluded from the test of the classification model.  
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Results 
Twenty-six ex-vivo Raman mapping experiments were performed on fresh mandible 
resection specimens from 22 patients treated with mandibulectomy for OCSCC. 
Patient and tumor characteristics are listed in the table 1.  
Table 1 - Patient and tumor characteristics. 
Patient Age Gender Tumor 
Location 
cTNM 
1 70 M t ngue T4N0M0 
2 67 F floor of 
mouth 
T1N0M0 
* 3 86 F mandible T4N0M0 
4 66 M floor of 
mouth 
T4aN0M
0 5 68 M flo r of 
mouth 
T4N0M0 
6 87 F mandible T4aN0M
0 7 69 M mandible T4aN0M 
8 52 M mandible T4aN2c
M0 9 67 F floor of 
mouth 
T2N0M0 
* 10 73 M mandible T4aN2b
M0 11 73 M mandible T4aN0M
0 12 78 M mandible T4aN0M
0 13 66 M mandible T4N0M0 
14 84 F mandible T4N2cM
0 15 54 M mandible T4aN2c
M0 16 69 M mandible T4aN2c
M0 17 81 M floor of 
mouth 
T4aN0M
0 18 60 M lower lip rT0N3M
0 # 19 59 F floor of 
mouth 
rT4aN0
M0 20 56 F buccal
mucosa 
T4N0M0 
21 61 F mandible T4aN0M
0 22 64 M floor of 
mouth 
T4aN0M
0 * Mandibulectomy (marginal) performed for reconstruction reasons.  
# Mandibulectomy (segmental) performed because of large lymph node metastasis with extra 
nodal spread and extensive bone invasion. 
Of these 26 maps, 17 maps (from 15 patients) were used for development of the 
tumor detection algorithm and final classification model (training set). The 
remaining 9 maps (from 7 different patients) were used for validation of the model 
(test set).  
The maps of the training set consisted on average of 423 spectra (ranging from 122 
to 727 spectra) and measured an average area of 128.7mm2 (ranging from 43.7 to 
253 mm2).  Seven Raman maps were obtained of bone sections containing tumor and 
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surrounding healthy bone (T-group, 7 patients), 10 Raman maps were obtained of 
patient’s samples containing only healthy bone (H-group, 8 patients). Figure 2 
shows examples of the Raman sections that were measured.  The bone section 
shown in figure 2.a consisted of healthy tissue and the bone section shown in figure 
2.b was invaded by tumor. The Raman spectrum in figure 2.c was obtained from the 
healthy bone tissue and the Raman spectrum in figure 2.d was obtained of tumor. 
Figures 2.e and 2.f show the tissue sections after H&E staining.  
 Spectral Analysis 
1) Analysis of the water concentration  
For the T-group, water concentrations were calculated from 1008 tumor spectra that 
were recorded at >3 mm distance from the tumor border. The distribution of water 
concentrations is shown in figure 3.a (orange). The mean of the water concentrations 
of the T-group was 77% with a standard deviation of 6%. 
For the H-group, a total of 4983 spectra were measured and were used to calculate 
water concentrations in the healthy bone tissue. The distribution of the water 
concentration in the H-group is also shown in figure 3.a (green). The H-group had a 
mean water concentration of 44% with a standard deviation of 17%. 
The Mann-Whitney U-test showed a significant difference between the water 
concentrations from the H-group and the T-group (p-value <0.0001).  
A ROC-curve was generated based on the water concentrations measured in both 
groups, in which the true positive rate (sensitivity) was plotted against the false 
positive rate (1-specificity) for different values of the water concentration threshold 
(Figure 3.b). The area under the curve, which is a measure for the discriminatory 
power of the test, was 0.96. Using a cut-off value of 60% for the water 
concentration, a sensitivity of 99% is obtained for the detection of tumor suspicious 
tissue, with a specificity of 83%.  
2) Analysis of the C-H stretching region 
For analysis of the spectral region containing C-H vibrations only the spectra from 
the T-group and from the H-group that showed a water concentration >60% (cut-off) 
were included (712 spectra from the H-group, and 1002 spectra from the T-group). 
The mean spectra of the two groups and their difference are shown in figure 3.c. The 
difference spectrum shows that the lipid to protein ratio in tumor tissue is higher 
than in healthy bone. The wavenumber region 2830 to 3020 cm-1 was used for PCA-
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LDA modeling because it contained the largest differences between the mean 
spectra from the two groups.  
The first 4 principal components were used as input in the LDA modeling.  
 Classification model for detection of OCSCC in the bone  
Model development 
The two-step tumor detection algorithm described above was used to develop the 
final classification model.  
 
 
Figure 2. Examples of fresh mandibulectomy sections of healthy cortical bone and bone 
invaded by tumor, with their characteristic Raman spectra and H&E images. a) Bone 
section from the edge of a mandible specimen, without tumor. b) Bone slice from the 
center of the specimen, where tumor is invading the bone. c) Spectrum acquired from 
the cortical region of the mandible (acquisition time: 1 second). d) Spectrum from tumor 
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tissue that was >3mm distant from the tumor border (acquisition time: 1 second). The 
two-dashed vertical gray lines are marking the CH-stretching region. e) H&E stained 
section obtained from the bone section a. f) H&E stained section obtained from the 
section b. Histopathological annotation: H for healthy bone and T for tumor. The tumor 
border is delineated with a red line. 
All spectra (5991) from the training set were used for development of this model.  
The ROC-curve shown in figure 3.d is the result of a leave-one-patient-out 
evaluation (cross validation per spectrum) of the classification model (combination 
of the water concentration analysis and the PCA-LDA model). It shows a 
discriminatory power of 98%.  
The LDA discrimination threshold that gave the highest combined sensitivity and 
specificity (Youden index) yielded a sensitivity of 94%, and a specificity of 93%. 
The threshold was used in the final classification model. 
 
Figure 3. Results of the spectral analysis and leave one patient out cross validation. a) 
Histogram of the normalized distributions of the water concentration for the tumor 
group (T-group, orange), and for the healthy bone group (H-group, green). b) ROC 
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curve generated (AUC of 0.96) to show the discriminating power of the water 
concentration model (sensitivity of 99% and specificity of 83% for water concentrations 
>60%). c) Mean spectrum of the T-group with a water concentration of >60% (orange), 
and the mean spectrum of H-group with a water concentration of ≤60% (green). The 
difference spectrum (tumor minus healthy) is shown in black. d) ROC curve generated 
(AUC of 0.98) to demonstrate the discriminatory power of the tumor detection 
algorithm (sensitivity of 94% and specificity of 93%). 
Model validation 
The independent test set consisted of 2033 spectra from 9 maps (from 7 patients). 
The average number of spectra per map was 226 (range from 110 to 509 spectra), 
from an average area of 74.4 mm2 (range from 27.5 to 147 mm2).  
The validation of the tumor detection algorithm (on the independent test set) using 
the discrimination threshold based on the Youden index, showed a sensitivity of 
95%, a specificity of 87%, and an accuracy of 95%. The results of the validation of 
the tumor detection model are presented in table 2 and illustrated in figure 4 with the 
prediction maps of the tumor detection algorithm (column b).  
Table 2 – Comparison of false positive rates* obtained in bone cross sections containing 
tumor and bone cross sections without tumor. 
Map number False Positive rate (%) Histopathology 
1 15 Bone section with tumor 
2 15 Bone section with tumor 
3 68 Bone section with tumor 
4 0.2 Bone section without tumor 
5 1.3 Bone section without tumor 
6 4 Bone section without tumor 
7 7.2 Bone section without tumor 
8 1.3 Bone section without tumor 
9 0 Bone section without tumor 
* False positive rate is the proportion of pixels from healthy tissue that are misclassified as 
tumor. 
Discussion 
In contrast to OCSCC soft tissue specimens in which the resection margins can be 
assessed by frozen sections during the operation, there is no standard technique than 
can be used intra-operatively for evaluation of bone resection margins for OCSCC. 
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A study published by Nieberler et al. (2016) demonstrated the benefits of cytological 
intra-operative assessment of the bone resection margins in head and neck 
carcinoma. They concluded that the intra-operative assessment can lead to a 
reduction of the residual carcinoma tissue in the bone resections margins from 17% 
to 7.8% (29). Although these results are very promising, a major disadvantage of the 
technique is that the analysis is mainly based on cells obtained from the bone 
marrow. This cytological sample preparation is difficult, the assessment is 
subjective, labor intensive, and requires the availability of highly trained 
professionals.  
 
Figure 4. Examples of the results obtained when testing the tissue classification model on 
3 bone slices from 3 patients (1-3). a) Photographs of fresh bone cross sections from the 
center of resection specimen with tumor invasion (based on radiologic examination) 
from which Raman spectra were obtained. b) Raman classification maps (orange: 
tumor, green: healthy bone) tumor border indicated in red. Black pixels correspond to 
absence of tissue or to spectra with low Raman signal quality. c) H&E-stained sections 
obtained from the measured bone surface, with tumor border (red), tumor (T) and 
healthy surrounding bone (H) indicated by pathologist. 
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In contrast to cytological assessment described by Nieberler et al. (2014, 2016), 
Raman spectroscopy based method is objective, does not require sample preparation 
and enables quick evaluation of whole bone resection surface.  
Since 2014, our group has been focused on applying high-wavenumber Raman 
spectroscopy for surgery guidance by intra-operative assessment of resection 
margins on OCSCC specimens (35).  
By using this technique, we found that we could differentiate OCSCC from 
surrounding healthy tissue based on water concentration with an accuracy of 98% 
(35). Recently, we have demonstrated that high-wavenumber Raman spectroscopy 
can be used in soft tissue specimens to locate the tumor border (36). The final aim of 
our research is the development of a clinical tool for ex-vivo and in-vivo real-time 
assessment of the soft and bone resection margins motivated by the main goal of 
surgery: adequate tumor resection while sparing as much healthy tissue as possible. 
The current ex-vivo study shows that the average water concentration found in 
tumor located in the bone was 77% ± 6%. This value is similar to the results found 
in tumor located in the soft tissue in a previous study (36). The average water 
concentration of healthy bone is 44%, which is lower than in healthy soft tissue 
(54%) (36). A large standard deviation in water concentration was found for healthy 
bone (17%), just as we found previously for healthy soft tissue (24%) (36).  
A two-step classification model was developed based on the water concentration 
information and the spectral information in the CH-stretching region. The model 
showed an accuracy of 95%, a specificity of 87% and a sensitivity of 95% when 
tested on an independent data-set.  
A further analysis of the false positive results (table 2) showed that most 
misclassifications occurred in bone sections containing tumor where 
histopathologically normal tissue in the proximity of tumor was classified as tumor 
(average false positive rate of 33%). This may be explained by epithelial-
mesenchymal transition (EMT), which is recognized as an initiating mechanism of 
the invasive and metastatic behavior of epithelial cancers (47). Therefore, EMT may 
be biochemically more similar to tumor than to healthy bone, which explains false 
positives in the bone sections containing tumor and healthy-looking tissue (table 2). 
This is also supported by the fact that, in bone sections without tumor (and without 
EMT) the average false positive rate was much lower (2.3% in average). Marro et al. 
(2014) showed that Raman spectroscopy can be used for molecular monitoring of 
epithelial mesenchymal transition in breast cancer cells (48).  
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For implementation of this technique for clinical decision making regarding the need 
for additional bone resection, a first approach could be to use the false positive rate 
encountered in bone sections without tumor as a threshold below which a tissue 
section is classified as tumor free.  This as well as more elaborate approaches will be 
the subject of further studies. 
These results convincingly show that Raman spectra of bone resection specimen 
provide the information to distinguish between healthy tissue and remaining tumor 
tissue.  
Implementation in the clinical workflow also requires the elimination of a practical 
issue that sometimes occurred. A lack of contact between the surface of the bone 
section and the fused silica window of the measurement cartridge leads to a low-
quality Raman signal. Therefore, it is important to cut the bone in a manner that it 
results in a flat and smooth surface. Alternatively, a method can be implemented by 
which the contours of the surface are automatically followed by the measurement 
system (such as, inViaTMQontorTM, Renishaw B.V., United Kingdom). 
In this study, regions within bone resection surfaces were selected that either 
appeared to the surgeon and pathologist to contain tumor, or, as controls, appeared to 
be free of tumor.  Of course, the aim for the future is to scan the complete resection 
surface by Raman spectroscopy.  
Our results show, that Raman spectroscopy could be applied ex-vivo for evaluation 
of bone resection margins (including bone marrow and cortical bone) during 
OCSCC surgery. We believe that this could improve the number of adequate 
resection margins, and consequently reduce the extent of adjuvant treatment. Equally 
important, having a method for intra-operative assessment of bone resection 
margins, might give surgeons the confidence to adjust initial cut line and resect the 
bone closer to the suspected tumor border. In this way, healthy bone might be 
spared, which will positively influence the reconstruction and reduce the possible 
post-operative complications. 
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CHAPTER 7 
 
 
Translation to the clinics: 
development of a fiber-optic Raman 
needle probe for intra-operative 
assessment of surgical margins in 
oral cancer based on water 
concentration 
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Introduction 
Every year >300,000 new cases of oral cavity squamous cell carcinoma (OCSCC) 
are diagnosed worldwide. The mortality rate of this type of cancer is high (145,000 
deaths per year worldwide). The 5-year survival rate is poor, around 50%. Surgery is 
often the treatment of choice for this type of cancer (1,2). Adequate tumor resection 
with acceptable remaining function and physical appearance is the main goal of the 
surgery (3). Achieving an adequate resection margin is difficult (clear margins, > 
5mm of surrounding healthy tissue). The current surgical success rate for OCSCC 
resection is only 15% (4,5). This low success rate clearly indicates that the current 
methods used for intra-operative assessment during OCSCC surgery (visual 
inspection and palpation) are subjective and insufficient to guarantee an adequate 
resection.  
Although, intra-operative assessment of resection margins for OCSCC surgery can 
be supported by the frozen section procedure, this procedure is limited (6-10). The 
major limitation is that only a fraction of the resection margin or wound bed can be 
investigated. Additionally, this method is associated with sampling errors, which are 
associated to false negative results (6-10).  
Ideally, the entire resection surface should be evaluated to consistently obtain a high 
surgical success rate and thereby improve clinical outcome of OCSCC patients.   
Therefore, an objective, and rapid method is needed for intra-operative assessment 
of complete resection margins. 
Raman spectroscopy is an objective optical technique that can be applied to obtain 
qualitative and quantitative information about the biochemical composition of 
tissues from the oral cavity.  
In a previous study we have established that Raman spectroscopy can be used to 
discriminate OCSCC from surrounding healthy soft tissue with a sensitivity of 99% 
and a specificity of 92%. The discrimination was based on differences in tissue 
water concentration (found to be significantly higher in the tumor than in the 
surrounding healthy soft tissue) (11).  
In a second study, we showed that the tumor border can be localized based on the 
water concentration distribution. The water concentration decreases from 76% (± 
8%) inside the tumor to 54% (± 24%) in the adequate margin (12). These findings 
demonstrate the potential of Raman spectroscopy for objective intra-operative 
assessment of the resection margins based on the water concentration. 
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The water concentration was determined based on measurements in the high-
wavenumber (HWVN) part of the Raman spectrum, which is mainly dominated by 
the CH-, OH-, and NH-stretching vibrations. Several studies demonstrated that for 
clinical applications the HWVN part of the Raman spectrum is as informative as the 
mostly used fingerprint (FP) region (13,14).  
The previous studies were performed using a confocal Raman microspectrometer. 
Signal collection times of 1 second were used, which resulted in spectra with a high 
signal to noise ratio, allowing a quick determination of the tissue water 
concentration. By optimizing the measurement volume and laser power, we believe 
that the signal collection time per measurement can be reduced to 0.1 second or less. 
This will enable inspection of large resection areas in the limited time available 
during surgery.  
To enable scanning of complete resection surface and deep tissue layers of a 
specimen, while this remains intact, the use of a Raman fiber-optic needle probe can 
be a solution.  
Raman fiber-optic probes have been used to detect brain cancer, esophageal cancer 
and gastric cancer (15-17). The Raman signal acquired with these probes, which 
were multi-fiber, were mostly from the top ~1mm layer of the tissue. Other studies 
showed that Raman fiber-optic probes can be fitted in hypodermic needles (18,19) 
for assessing deeper soft tissue layers. The main requisite for this approach is to 
have a thin needle for optimal tissue penetration (specimen shape and size need to 
remain intact). Since the needle needs to be thin, a solution is to have instead of a 
multi-fiber probe a single optical fiber, which may be used for both, excitation and 
collection (20).  
In this paper, we present a Raman spectroscopy system that uses a single-fiber-optic 
needle probe for discriminating oral cavity squamous cell carcinoma from healthy 
tissue based on water concentration. We demonstrate that the probe can be used to 
inspect the resection surface and the deep tissue layers. This is an important step 
towards the development of an intra-operative tool for assessing the entire tumor 
resection surface, which may allow an adequate tumor removal and thereby 
improvement of patient outcome. 
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Materials and Methods 
 Tissue Samples 
The Medical Ethics Committee of the Erasmus MC has approved this study (MEC-
2013-345, 2015-amendments). Informed consent was obtained from the patients 
prior to the surgical procedure. For each patient, intra-operative assessment of the 
resection surface of the freshly excised oral cavity squamous cell carcinoma 
specimen was conducted by the pathologist and surgeon. Intra-operative assessment 
of the resection surface was performed by visual inspection and palpation. The 
pathologist and the surgeon indicated the regions where they expected the smallest 
distance between the tumor border and the resection cut surface. Raman ex-vivo 
experiments were performed on the regions indicated by the pathologist and 
surgeon. After the experiments, the resection specimen was immersed in formalin 
and sent for routine histopathological evaluation.  
 Fiber-optic Raman needle probe instrument 
A new prototype Raman instrument, equipped with an automated fiber-optic needle 
probe for assessing soft tissue resection margins, was developed by RiverD 
International B.V. (The Netherlands), as part of a research project funded by the 
Dutch Cancer Foundation (project number: 106467) (figure 1).  
The Raman Module 
The equipment was placed in a laboratory of the Pathology department, which is 
close to the operating room. The setup is comprised of a custom-designed HWVN-
Raman Module (RiverD International B.V., The Netherlands), enabling signal 
collection in the spectral range of 2500-4000 cm-1, a 671 nm laser (Gem671, 50 mW 
– 250 mW, LaserQuantum, UK) and a charge-coupled device (CCD) camera fitted 
with a back-illuminated deep depletion CCD-chip (Andor iVac, 316 LDC-DD, 
Andor Technology Ltd., UK).  
The Raman module is connected to the needle probe with a cable containing a fiber 
patch-cord and electrical wiring.  
Two different patch cords can be used by the equipment: one consisted of a step 
index 100 µm-core fiber (NIR100/110AL-300-FC/PC-FC/PC-MS44, Art Photonics 
GmbH, Germany), and another consisted of a gradient index 50 µm core fiber (LWL 
Cable GI50/125AL-300-FC/PC-FC/PC-MS44, Art Photonics GmbH, Germany).   
15432-Barroso_BNW.indd   175 05-04-18   08:55
 176 
The patch-cords are 3 m in length with FC/PC connectors at both ends, and have a 
protective silicone-coated stainless steel reinforced tubing (outer diameter of 4.4 
mm).   
The spectral resolution of the fiber-optic Raman equipment is >7cm-1 when the 50 
µm-core fiber is used and >15 cm-1 when used the 100 µm-core fiber.  
 
Figure 1. First prototype: fiber optic needle probe Raman instrument. 
 
Figure 2. Prototype fiber optic Raman needle probe. 
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The needle probe 
The needle probe consists of a fiber optic needle (30G x 12 mm Omnican® insulin 
needle) attached to an actuator (via FC/PC) that drives the needle through a metal 
spoon to a maximum depth of 10mm into the tissue (SmarAct type SLC1730L linear 
positioned, Smaract GmbH, Germany).  
The actuator is located inside the hand held plastic housing/holder of the probe 
(figure 2). The patch cord that conducts/transmits the light is fixed to the actuator. 
Two different fiber-optic needles can be used, one with a 100 µm-core optical fiber, 
and another with a 50 µm-core optical fiber (figure 3).  
The 100µm-core fiber-optic needle (30G GNIR100/110AL, AP11396, art photonics 
GmbH, Germany) is a 30 gauge needle beveled at 38 degrees that can be connected 
to the 100µm patch cord. The needle contains the optical fiber (step index 
silica/silica, core of 100µm and cladding 110µm, coated with aluminum), also 
beveled at 38 degrees on the tip, and terminated with a FC/PC connector. 
 
Figure 3. Example of a disposable 50µm-core fiber-optic needle (art photonics GmbH, 
Germany). 
 
The 50µm-core fiber-optic needle (30G GI50/125AL, AP11353, art photonics 
GmbH, Germany) is identical, but then with a graded index 50µm optical fiber, that 
can be connected to the 50µm patch cord.  
A spoon (with a hole, see figure 2) is located at the end of the hand-held probe. The 
spoon can be placed on the resection surface of the specimen and the needle will be 
penetrating the resection surface through the hole of the spoon. After measuring the 
needle is automatically retracted. 
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Determination of the depth sensitivity of the probe 
Since the ultimate goal of this research is to assess surgical resection margins of 
OCSCC with a fiber optic needle probe that inspects tissue (up to 10 mm in depth) 
with a precision of <1 mm, it is crucial to guarantee that the depth sensitivity of the 
instrument matches with the requirements specified. 
To estimate the depth sensitivity of the probe in tissue, a plastic container filled with 
water was prepared (non-scattering solution).  
The needle probe was vertically immersed in the water of the container. Every 10 
µm a Raman spectrum was recorded, and the measurement position annotated. 
Measurements were performed until the probe touched plastic, which was the 
bottom of the recipient.  
After the experiment, the Raman spectra were normalized to the total intensity.  
The intensity of the water band was integrated in the range: 3350-3550 cm-1. In this 
way, the intensity of the water band was recorded as a function of depth. The first 
derivative of the intensity of OH band as a function of depth was calculated. The 
width at which the value is half of the minimum value was defined as the depth 
sensitivity.  
The depth sensitivity, was experimentally determined for both sizes of fiber-optic 
needle probes. For both probes the full half width maximum of the step response 
(measured in a non-scattering medium) was determined and it was approximately 
100 µm. 
 Handling of tissue samples & needle probe measurements 
After intra-operative assessment, measurements were performed with the 50 µm-
core Raman fiber-optic needle probe system in the suspected region of the specimen, 
along a straight line indicated by pathologist and surgeon as illustrated in figure 4.a-
d.  
Water profile measurements for assessment of the resection margin 
Water profiles measurements were performed with the needle probe to assess the 
resection margins.  
The spoon of the needle probe was positioned on the resection surface, at the region 
of interest. For each location of interest, the Raman needle probe was programmed 
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to measure from the resection surface (at 0 mm) to a depth of 6mm in steps of 1mm. 
The Raman needle probe was programmed to collect 100 spectra per each 
millimeter, to ensure a high signal quality. Each spectrum was collected with an 
acquisition time of 0.1  s. The laser power at the tip of the fiber-optic Raman needle 
probe was ≈40 mW.  
Each water profile measurement was separated 5-10 mm apart (figure 4.b-d). To 
mark each location that was measured a colored acupuncture needle was used (figure 
4.b-d). 
After measuring all the locations of interest, an incision was made, perpendicularly 
to the resection surface and along a straight line that is in proximity to the 
acupuncture needles that demarcate the measured locations (figure 4.c). This 
allowed a macroscopic inspection of the distance between the tumor border and the 
measured locations at the resection surface (figure 4.d). 
Measurements on the tissue cross section for inspection of the water 
concentration in tumor and in healthy tissue 
The incision made along the straight line allowed direct access to macroscopically 
visible tumor and healthy surrounding tissue.  
Measurements were performed with the fiber-optic needle probe only at the surface 
of the cross section in order to test if the measurements with the Raman needle probe 
yielded the same results that were obtained in our previous studies (11,12). Ten to 50 
frames of 0.1 second were collected per location measured. The locations were 
annotated on a photograph of the cross section. Measurements were separated 5 mm 
apart.  
For the measurements on the cross section the laser power at the tip of the fiber-
optic Raman needle probe was ≈99 mW.  
After the experiment, care was taken to preserve the orientation of the specimen and 
the tissue was sent to the pathology department for the final processing. 
Spectral calibration and Pre-processing 
For calibration and pre-processing of the spectra software was developed with 
MATLAB (R2014b). Calibrations of the relative wavenumber axis and of the 
intensity axis were carried out as described previously (21). The shape and intensity 
of the tissue background signal were determined using a method based on a multiple 
regression fitting algorithm, developed by Barroso et al. (2017) (22). After 
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subtraction of the tissue background signal the water concentration was calculated 
per each spectrum measured according to the method developed by Caspers et al. 
(2001) and described in detail elsewhere (23, 24).  
 
Figure 4. Overview of the handling and measurement protocols with fiber-optic needle 
probe of a fresh tongue specimen. a) Intra-operative assessment of the specimen by 
pathologist and surgeon: visual inspection, palpation of the resection surface, and 
indication of the possible suspected region. The location of the possible suspected region 
determines where Raman measurements are performed (along a straight line). b) Water 
profile measurements with the fiber-optic Raman needle probe are performed and 
marked with colored acupuncture needles. c) Cut along the measured line. d) 
Macroscopic inspection of the distance between the tumor border and the measured 
locations at the resection cut surface (marked with needles). 
 Water concentration Analysis 
Water profile measurements for assessment of the resection margin 
For each depth scan measurement of 0 to 6 mm in depth, the mean and standard 
deviation of the water concentrations measured per millimeter were calculated. In 
this way, the mean water concentration in the tissue was determined as a function of 
depth. 
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Measurements on the tissue cross section for inspection of the water 
concentration in tumor and in healthy tissue 
For each location measured superficially in the cross section, the mean and standard 
deviation of the water concentrations were calculated. For each location, also the 
distance to the resection surface was registered, so that the water concentrations 
were defined as a function of depth. 
 Histopathology correlation 
Haematoxylin and eosin (H&E) stained thin sections were made from the cross-
section surfaces used for macroscopic inspection of the distance between the tumor 
border and the resection surface (figure 4.b-d) and for inspection of the water 
concentration in tumor and healthy tissue, at the locations measured superficially by 
the Raman needle probe.  
Histopathological evaluation of the H&E stained section was performed. The tissue 
spectra, and corresponding water concentrations were annotated as tumor or healthy 
tissue based on the histopathological evaluation. Also based on the H&E stained thin 
section, the pathologist measured the smallest distance between the tumor border 
and the resection cut surface. 
 
Results  
 Tissue Samples 
Two patients were included in the study both with OCSCC of the tongue. Therefore, 
the first results of the fiber-optic Raman needle probe for assessment of the resection 
margins and inspection of the water concentration of tumor and healthy tissue were 
based on OCSCC tongue specimens.  
Patients and tumor characteristics are described in the table 1.  
Needle probe measurements & water concentration analysis 
Water profile measurements for assessment of the resection margin 
Five water profile measurements were performed with the needle probe at 5 different 
positions on an OCSCC tongue resection surface (patient 1, see table 1). 
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For each water profile, the mean and the standard deviation of the water 
concentrations were calculated per millimeter. These values are shown in the table 2.  
 
Table 1. Clinical and hitopathological characteristics of the patients and tissue samples. 
Patient Age Gender Location cTNM pTNM OCSCC Grading 
1 60 F tongue cT2N0M0 pT2N1 Moderate differentiated 
2 83 M tongue cT4N0M0 pT2N0 Moderate to poor differentiated 
 
Table 2. Water profile measurements performed on a tongue resection specimen with 
the fiber-optic Raman needle probe. 
Depth from the  
resection cut surface 
Needle Color 
Green Red Pink Black Blue 
M
ea
n 
[H
2O
]±
st
d(
%
) 0mm 66.8±5.2 9.4±0.5 70.9±5.5 48.5±1.8 75.8±0.8 
1mm 54.3±5.5 22±2.6 68.2±1.7 74.7±1.4 77.3±0.5 
2mm 28.5±7.05 18.2±0.9 63.9±1.2 46.3±2.6 77.2±0.6 
3mm 23.6±1.9 15.6±0.7 63.5±1 28.5±1.6 78.3±3.4 
4mm 24.3±2.5 14.8±0.7 64.4±1.2 30±2.4 72.1±3.3 
5mm 23.3±2.8 16.3±1.3 62±1.8 64.4±2 63.7±1 
6mm 21.3±2.8 19.3±1.2 60.4±1.4 64.5±1.2 60.8±1.1 
 
Measurements on the tissue cross section for inspection of the water 
concentration in tumor and in healthy tissue 
On the cross section of another tongue specimen (patient 2, see table 1), 4 
measurements were performed, see figure 5. 
The mean and standard deviation of the water concentrations measured were 
calculated for the 4 different locations between the two pink pins (figure 5).  
At the location 1, which is at approximately 0 mm from the resection surface, the 
mean water concentration was 61% and the standard deviation was 8.6%.  
At the location 2, which is at 5 mm from the resection surface, the mean water 
concentration was 27% and the standard deviation was 0.5%.  
At the location 3, which is at 10 mm from the resection surface, the mean water 
concentration was 72% and the standard deviation was 0.7%.  
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The location 4 (at 15 mm from the resection surface) had a mean water 
concentration of 75.4% and a standard deviation of 0.6%.  
 
Figure 5. Cross section view of the tongue specimen inspected superficially with the 
fiber-optic Raman needle probe. The start point and end point of the measurements are 
marked with pink spherical pins. Position 1 marks the start point. Position 4 marks the 
end point. Measurements were performed along the dashed line (5mm apart from each 
other) on the cross section of the specimen (1-4). The measurements can be assigned as 
function of depth (0-15mm). 
 Histopathology correlation 
H&E stained sections made from the cross sections were used for inspection of the 
distance between the tumor border and the resection surface (figure 6), and for 
inspection of the water concentration in tumor and healthy, when performing 
superficial measurements on the cross section (figure 7). 
 
Figure 6. H&E stained section made of the cross section from the tongue specimen of 
patient 1 where water profile/depth scan measurements were performed. The resection 
surface was marked with ink during the gross pathology of the specimen. The resection 
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margin (smallest distance between the resection surface marked with ink and the border 
of the tumor) was measured and it is shown (6.05 mm). The resection margin is 
adequate. Healthy tissue (H) and tumor (T) are also marked. 
 
Figure 7. Illustration of superficial measurements performed with the fiber-optic Raman 
needle probe on a cross section of the specimen of patient 2. a) Cross section view of the 
tongue specimen inspected. The start point and end point of the measurements are 
marked with pink spherical pins and with numbers (from 1 to 4). The measurements can 
be assigned as function of depth (0-15mm). b) H&E stained section of the cross section 
measured. Based on the H&E stained section measurements 1 and 2 are healthy (H) and 
measurements 3 and 4 are from tumor (T). c) Mean spectra measured per location. At 
each location 10 to 50 frames were measured (0.1s acquisition time). Spectra obtained 
from healthy tissue are shown in green (1 and 2). Spectra obtained from tumor are 
shown in red (3 and 4). 
 
Discussion 
For this study, a thin fiber optic needle probe prototype, consisting of a single optical 
fiber inserted into a 30G hypodermic needle was developed.  
The first experiments performed by this prototype are shown. This fiber optic probe 
enables collection of HWVN Raman spectra.  
The measurements performed superficially on the tongue cross section (figure 7) 
with the fiber-optic Raman needle probe show that tumor has high water 
concentration and healthy tissue has generally low water concentration. This 
confirms what was found in previous studies (11,12). These measurements form the 
basis for using a fiber-optic Raman needle probe for assessment of soft tissue 
resection margins of OCSCC specimens.  
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The water profile can be used to determine the distance between the resection 
surface and the tumor border. If the probe measures high water concentration at a 
distance of less than 5 mm from the resection surface, it means that the margin is 
inadequate and, therefore, an extra-resection should be performed. If the probe 
measures low water concentration along a distance of more than 5 mm from the 
resection surface, it means that at that specific location the margin is adequate. 
The performed water profiles are summarized in the table 2. Two water profiles, 
marked with the red and green needles, had low values of water concentration along 
6 mm in depth. Therefore, knowing that tumor has always high water concentration 
and healthy tissue has in average low water concentration, for these two locations 
the tissue measured is healthy, which means that the distance between the resection 
surface and the tumor border is >5 mm (adequate). Based on the histopathological 
assessment, see figure 6, it can be confirmed that the measured tissue is healthy (the 
smallest distance found between the tumor border and the resection cut surface was 
6.05 mm). This indicates that the resection margin is adequate (>5 mm).  
For three water profile measurements (also shown in the table 2), high water 
concentrations were found, sometimes in between low water concentrations. 
Knowing that the tissue is healthy (based on histopathological evaluation), the 
reason why high water concentrations can be found also in healthy tissue may be 
explained by earlier studies (12). Results obtained in these earlier studies show that 
the healthy tongue tissue is characterized in average by a low water concentration 
with a high standard deviation 54%±24%. This means that in healthy tissue also 
some high water concentrations can be encountered (12). 
The fiber-optic Raman needle probe system has a depth sensitivity that it is different 
from the depth sensitivity of the setup used in the previous studies, which supported 
the development of the current equipment. Therefore, more studies will be 
performed in order to determine the optimal water cut-off that determines the tumor 
border from a profile. Additionally, more investigation will be made to know what 
other sampling/measuring strategies can be developed to reliably and accurately 
determine the distance between the tumor border and the resection surface of 
OCSCC specimens.  
Some technical issues/limitations were observed when experimenting the fiber-optic 
Raman needle probe. For some experiments, the needle did not penetrate smoothly 
in the tissue (especially, when measuring dense/fibrotic tissue), and, in many cases, 
the needle was compressing the tissue before penetrating the resection surface. The 
needle can become contaminated after a water profile measurement, therefore, in 
between water profiles the needle was cleaned with an ultrasonic bath. The solutions 
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for these problems are currently being investigated and the technical and functional 
characteristics of the probe will be further optimized with respect to speed and 
reliability. In the future, some non-expert personnel may be able of using the probe 
without observing any technical issue. 
The quality of the signal measured (acquisition time of 0.1s and laser power of ≈40-
100 mW) with the needle probe seems, in most cases, adequate for an accurate 
calculation of the water concentration (shot-noise does not limit the calculation of 
the water concentration).  
Based on these preliminary results, the proof of concept is made and we believe that 
a fiber-optic Raman needle probe instrument is an excellent candidate for 
assessment of OCSCC resection margins and its implementation may significantly 
improve the number of adequate resections.  
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General discussion  
In head and neck surgical oncology, the lack of intra-operative methods to 
discriminate tumor from non-tumor with sufficient or clinically relevant sensitivity 
and specificity is an issue. This thesis provides a solution for that clinical necessity.  
The most common type of cancer in head and neck region is oral cavity squamous 
cell carcinoma (OCSCC). Therefore, in this thesis, the potential of Raman 
spectroscopy for intra-operative assessment of soft resection margins and bone 
resection surfaces of freshly resected OCSCC specimens was investigated. Raman 
spectroscopy is a valuable solution because this technique is objective, can be 
performed in-vivo and or ex-vivo, the tissue samples do not need preparation, and 
can be processed in real-time (1).  
The Raman systems used in this thesis operate with the high-wavenumber region of 
the Raman spectrum (wavenumbers ranging from about 2400 cm-1 up to 4000 cm-1). 
The interest for using high-wavenumber Raman spectroscopy was based on two 
facts: a) Koljenović et al. showed that, for discriminating cancer from healthy tissue, 
essentially the same diagnostic information is obtained in either of the two spectral 
regions (fingerprint or high-wavenumber) (1), and b) Raman spectroscopy in the 
high-wavenumber region has significant advantages for ex-vivo and in-vivo use 
when compared to the commonly used fingerprint region. The signal intensity in the 
high-wavenumber region is higher than in the fingerprint region, and measurements 
can be performed in shorter integrations times. Additionally, fiber-optic materials 
like fused silica do not have Raman signal at the high-wavenumber region (1), which 
enables the use of simple and cheap single fiber-optic probes that can be easily 
inserted in endoscopes and/or needles to perform in-vivo measurements in hollow 
organs or surface assessment of solid organs such as, oral cavity (2,3), lung (4,5), 
upper gastrointestinal tract (6-8) and colorectal (9,10).   
For the measurements described in this thesis, both, microscope and optical fibers 
were used for illumination and collection of light, a 671 nm excitation wavelength 
was used as excitation light source, and Raman signal was collected in the range 
≈800-920 nm. Combining these characteristics in a Raman instrument, minimal 
absorption of the light by water and hemoglobin (HbO2 and Hb), which contribute to 
degradation and camouflage of the Raman signal, was guaranteed.  
Some important findings have supported the development of intra-operative 
guidance (IOG) Raman tools for assessment of the resection margins.  
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This thesis shows that Raman spectroscopy can discriminate OCSCC from the 
surrounding healthy soft tissue based on the water concentration as determined from 
the high-wavenumber spectra (11), with 99% sensitivity and 92% specificity (170-
point measurements/ 14 patients) (10).  
The method used to calculate the water concentration can be seen as a limitation 
because it was devised for protein−water mixtures and does not take into account the 
signals from lipids, which also contribute to the CH-stretching Raman band 
(2910−2966 cm−1). However, the measurements with a high signal from lipids have 
shown consistently low water contribution, and were always associated with healthy 
tissue. Therefore, even though the determination of the water concentration is based 
on a protein model, the signal contributions from lipids are unlikely to influence our 
discrimination results regarding discrimination of tumor and healthy tissue (10).  
Also, for this thesis, a method, called multiple regression fitting (MRF), for 
subtraction of luminescence background of high-wavenumber Raman spectra from 
freshly resected human oral tissue was developed, and its performance was 
compared with the most used method, polynomial baseline fitting (PBF) (12). MRF 
does not require an a priori choice of the polynomial order for fitting the 
background signal, and this is important because, as it is also shown in this thesis, no 
single polynomial order can optimally characterize all backgrounds that are 
encountered in high-wavenumber tissue spectra. Therefore, MRF is more robust than 
and preferable to PBF. This was an important development because it facilitates the 
analysis of Raman signal and reduces the influence of the luminescence background 
in the calculation of the water concentration in tissue (12). 
Knowing that OCSCC could be discriminated from healthy tissue based on the water 
concentration and that the calculation of the water concentration would not be 
influenced by the luminescence properties of tissue, in this thesis, the changes in 
water concentration across the OCSCC border toward the healthy surrounding tissue 
(located at >5 mm from the tumor border) were investigated (25 mapping 
experiments/ 20 patients). During this study, it was discovered that a transition from 
a high to a lower water concentration, from OCSCC (76%±8%) toward healthy 
surrounding tissue (54%±24%), takes place over 4 to 6 mm across the OCSCC 
border. This information can be used to detect the location of the OCSCC border 
(13). 
Furthermore, also in this thesis, it is demonstrated that Raman spectroscopy can 
detect OCSCC in bone resection surfaces with high sensitivity (96%) and specificity 
(83%) during mandibular resections (26 mapping experiments/ 22 patients) (14). 
These results demonstrate that Raman spectra of bone resection specimen provide 
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valuable information to distinguish between healthy tissue and OCSCC. Therefore, 
Raman spectroscopy could be applied ex-vivo for evaluation of bone resection 
margins (including bone marrow and cortical bone) during OCSCC surgery. 
However, implementation in the clinical workflow also requires the elimination of a 
practical issue that sometimes occurred: the lack of contact between the surface of 
the bone section and the fused silica window of the measurement cartridge. This 
problem leads to a low-quality Raman signal. Also, to guarantee a good quality of 
the Raman signal, it is important to cut the bone in a manner that it results in a flat 
and smooth surface. Alternatively, a method can be employed by which the contours 
of the surface are automatically followed by the measurement system (such as, 
inViaTMQontorTM, Renishaw B.V., United Kingdom). 
Finally, a Raman needle probe prototype, consisting of a single optical fiber inserted 
into a 30G hypodermic needle is presented and the first experiments performed by 
this prototype are shown. The fiber-optic probe enables collection of high-
wavenumber Raman spectra and the first measurements performed on OCSCC 
confirm what was found in earlier work (tumor has high water concentration and 
healthy tissue has in average low water concentration). The water profile measure 
through the fiber-optic needle probe will be used to determine the distance between 
the resection surface and the tumor border. In this way, when the probe measures 
high water concentration at a distance of less than 5 mm from the resection surface, 
it means that the margin is inadequate. If the probe measures low water 
concentration along a distance of more than 5mm from the resection surface, it 
means that at that specific location the margin is adequate. Additionally, some 
technical issues were observed when experimenting the fiber-optic Raman needle 
probe: the needle did not penetrate smoothly in the tissue (especially, when 
measuring dense/fibrotic tissue). In many cases, the needle was compressing the 
tissue before penetrating the resection surface. The solutions for these problems are 
currently being investigated and the technical and functional characteristics of the 
probe will be further optimized with respect to speed and reliability.  
Based on these preliminary results the proof of concept is made and we believe that 
a fiber-optic Raman needle probe instrument will be an excellent candidate for 
assessment of OCSCC soft tissue resection margins. 
The use of the IOG tools developed in this thesis may contribute positively to the 
future of the head and neck surgical oncology field, see figure 1.  
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Figure 1. Diagram that demonstrates the impact of this thesis in the future of head and 
neck surgical oncology.  
Outlook  
 Raman pathology system for assessment of bone resection 
surfaces 
Studies have reported that tumor-positive bone resections are found in 2-21% of the 
cases when a mandibulectomy for OCSCC is performed (15-19). Additionally, there 
is no standard technique available for assessment of bone resection surfaces (20-25). 
Therefore, the Raman system for assessment of bone resection surfaces could be 
implemented for clinical decision making regarding the need for additional bone 
resection when a mandibulectomy for OCSCC is performed.  
From the technical point of view, the first approach could be to apply the tumor 
detection algorithm created on every bone resection surface and use the false 
positive rate encountered in bone sections without tumor as a threshold below which 
the bone section is classified as tumor free. However, this, as well as more elaborate 
approaches, should be the subject of further studies. 
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From the clinical point of view, the aim for the future is to scan the complete 
mandibular resection surface by Raman spectroscopy during the mandibulectomy 
procedure. The result should be delivered to the surgeon in less than 20 minutes. If 
the result demonstrates bone resection surfaces are tumor free, the reconstruction 
surgery can start, and it is guaranteed that tumor was not left in the bone of the 
patient. If the result is the resection surface(s) contain(s) tumor, the surgeon can 
resect an extra bone slice during the first surgery, aiming for a tumor-free patient, 
adequate resection.  
Future studies should clarify whether this could improve the number of tumor free 
bone resections, and consequently reduce the extent of adjuvant treatment. Equally 
essential, having a method for intra-operative assessment of bone resection surfaces, 
might give surgeons the confidence to adjust initial cut line and resect the bone 
closer to the suspected tumor border. In this way, healthy bone might be spared, 
which will positively influence the reconstruction and reduce the possible post-
operative complications. 
 Raman pathology system for assessment of soft tissue 
resection margins 
The Raman needle probe system could be implemented for assessment of the entire 
soft tissue resection margin during OCSCC surgery. The Raman instrument could be 
placed in the operating room. After resection of the specimen, one operating room 
assistant could be responsible for using the Raman needle probe to inspect the 
resection margins of the specimen. The assistant should place the needle probe 
perpendicularly to the surgical cut surface. The assistant could use the automatic 
depth scan to know what is the smallest distance between the surgical cut surface 
and the tumor border. This means that the resection margin of every resected 
specimen could be evaluated during the operation. If the margin is inadequate in a 
certain location, the surgeon would be informed, and he/she could perform an extra-
resection at the inadequate place. In this way, a resection that would be inadequate 
turns into an adequate resection. Further studies are being developed to assure that 
the location of inadequate margins can be informed to the surgeon in an accurate, 
simple and elegant manner (26).   
Clinical studies have been initiated to monitor whether the use of the Raman needle 
probe system for assessment of soft tissue resection margins during OCSCC surgery 
will impact positively the outcome of the surgical procedures. The use of this 
objective tool should increase the number of adequate margins, lower the rate of 
adjuvant radiation therapy, and decrease the mortality rate of the patients that 
undergo OCSCC surgical procedures. 
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The fiber-optic Raman needle probe system has a depth sensitivity that is different 
from the depth sensitivity of the setup used in the previous studies. Therefore, more 
studies need to be performed to determine the optimal water concentration cut-off to 
determine the tumor border from the water profile with high accuracy.  
Also, more research need to be conducted to know what other sampling/measuring 
strategies can be developed to more reliably and accurately determine the distance 
between the tumor border and the resection surface of OCSCC specimens.  
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Summary 
Clinical necessities in surgical oncology are based on the same fundamental issue: 
lack of pre- and intra-operative methods with sufficient and/or clinically relevant 
sensitivity and specificity. This thesis provides a technical solution for these clinical 
necessities in head and neck surgical oncology.  
In this thesis we investigated the potential of Raman spectroscopy for ex-vivo intra-
operative surgical guidance.  
This thesis shows that oral cavity squamous cell carcinoma (OCSCC) can be 
discriminated from surrounding healthy soft tissue and healthy bone using Raman 
spectroscopy with a high sensitivity and specificity (respectively, sensitivity of 99% 
and 96% and specificity of 92% and 83%). The discrimination is mainly based on 
the water concentration of these tissues, determined by using the Raman spectrum. 
OCSCC has more water content than the surrounding healthy tissue or bone. The 
information on the water concentration also proved to be useful for detection of the 
OCSCC border. 
To guarantee that the calculation of the water concentration and the processing of 
the spectra is not influenced by noise or signal that did not result from Raman 
scattering, a method (multiple regression fitting, MRF) for subtraction of 
luminescence background was created. Its performance was compared to the current 
most used method (polynomial baseline fitting, PBF). Results indicate that MRF is 
more robust and therefore preferable to PBF. 
Additionally, a Raman needle probe for intra-operative assessment of soft tissue 
resection margins was developed and is being optimized to guide surgeons towards 
an adequate OCSCC resection.  
Finally, intra-operative use of Raman pathology systems for assessment of soft 
tissue resection margins and bone resection surfaces may affect positively the 
outcome of head and neck surgery. The intra-operative use of these tools may: 
decrease the number of inadequate margins, lower the rate of adjuvant radiation 
therapy, and decrease the mortality rate of the patients that undergo OCSCC surgery. 
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Sumário 
As necessidades clínicas em oncologia cirúrgica baseiam-se na mesma questão 
fundamental: falta de métodos pré e intra-operatórios com suficiente e/ou 
clinicamente relevante sensibilidade e especificidade. Esta tese fornece uma solução 
para estas necessidades clínicas em oncologia cirúrgica de cabeça e pescoço. 
Nesta tese, foi investigado o potencial de espectroscopia de Raman para a orientação 
cirúrgica intra-operatória a partir de espécimes (ex-vivo).  
Esta tese demonstra que, usando espectroscopia de Raman, o carcinoma de células 
escamosas da cavidade oral (CCEO) pode ser discriminado de tecido mole saudável 
circundante e de osso saudável com elevada sensibilidade e especificidade 
(respectivamente, sensibilidade de 99% e 96%, e especificidade de 92% e 83%). A 
discriminação é fundamentalmente baseada na concentração de água existente 
nesses tecidos que é determinada a partir do espectro Raman. CCEO tem maior 
concentração de água do que o tecido mole saudável circundante e o osso. A 
informação referente à concentração de água também provou ser útil para a detecção 
da borda do tumor. 
Para guarantir que o cálculo da concentração de água e o processamento dos 
espectros não sejam influenciados pelo ruído ou sinal que não resultou de dispersão 
Raman, foi criado um método (multiple regression fitting, MRF) para a subtração de 
fundo de luminescência. A performance deste método foi comparada ao método 
mais utilizado actualmente (polynomial baseline fitting, PBF). Os resultados 
indicam que o método MRF é mais robusto e, por conseguinte, preferível ao PBF. 
Para além disso, foi desenvolvida uma sonda de agulha Raman, para a avaliação 
intra-operatória das margens de ressecção de tecido mole. 1Presentemente, a sonda 
está a ser optimizada para orientar os cirurgiões a obter margens adequadas aquando 
a ressecção de CCEO. 
Por último, o uso intra-operatório de sistemas patológicos baseados em  tecnologia 
Raman, para a avaliação das margens de ressecção do tecido mole e das superfícies 
ósseas de ressecção, pode afectar positivamente o resultado da cirurgia oncológica 
de cabeça e pescoço. O uso intra-operatório destes equipamentos possibilita: a 
diminuição do número de margens inadequadas, a redução da dose de radiação da 
terapia adjuvante e a diminuição da taxa de mortalidade dos pacientes que foram 
submetidos a cirurgia para remoção de CCEO. 
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Samenvatting  
Klinische benodigdheden in de oncologische chirurgie zijn gebaseerd op hetzelfde 
fundamentele probleem: gebrek aan pre- en intra-operatieve methoden met 
voldoende en/of klinisch relevante sensitiviteit en specificiteit. Dit proefschrift biedt 
een technische oplossing voor deze klinische noodzaak in hoofd-hals oncologische 
chirurgie. 
In dit proefschrift hebben we het potentieel van Raman spectroscopie voor ex-vivo 
intra-operatieve chirurgische begeleiding onderzocht. 
Dit proefschrift laat zien dat plaveiselcelcarcinoom (PCC) van de mondholte 
onderscheiden kan worden van omringend gezond weefsel en bot met het gebruik 
van Raman spectroscopie, met een hoge sensitiviteit en specificiteit (respectievelijk, 
een sensitiviteit van 99% en 96% en een specificiteit van 92% en 83%). De 
discriminatie is voornamelijk gebaseerd op de waterconcentratie van deze weefsels, 
bepaald met behulp van het Raman spectrum. Het PCC heeft meer waterinhoud dan 
het omringende gezonde weefsel of gezond bot. De informatie over de 
waterconcentratie bleek ook van nut voor de detectie van de tumor grens. 
Om te garanderen dat de berekening van de waterconcentratie en de verwerking van 
de spectra niet wordt beïnvloed door ruis of signalen, die niet het resultaat zijn van 
Raman verstrooiing, is voor dit proefschrift een methode (multiple regressie fitting, 
MRF) voor het aftrekken van de luminescentie achtergrond gemaakt. De uitkomst 
werd vergeleken met de huidige meest gebruikte methode (polynoom baseline 
fitting, PBF). De resultaten geven aan dat MRF meer robuust is en de voorkeur heeft 
boven PBF. 
Daarnaast is er een Raman-probe ontwikkeld voor intra-operatieve beoordeling van 
de resectiemarges voor zachte weefsels en wordt deze geoptimaliseerd om de 
chirurgen te begeleiden naar een adequate tumor resectie. 
Ten slotte kan het intra-operatieve gebruik van Raman pathologie systemen voor de 
beoordeling van resectiemarges voor zachte weefsels en bot resectievlakken de 
uitkomst van hoofd-hals chirurgische ingrepen positief beïnvloeden. Het intra-
operatieve gebruik van deze hulpmiddelen zou: het aantal inadequate marges kunnen 
verlagen, de toepassing van adjuvante radiotherapie verlagen en de mortaliteit 
verlagen van de patiënten, die een operatie ondergaan wegens een PCC van de 
mondholte. 
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